<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article
	xmlns:mml="http://www.w3.org/1998/Math/MathML"
	xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.1" xml:lang="en">
	<front>
		<journal-meta>
			<journal-id journal-id-type="publisher-id">psr</journal-id>
			<journal-id journal-id-type="journal-code">psr</journal-id>
			<journal-id journal-id-type="doi-code">psr</journal-id>
			<journal-title-group>
				<journal-title>Physical Sciences Reviews</journal-title>
			</journal-title-group>
			<issn pub-type="epub">2365-659X</issn>
			<publisher>
				<publisher-name>De Gruyter</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="publisher-id">psr-2022-0288</article-id>
			<article-id pub-id-type="doi">10.1515/psr-2022-0288</article-id>
			<title-group>
				<article-title>Dipeptidyl peptidase IV: a multifunctional enzyme with implications in several pathologies including cancer</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<name>
						<surname>Arrebola Sánchez</surname>
						<given-names>Yarini</given-names>
					</name>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_001"/>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Almeida García</surname>
						<given-names>Fabiola</given-names>
					</name>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_001"/>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Ojeda del Sol</surname>
						<given-names>Daniel</given-names>
					</name>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_001"/>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Valdés-Tresanco</surname>
						<given-names>Mario E.</given-names>
					</name>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_001"/>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_002"/>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Ortiz</surname>
						<given-names>Carlos David</given-names>
					</name>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_001"/>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Sánchez Ramírez</surname>
						<given-names>Belinda</given-names>
					</name>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_003"/>
				</contrib>
				<contrib contrib-type="author" corresp="yes">
					<name>
						<surname>Pascual Alonso</surname>
						<given-names>Isel</given-names>
					</name>
					<xref ref-type="aff" rid="j_psr-2022-0288_aff_001"/>
					<email xlink:href="mailto:isel@fbio.uh.cu">isel@fbio.uh.cu</email>
				</contrib>
				<aff id="j_psr-2022-0288_aff_001">
					<institution content-type="dept">Center for Protein Studies, Faculty of Biology</institution>,
					<institution content-type="university">University of Havana</institution>,
					<city>Havana</city>,
					<country country="CU">Cuba</country>
				</aff>
				<aff id="j_psr-2022-0288_aff_002">
					<institution content-type="dept">Department of Biological Sciences</institution>,
					<institution content-type="university">University of Calgary</institution>,
					<city>Calgary</city>,
					<country country="CA">Canada</country>
				</aff>
				<aff id="j_psr-2022-0288_aff_003">
					<institution content-type="university">Centro de Inmunología Molecular</institution>,
					<city>La Habana</city>,
					<country country="CU">Cuba</country>
				</aff>
			</contrib-group>
			<author-notes>
				<corresp id="cor1">
					<bold>Corresponding author: Isel Pascual</bold>,
					<institution content-type="dept">Center for Protein Studies, Faculty of Biology</institution>,
					<institution content-type="university">University of Havana</institution>,
					<addr-line>25 # 455, between J and I, Plaza de la Revolución</addr-line>,
					<city>Havana</city>,
					<addr-line>CP 10 400</addr-line>,
					<country country="CU">Cuba</country>, E-mail:
					<email xlink:href="mailto:isel@fbio.uh.cu">isel@fbio.uh.cu</email>
				</corresp>
			</author-notes>
			<pub-date pub-type="issue">
				<day>31</day>
				<month>08</month>
				<year>2024</year>
			</pub-date>
			<pub-date pub-type="epub">
				<day>11</day>
				<month>05</month>
				<year>2023</year>
			</pub-date>
			<pub-date pub-type="cover-date">
				<day>01</day>
				<month>08</month>
				<year>2024</year>
			</pub-date>
			<volume>9</volume>
			<issue>8</issue>
			<fpage>2541</fpage>
			<lpage>2596</lpage>
			<history>
				<date date-type="received">
					<day>30</day>
					<month>10</month>
					<year>2022</year>
				</date>
				<date date-type="accepted">
					<day>11</day>
					<month>04</month>
					<year>2023</year>
				</date>
			</history>
			<permissions>
				<copyright-statement>© 2023 Walter de Gruyter GmbH, Berlin/Boston</copyright-statement>
				<copyright-year>2023</copyright-year>
				<copyright-holder>Walter de Gruyter GmbH, Berlin/Boston</copyright-holder>
			</permissions>
			<related-article related-article-type="pdf" xlink:href="10.1515_psr-2022-0288.pdf"/>
			<abstract>
				<title>Abstract</title>
				<p>Ectopeptidases are particularly interesting due to their potential to regulate/dysregulate the peptide mediated signaling cellular pathways because the active site located to the extracellular space. Dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5) is currently one of the ectopeptidases that has a great and complex influence on important physiological and pathological processes. Due to its influence on the immune system, type 2 diabetes mellitus, pulmonary pathologies, cardiovascular system, viral infections and cancer, DPP-IV is very attractive as a possible therapeutic target. However, its versatility makes such expectations very difficult. The aim of this work is to summarize relevant structural and functional aspects of DPP-IV and the role of this protein in several pathologies with special emphasis on cancer. DPP-IV role in cancer seems to depend on specific location, histologic type of tumour, tumour microenvironment, and presence/absence of molecules able to interact with DPP-IV. Because of DPP-IV controversial effects, generalizations are difficult and most of the time the role of DPP-IV must be analyzed case by case. However, new evidences in cell lines, animal models and clinical studies suggest that DPP-IV inhibitors open a promissory window through new therapeutic strategies against some cancers.</p>
			</abstract>
			<kwd-group>
				<title>Keywords</title>
				<kwd>cancer</kwd>
				<kwd>dipeptidyl peptidase IV</kwd>
				<kwd>ectopeptidases</kwd>
				<kwd>human diseases</kwd>
				<kwd>inhibitors</kwd>
			</kwd-group>
			<funding-group>
				<award-group award-type="grant" id="award-grp1">
					<funding-source>Oficina de GestiÃ³n de Fondos y Proyectos Internacionales del Ministerio de Ciencia, TecnologÃ-a y Medio Ambiente de la RepÃºblica de Cuba</funding-source>
					<award-id>PN223LH010-010 2021-2023</award-id>
				</award-group>
				<award-group award-type="grant" id="award-grp2">
					<funding-source>Ministerio de Ciencia, Tecnología y Medio Ambiente</funding-source>
					<award-id>Unassigned</award-id>
				</award-group>
			</funding-group>
			<counts>
				<fig-count count="004"/>
				<table-count count="005"/>
				<ref-count count="406"/>
				<page-count count="056"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<sec id="j_psr-2022-0288_s_001">
			<label>1</label>
			<title>Introduction: cancer is coming and we need more and more effective weapons to stop or ameliorate it</title>
			<p>Nowadays cancer
				<?index value="cancer"?> is responsible about 1/6 of deaths worldwide, being the second leading cause of death. In 2020, nearly 9.6 million of people lost their lives at the behest of cancer [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_001">1</xref>]. Countries with small and medium economies account for around 70 % of cancer deaths. Globally, the most frequently diagnosed cancers are three: lung cancer (11.6 % of total cases), women breast cancer (11.6 %), and colorectal malignancies (10.2 %). Regarding to mortality caused by cancers, once again lung cancer is the one that contributes the most (18.4 %), followed a little further away by colorectal (9.2 %) and stomach malignancies (8.2 %) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_001">1</xref>].
			</p>
			<p>Predictions of the World Health Organization do not hide nor underestimate a gray near horizon: for the next 20 years, cancer incidences are predicted to increase by at least 60 %. Among the approximately 18 million people diagnosed with cancer worldwide in 2018, close to 10 million lost their lives. It is expected that, by 2040, these new cases will increase to an estimated number between 27 and 39 million. Once again, the most affected will be the countries with small and medium-sized economies, where more than 2/3 of all new cases are expected to be diagnosed [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_001">1</xref>].
			</p>
			<p>The integral management of cancer demands a large financial support, sophisticated equipment, and multiple strategies not only for prevention and diagnosis, but also for treatment and for palliative cares. Numbers speaks without hesitation: more than 600 types of cancer appear on the International Classification of Diseases; some of them require refined and specific diagnoses and/or treatments [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_001">1</xref>]. One of the promissory target for cancer treatment is the modulation of the activity of the particular enzymes involved in critical events during carcinogenesis and metastasis [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_002">2</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_004">4</xref>].
			</p>
			<p>It is known that carcinogenesis is accompanied by the increasing loss of regulatory mechanisms at the molecular and cellular levels. This set of dysregulations (also known as the hallmarks of cancer) will ultimately determine the appearance of the malignant phenotype. Significant advances have been made in the understanding of cancer in recent years; therefore, the cancer hallmarks list has grown since it was first proposed several years ago. Towards the end of 2022, a referential author like Hanahan has proposed the following list, which is, in our opinion, the most up-to-date and complete. According to him, a cancerous lineage must be able to: metabolically reprogram itself, evade different forms of cell death, sustainably proliferate, evade growth inhibitory signals, gain access to the vasculature and/or promote angiogenesis, escape “surveillance” of the immune system, invade other tissues, and metastasize. In addition, disrupted differentiation and cell plasticity seem to be emerging as two new but (for now at least) weak or discrete hallmarks [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_002">2</xref>]. Most of the hallmarks are directly conditioned by anomalies in the cell signaling circuits. Among these anomalies, the most notorious are the constitutive expression/overexpression of oncogenes and the reduced/null expression of genes involved in tumour suppression. Several molecular signals secreted by the tumour and/or its microenvironment usually trigger most of these aberrant circuits. In this context, the modulation of cell signalling (autocrine, paracrine and juxtacrine) by signaling peptides, hormones, cytokines, and growth factors are relevant for the altered above mentioned processes. Being determinant in the levels of most of these ligands, the rate of extracellular proteolysis will therefore be determinant during tumour genesis and progression [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>]. In that way, peptidases (enzymes that cleavage peptide bounds) are particularly interesting due to their potential to regulate/dysregulate the peptide mediated signaling cellular pathways [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_004">4</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_005">5</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_006">6</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_007">7</xref>]. The crucial importance of these enzymes during tumour evolution is noticed by the fact that their expression pattern often changes (increases or decreases) in many tumour cells. Through their influence on the balance of peptide signals, peptidases are capable of modulating (directly or indirectly) key processes for the tumour such as proliferation, immortalization, angiogenic capacity, migration and metastasis [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>]. In particular, some peptidases are anchored to the cell membrane, are multifunctional and expose their active site to the outside of the cell: they are called ectopeptidases. Since they expose the catalytic site into the extracellular medium, they show relevant physiological and/or pathological roles (including the processing of various peptide signals such as growth factors, hormones and neuropeptides) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_004">4</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_005">5</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_006">6</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_007">7</xref>]. Thus, nowadays ectopeptidase has emerged as potential therapeutic targets against several diseases in general, and against cancer in particular [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_008">8</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_009">9</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_010">10</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_011">11</xref>].
			</p>
			<p>A remarkable example of an ectopeptidase
				<?index value="ectopeptidase"?> extensively studied in recent years is the dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_012">12</xref>], also called CD26 or adenosine deaminase binding protein (ADABP) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_013">13</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_014">14</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_015">15</xref>]. In humans, it is widely distributed in several cellular types from diverse organs [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_016">16</xref>]. DPP-IV has a relevant role in several physiological or pathological processes. It contributes to control: energetic metabolism, immune response, cell adhesion, apoptosis, inflammation and several types of cancer [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_017">17</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_018">18</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_019">19</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_020">20</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_021">21</xref>]. Due to the importance of DPP-IV in glucose homeostasis, several DPP-IV inhibitors have been used successfully in the treatment of type 2 diabetes mellitus (T2DM) in humans [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_020">20</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_022">22</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_023">23</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_024">24</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_025">25</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_026">26</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_027">27</xref>]. Due to the high complexity of cancer, research on DPP-IV and cancer is not as advanced as it is for DPP-IV and T2DM [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_026">26</xref>]. However, in recent years, much evidence has emerged pointing to this enzyme as a possible target against certain types of cancer [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_028">28</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_029">29</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_030">30</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_031">31</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_032">32</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_033">33</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_034">34</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_035">35</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_036">36</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_037">37</xref>].
			</p>
			<p>In the following sections, we will review relevant structural and functional aspects of DPPIV, as well as its relationship with various pathologies, including (with particular emphasis) cancer.</p>
		</sec>
		<sec id="j_psr-2022-0288_s_002">
			<label>2</label>
			<title>DPP-IV general characteristics: an interesting peptidase that is more than just an enzyme</title>
			<p>The enzyme dipeptidyl peptidase IV (DPP-IV or DPP4, EC 3.4.14.5) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_012">12</xref>] is a highly conserved type II transmembrane glycoprotein mainly expressed as a dimer. Each monomer is 766 residues in length and it is formed by the succession of a cytoplasmic tail of six residues located towards the N-terminus, a short transmembrane segment and a voluminous extracellular domain [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_038">38</xref>] (
				<xref ref-type="fig" rid="j_psr-2022-0288_fig_001">Figure 1</xref>). In body fluids (semen, blood and bile) a soluble isoform of DPP-IV has been found that has lost the intracellular and transmembrane sections, but retains enzymatic activity [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_039">39</xref>].
			</p>
			<fig fig-type="figure" id="j_psr-2022-0288_fig_001">
				<label>Figure 1:</label>
				<caption>
					<p>Primary structure of human DPPIV. It consists of a short cytoplasmic tail, a single transmembrane region, and a large extracellular domain composed of a glycosylated region, a cysteine-rich region, and a catalytic region. Here they are labeled in yellow, green, cyan, blue and violet, respectively.</p>
				</caption>
				<graphic xlink:href="graphic/j_psr-2022-0288_fig_001.jpg"/>
			</fig>
			<p>DPP-IV is a serine peptidase belonging to the S9 family of the SC clan [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_012">12</xref>]. It can acts as an enzyme, as a cell surface marker and as a protein able to associate/interact with other membrane or extracellular proteins (
				<xref ref-type="fig" rid="j_psr-2022-0288_fig_002">Figure 2</xref>). Its extracellular domain possesses the active site, which hydrolyzes dipeptides from the N-terminus of small peptides that contain alanine (Ala) or, even better, proline (Pro) in the second position counting from the N-terminus [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_040">40</xref>]. Often, the binding of several proteins to human DPP-IV results in extra-enzymatic interactions. Among these proteins able to strongly bind DPP-IV are adenosine deaminase (ADA), caveolin-1, mannose 6-phosphate/insulin-like growth factor II receptor, caspase recruitment domain-containing protein 11 (CARD11), the CD45 tyrosine phosphatase, the plasminogen receptor, the Na
				<sup>+</sup>/H
				<sup>+</sup> exchanger isoform NHE3, the chemokine receptor CXCR4, MERS-CoV spike proteins, TAT and gp-120 HIV proteins, and the extracellular matrix proteins fibronectin (FN), collagen and vitronectin [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_041">41</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_042">42</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_043">43</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_044">44</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_045">45</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_046">46</xref>].
			</p>
			<fig fig-type="figure" id="j_psr-2022-0288_fig_002">
				<label>Figure 2:</label>
				<caption>
					<p>DPP-IV functions. Gray solid lines indicate direct effects of DPP-IV on a physiologic and/or pathologic process via one or more of its three main roles: Enzyme, surface marker molecule and protein–protein interacting. Gray discontinue lines indicate DPP-IV indirect influence due to DPP-IV pleiotropic effects.</p>
				</caption>
				<graphic xlink:href="graphic/j_psr-2022-0288_fig_002.jpg"/>
			</fig>
			<sec id="j_psr-2022-0288_s_002_s_001">
				<label>2.1</label>
				<title>DPP-IV gene and protein expression: a vast picture across human tissues</title>
				<p>The gene of human DPP-IV (hDPP-IV) is contained on the long arm of chromosome 2 (2q24.3). It has approximately 70 kb with 16 exons (with sizes between 45 bp and 1.5 kb) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_019">19</xref>] as well as binding sites for transcription factors that are typical of housekeeping genes [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_047">47</xref>]. mRNA for DPP-IV has been found in cells from gastrointestinal and proximal digestive tract, kidney, skin, liver and gallbladder, endocrine glands like pancreas and ovarian, prostate, urinary bladder, muscle, respiratory system, connective tissues, eye, brain and lymphoid tissues including bone marrow [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_048">48</xref>].
				</p>
				<p>In humans, the DPP-IV membrane isoform has four variants, all of them encoded by different transcripts (differential splicing) of the same gene. Among these four variants, there are three very close forms (with 766, 765 and 764 residues respectively) and a slightly smaller fourth, with 748 residues [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_049">49</xref>]. As there are specific variations in size, the glycosylation sites are not exactly in the same position for the four variants, although in all cases it is an N-glycosylation with N-acetyl glucosamine (GlcNAc) in asparagine residues.
					<xref ref-type="table" rid="j_psr-2022-0288_tab_001">Table 1</xref> summarizes some features of the four variants. Until now, the variant encoded by transcript 1 (766 residues variant) has been the most observed and it is referred to as the major variant [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_051">51</xref>]. In addition to the position of the glycosylations, variant two differs from variant one in the replacement of the T
					<sup>32</sup> substitution by N
					<sup>32</sup>, as well as the loss of D
					<sup>33</sup> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_052">52</xref>]. Variant 3 is characterized by the absence of G
					<sup>31</sup> and T
					<sup>32</sup> with respect to variant 1 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_053">53</xref>]. In variant 4, the changes are slightly more drastic (it has eight fewer residues than variant 1) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_054">54</xref>]. It would be interesting to know what physiological/pathological conditions could modify the preponderance of variant 1. Does variant 1 prevail in all cells or only in those observed so far? Can this preponderance be altered depending on the cell cycle, the stage of cell differentiation, or the emergence of a tumour phenotype? More studies are needed to achieve the answers.
				</p>
				<table-wrap id="j_psr-2022-0288_tab_001">
					<label>Table 1:</label>
					<caption>
						<p>pDPP-IV and hDPP-IV: size, molecular weight and glycosylation sites.</p>
					</caption>
					<table frame="hsides">
						<colgroup>
							<col align="left"/>
							<col align="right"/>
							<col align="right"/>
							<col align="left"/>
							<col align="left"/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">DPP-IV variant</th>
								<th align="right">Size</th>
								<th align="right">Molecular weight of the monomer (Da)</th>
								<th align="left">N-Glicosilation sites (GlcNAc)</th>
								<th align="right">References</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>pDPP-IV</td>
								<td>766</td>
								<td>88,112</td>
								<td>N
									<sup>85</sup> N
									<sup>92</sup> N
									<sup>150</sup> N
									<sup>179</sup> N
									<sup>219</sup> N
									<sup>229</sup> N
									<sup>279</sup> N
									<sup>321</sup> N
									<sup>685</sup>
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_050">50</xref>]
								</td>
							</tr>
							<tr>
								<td>hDPP-IV (variant 1)</td>
								<td>766</td>
								<td>88,148</td>
								<td>N
									<sup>85</sup> N
									<sup>92</sup> N
									<sup>150</sup> N
									<sup>219</sup> N
									<sup>229</sup> N
									<sup>281</sup> N
									<sup>321</sup> N
									<sup>520</sup> N
									<sup>685</sup>
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_051">51</xref>]
								</td>
							</tr>
							<tr>
								<td>hDPP-IV (variant 2)</td>
								<td>765</td>
								<td>88,046</td>
								<td>N
									<sup>84</sup> N
									<sup>91</sup> N
									<sup>149</sup> N
									<sup>218</sup> N
									<sup>228</sup> N
									<sup>280</sup> N
									<sup>320</sup> N
									<sup>519</sup> N
									<sup>684</sup>
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_052">52</xref>]
								</td>
							</tr>
							<tr>
								<td>hDPP-IV (variant 3)</td>
								<td>764</td>
								<td>87,990</td>
								<td>N
									<sup>83</sup> N
									<sup>90</sup> N
									<sup>148</sup> N
									<sup>217</sup> N
									<sup>279</sup> N
									<sup>319</sup> N
									<sup>518</sup> N
									<sup>683</sup>
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_053">53</xref>]
								</td>
							</tr>
							<tr>
								<td>hDPP-IV (variant 4)</td>
								<td>748</td>
								<td>86,012</td>
								<td>No data available</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_054">54</xref>]
								</td>
							</tr>
						</tbody>
					</table>
				</table-wrap>
				<p>There seems to be no immediate correlation between DPP-IV mRNA levels and the enzyme detected in the cells membrane; for example, the pancreas
					<?index value="pancreas"?> and lung have similar levels of DPP-IV expression, but the amount of DPP-IV mRNA detected in the lung is significantly less than that detected in the pancreas [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_055">55</xref>]. Furthermore, in the brain, eye, skin, muscle, bone marrow and connective tissues there is DPP-IV mRNA, but its expression is not observed under physiological conditions [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_048">48</xref>].
				</p>
				<p>As it was mentioned earlier, DPP-IV is expressed as a highly glycosylated, type II integral membrane protein [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_038">38</xref>]. The protein is normally found as a homodimer of 220–290 kDa molecular weight [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_056">56</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_057">57</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_058">58</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_059">59</xref>], but also can form tetramers of around 900 kDa. Each monomer is made up of two domains: a β-propeller domain (residues 58 to 497) and an αβ-hydrolase domain (residues 39 to 51 plus residues 501 to 706) (
					<xref ref-type="fig" rid="j_psr-2022-0288_fig_003">Figure 3A</xref>). hDPP-IV has nine N-glycosylation sites, most of which are located in the β-propeller region, close to the dimerization site. These glycosylations probably protect the mature protein from the extracellular proteolytic machinery [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_057">57</xref>]. hDPP-IV and porcine DPP-IV (pDPP-IV) are structurally very close: the two have 766 residues and share 88 % sequence identity; therefore, both enzymes not only show extremely similar functional behaviours against pH and temperature, but are also susceptible to being inhibited by the same molecules, including various divalent cations [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_060">60</xref>]. Only three glycosylatons change: there is no glycosylation at position N
					<sup>520</sup>, there is one glycosylation at N
					<sup>179</sup>, and another at N
					<sup>279</sup> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_050">50</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_051">51</xref>]. This makes pDPP-IV an adequate surrogate model when the human enzyme is not available due to ethical or economic reasons [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_060">60</xref>]. pDPP-IV is included in
					<xref ref-type="table" rid="j_psr-2022-0288_tab_001">Table 1</xref> for better visualization of its structural similarities to hDPP-IV (variant 1). In recent years, rat DPP-IV has been shown to possess several of the properties described for its human and pig counterparts, suggesting a high structure–function similarity in mammals [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_061">61</xref>].
				</p>
				<fig fig-type="figure" id="j_psr-2022-0288_fig_003">
					<label>Figure 3:</label>
					<caption>
						<p>Structural elements of the human DPP-IV. (A) Monomeric structure of a DPP-IV. Each monomer is composed of one αβ-hydrolase and one β-propeller domain. (B) Access to the active site of DPP-IV. Discontinuous ellipse indicates the access zone for substrates. The violet arrow indicates the exit for the dipeptide resulting from the catalytic hydrolysis. (C) Active site of DPP-IV. Residues of the catalytic triad (S
							<sup>630</sup>, H
							<sup>740</sup> and D
							<sup>708</sup>) and those involved in substrate binding (E
							<sup>205</sup>, E
							<sup>206</sup> and R
							<sup>125</sup>) are highlighted.
						</p>
					</caption>
					<graphic xlink:href="graphic/j_psr-2022-0288_fig_003.jpg"/>
				</fig>
				<p>The dimeric and soluble isoform of DPP-IV begins from S
					<sup>39</sup> and it originates from endothelial membrane DPP-IV, which probably undergoes proteolytic cleavage [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_062">62</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_063">63</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_064">64</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_065">65</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_002_s_002">
				<label>2.2</label>
				<title>DPP-IV active site structure: catalytic triad, residues of interest and substrate specificity</title>
				<p>The DPP-IV catalytic domain, also known as the αβ-hydrolase domain, has a unique architecture, as it consists of an eight-stranded β-sheet surrounded by 12 α-helixes (
					<xref ref-type="fig" rid="j_psr-2022-0288_fig_003">Figure 3A</xref>) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_066">66</xref>]. A lateral opening of about 15 Å allows access to the cavity where the active site of hDPP-IV is located, so that only small substrates of a peptide nature (fragments of unfolded proteins and unfolded peptides) can gain access to the active site. A tunnel formed by the β-propeller domain allows the products of the reaction to leave the active site (
					<xref ref-type="fig" rid="j_psr-2022-0288_fig_003">Figure 3B</xref>) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_067">67</xref>].
				</p>
				<p>The catalytic triad (S
					<sup>630</sup>, D
					<sup>708</sup> and H
					<sup>740</sup>) (
					<xref ref-type="fig" rid="j_psr-2022-0288_fig_003">Figure 3C</xref>) is located in the interphase between the β-propeller and αβ-hydrolase domains. Although it does not belong to the catalytic triad, the Y547 residue appears to stabilize the reaction intermediate tetrahedral oxyanion and is therefore essential during catalysis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_061">61</xref>]. At the binding site, there are two glutamate residues (E
					<sup>205</sup> and E
					<sup>206</sup>) that contribute to linearize the peptide substrate through salt bridges that are established with the N-terminus of the substrate (
					<xref ref-type="fig" rid="j_psr-2022-0288_fig_003">Figure 3C</xref>). These residues, whose presence is characteristic of the DPP-IV family, only leave space for two amino acids before the peptide reaches the reactive serine residue in the active center, which explains why the enzyme has dipeptidyl aminopeptidase-type activity. The importance of both residues has been confirmed by site-directed mutagenesis experiments [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_068">68</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_069">69</xref>].
				</p>
				<p>The DPP-IV S1 site is narrow because it is made up of bulky residues: Y
					<sup>631</sup>, V
					<sup>656</sup>, W
					<sup>659</sup>, Y
					<sup>662</sup>, Y
					<sup>666</sup> and V
					<sup>711</sup>. This means that, for a peptide to be hydrolyzed by DPP-IV, it must not only be small and unfolded, but in the second position from its N-terminus it must contain a small residue (proline, alanine or glycine) that can be accommodated in such a restricted space [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_061">61</xref>]. Since few peptides possess proline at the mentioned position, this strongly determines the specificity of DPP-IV. Homodimerization, which requires the αβ-hydrolase domain as well as a protrusion from the fourth sheet of the β-propeller [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_069">69</xref>], is essential for catalysis. Proof of this is that point mutations that prevent dimerization (example: change of H
					<sup>750</sup> to E) also prevent catalysis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_070">70</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_002_s_003">
				<label>2.3</label>
				<title>DPP-IV β-propeller domain: a singular structure from a singular protein</title>
				<p>Usually a β-propeller domain is formed by the clustering of a minimum of four and a maximum of eight β-sheets, each of which contains between 30 and 50 residues arranged in four anti-parallel strands [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_071">71</xref>]. The structure is highly symmetric, as the β-sheets are arranged radially and form a central tunnel of about 30–45 Å [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_071">71</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_072">72</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_073">73</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_074">74</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_075">75</xref>]. Due to their relative structural flexibility, β-propeller may be involved both in enzyme catalysis and in the establishment of protein-protein interactions in those proteins that possess them [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_076">76</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_077">77</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_078">78</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_079">79</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_080">80</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_081">81</xref>]. Interestingly, alterations in several of these proteins have been related to the appearance and evolution of pathologies such as: arterial hypertension, arthritis, infections, Alzheimer’s disease, familial hypercholesterolemia, Huntington disease, retinitis and cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_082">82</xref>].
				</p>
				<p>Among the β-propells of leukocyte membrane proteins, the β-propell of DPP-IV is unique both in number of β-sheets (eight) and in organization, being one of the least organized described to date. Note that the other two leukocyte surface antigens that carry β-propeller domains (CD100 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_083">83</xref>] and the α-chain integrins [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_084">84</xref>]) have much more organized seven β-sheet β-propellers [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_083">83</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_084">84</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_085">85</xref>]. In the case of DPP-IV, an antiparallel β-sheet penetrates between strands one and two of the second β-sheet of the domain. This “intrusive sheet” possesses, in turn, a residue (R
					<sup>125</sup>) that stabilizes (via a salt bridge with E
					<sup>205</sup>) the C-terminal turn of an α-helix that is inserted between the third and fourth β-sheet of the domain. Another antiparallel β-sheet is introduced between the third and fourth strands of the fourth β-sheet. This complex arrangement is highly relevant both for dimerization and for catalysis and interaction with other proteins of physiological and/or pathological relevance such as ADA, FN, collagen and HIV gp120 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_086">86</xref>].
				</p>
				<p>Interestingly, it has been observed that the R
					<sup>125</sup> residue is capable of interacting not only with substrates, but also with certain inhibitors, which makes it a frequent target during the in silico design of strategies to inhibit DPP-IV [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_057">57</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_058">58</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_061">61</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_066">66</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_087">87</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_088">88</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_089">89</xref>]. From bacteria to humans, R
					<sup>125</sup> is highly conserved. Similarly, E
					<sup>205</sup>, which, as we said, is stabilized by R
					<sup>125</sup> via a salt bridge, is highly conserved. In fact, the helix to which E
					<sup>205</sup> belongs (D-W-X-Y-E-E
					<sup>205</sup>-E-X) is conserved in all members of the DPP-IV family [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_090">90</xref>] (
					<xref ref-type="fig" rid="j_psr-2022-0288_fig_004">Figure 4</xref>).
				</p>
				<fig fig-type="figure" id="j_psr-2022-0288_fig_004">
					<label>Figure 4:</label>
					<caption>
						<p>β-propeller domain of human DPP-IV. (A) Front view of the β-propeller domain, showing the displacement of β-sheets around a central tunnel of 30–45 Å in diameter. (B) Side view.</p>
					</caption>
					<graphic xlink:href="graphic/j_psr-2022-0288_fig_004.jpg"/>
				</fig>
			</sec>
			<sec id="j_psr-2022-0288_s_002_s_004">
				<label>2.4</label>
				<title>DPP-IV cellular expression: a very wide spread molecule</title>
				<p>Various DPP-IV homologues have been reported in bacteria [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_091">91</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_092">92</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_093">93</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_094">94</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_095">95</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_096">96</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_097">97</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_098">98</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_099">99</xref>], fungi [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_100">100</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_101">101</xref>] and mammals [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_040">40</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_102">102</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_103">103</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_104">104</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_105">105</xref>]. Evidence suggests that the overall structure of DPP-IV from bacteria is similar to that of DPP-IV from mammals, but they differ in several respects. In all cases, a few variations of residues have been observed around the active site resulting from insertions or deletions at the genetic level. In general, bacteria DPP-IV and mammal DPP-IV shares several properties in spite of structural differences [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_091">91</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_092">92</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_093">93</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_094">94</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_095">95</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_096">96</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_097">97</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_098">98</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_099">99</xref>], but we need more crystals from bacteria of different groups to be able to reach more complete conclusions.
				</p>
				<p>In mammals, DPP-IV is abundantly expressed in tissues of various organs such as kidney, intestine, lung, brain, liver, pancreas, bladder, pancreas, spleen, thymus, lymph nodes, uterus, skin, as well as in sperm, lymphocytes and endothelium [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_086">86</xref>]. In humans, it has enhanced expression inparathyroid gland, kidney, placenta, prostate gland, intestine [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_048">48</xref>], semen [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_106">106</xref>] and several immune cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_086">86</xref>]. Under normal conditions, the kidney and seminal fluid have the highest specific activity of hDPP-IV.
					<xref ref-type="table" rid="j_psr-2022-0288_tab_002">Table 2</xref> summarizes the main cellular types expressing human DPP-IV found in tissues of high expression of this protein.
				</p>
				<table-wrap id="j_psr-2022-0288_tab_002">
					<label>Table 2:</label>
					<caption>
						<p>Main types of human cells expressing human DPP-IV. Dependence of this expression on various tissues and/or organs. Check marks indicate confirmed DPP-IV expression. Crucified circles indicate non-confirmed expression to date. Adapted from The Human Protein Atlas [
							<xref ref-type="bibr" rid="j_psr-2022-0288_ref_107">107</xref>].
						</p>
					</caption>
					<table frame="hsides">
						<colgroup>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
						</colgroup>
						<thead>
							<tr>
								<th align="left" rowspan="2">Organ or tissue</th>
								<th align="center" colspan="8">Cellular type</th>
							</tr>
							<tr>
								<th align="left">Plasma cells</th>
								<th align="left">T-cells</th>
								<th align="left">Mast cells</th>
								<th align="left">Neutrophils</th>
								<th align="left">Macrofages</th>
								<th align="left">Fibroblasts</th>
								<th align="left">Smooth muscle cells</th>
								<th align="left">Endotelial cells</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Adipose subcutaneous</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Adipose visceral</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Breast</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Colon</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Heart muscle</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Kidney</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Liver</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Lung</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Pancreas</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Prostate</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Skeletal muscle</td>
								<td>✓</td>
								<td/>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Skin</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Stomach</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Testis</td>
								<td>⊗</td>
								<td>✓</td>
								<td>⊗</td>
								<td>⊗</td>
								<td>✓</td>
								<td>⊗</td>
								<td>⊗</td>
								<td>✓</td>
							</tr>
							<tr>
								<td>Tyroid</td>
								<td>✓</td>
								<td>✓</td>
								<td>⊗</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
								<td>✓</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn-group>
							<fn>
								<p>Cite: The Human Protein Atlas (Accessed September 11, 2022, at
									<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue+cell+type">http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue+cell+type</ext-link>).
								</p>
							</fn>
						</fn-group>
					</table-wrap-foot>
				</table-wrap>
			</sec>
		</sec>
		<sec id="j_psr-2022-0288_s_003">
			<label>3</label>
			<title>DPP-IV main functions: how versatile protein is DPP-IV!</title>
			<p>As we have said before, various DPP-IV homologues have been reported in bacteria [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_091">91</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_092">92</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_093">93</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_094">94</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_095">95</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_096">96</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_097">97</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_098">98</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_099">99</xref>], fungi [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_100">100</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_101">101</xref>] and mammals [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_040">40</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_102">102</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_103">103</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_104">104</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_105">105</xref>], where shows a very high expression
				<?index value="expression"?> at the brush border of the gastrointestinal tract [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_086">86</xref>]. This suggests that the ancestral function of DPP-IV might be nutritional via the partial digestion of peptides. It is reasonable to believe that, during the evolution, this putative pristine function (the mere digestion) moved into others more sophisticated (like regulating signals mediated by peptides) while organisms were increasing their complexity. In humans, this ancestral role may still be preserved in those DPP-IV from saliva, enterocytes, and bile [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_108">108</xref>].
			</p>
			<p>DPP-IV can act as peptidase, receptor/cell surface marker as well as a member of protein-protein interactions, depending on the cell type and the intracellular and extracellular conditions of those cells where it is expressed (
				<xref ref-type="fig" rid="j_psr-2022-0288_fig_002">Figure 2</xref>). It can be involved in complex process associated to cellular cycle such as the proliferation of normal smooth muscle cell [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_109">109</xref>] or the apoptosis of wide cellular types. To date, its main natural protein ligands are ADA [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_110">110</xref>], Na
				<sup>+</sup>/H
				<sup>+</sup> ion exchanger [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_111">111</xref>], FN [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_112">112</xref>], caveolin 1, and chymosin CXC receptor 4 (CXCR4) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_113">113</xref>]. Within the functions of DPP-IV, those related the implication of its peptidase activity in different pathologies have been the most studied to design new therapeutic schemes based on a specific and selective inhibition of hDPP-IV [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_010">10</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_014">14</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_016">16</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_018">18</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_020">20</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_026">26</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_030">30</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_035">35</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_114">114</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_115">115</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_116">116</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_117">117</xref>].
			</p>
			<p>In humans, several cytokines
				<?index value="cytokines"?>, growth factors and some neuropeptides
				<?index value="neuropeptides"?> have proline
				<?index value="proline"?> or alanine at its penultimate position, a structural motif that influences both their biological activities and protection against non-specific protelytic degradation [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_118">118</xref>]. Therefore, these peptides are natural substrates of DPP-IV, which further regulates their biological functions [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_119">119</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_120">120</xref>]. Natural substrates of DPP-IV include at least nine chymosins, glucagon like peptides 1 (GLP-1) and 2 (GLP-2), neuropeptide Y (NPY), peptide YY (PYY), substance P (SP), glucose insulinotropic peptide (GIP) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_110">110</xref>], human chorionic gonadotropin (hCG), human pancreatic polypeptide (hPP), corticotropin-like intermediate lobe peptide (CLIP), gastrin releasing peptide (GRP) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_121">121</xref>] and adenylate cyclase activating polypeptide (PACAP) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_122">122</xref>]. Soluble DPP-IV also can hydrolyze oxyntomodulin and stromal cell-derived factor 1 (SDF-1), also named as CXCL12 [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_123">123</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_124">124</xref>]. It has been suggested that hDPP-IV is capable of degrading collagen and thus facilitating cell traffic through the extracellular matrix (in this sense, it is known that DPP-IV is one of the key molecules during lymphocyte migration from the cortex to the medulla of the thymus) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_108">108</xref>]. Furthermore, DPP-IV from rat is known to possess gelatinase activity on collagen [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_125">125</xref>].
				<xref ref-type="table" rid="j_psr-2022-0288_tab_003">Table 3</xref> summarizes natural substrates of DPP-IV as well as their half-life time and kinetic behaviour versus DPP-IV. The large number of substrates and their differences in kinetics and half-life time gives a first idea of the complex network of interactions mediated by the enzymatic activity of DPP-IV.
			</p>
			<table-wrap id="j_psr-2022-0288_tab_003">
				<label>Table 3:</label>
				<caption>
					<p>Main natural substrates of human DPP-IV: region where hydrolysis occurs, half-life time and kinetic behaviour versus human DPP-IV.</p>
				</caption>
				<table frame="hsides">
					<colgroup>
						<col align="left"/>
						<col align="left"/>
						<col align="left"/>
						<col align="left"/>
						<col align="left"/>
					</colgroup>
					<thead>
						<tr>
							<th align="left">DPP-IV substrate</th>
							<th align="left">N-terminal sequence</th>
							<th align="left">Half-life time (min)</th>
							<th align="left">
								<italic>k</italic>
								<sub>cat</sub>/
								<italic>K</italic>
								<sub>M</sub> (10
								<sup>6</sup> M
								<sup>−1</sup> s
								<sup>−1</sup>)
							</th>
							<th align="right">References</th>
						</tr>
					</thead>
					<tbody>
						<tr>
							<td>CXCL12</td>
							<td>KPVSLSYRC-</td>
							<td>&lt;1</td>
							<td>5 ± 2</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>MDC69</td>
							<td>GPYGANMED-</td>
							<td>1.6</td>
							<td>4 ± 1</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>MDC67</td>
							<td>YGANMED-</td>
							<td>5.5</td>
							<td>0.5 ± 0.1</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>I-TAC</td>
							<td>FPMFKRGRC-</td>
							<td>2</td>
							<td>1.2 ± 0.1</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>IP-10</td>
							<td>VPLSRTVRC-</td>
							<td>4</td>
							<td>0.5 ± 0.1</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>Mig</td>
							<td>TPVVRKGRC-</td>
							<td>24</td>
							<td>0.4 ± 0.2</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>Eotaxin</td>
							<td>GPASVPTTC-</td>
							<td>30</td>
							<td>0.08 ± 0.01</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>RANTES</td>
							<td>SPYSSDTTP-</td>
							<td>4 00</td>
							<td>0.04 ± 0.01</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>LD78β</td>
							<td>APLAADTPT-</td>
							<td>6000</td>
							<td>0.003 ± 0.001</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_126">126</xref>]
							</td>
						</tr>
						<tr>
							<td>GLP-1</td>
							<td>HAEGTFTS-</td>
							<td>1.5–5</td>
							<td>0.42 ± 0.07</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_127">127</xref>], [
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_128">128</xref>], [
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_129">129</xref>], [
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>]
							</td>
						</tr>
						<tr>
							<td>GLP-2</td>
							<td>HADGSFSD-</td>
							<td>7</td>
							<td>0.09 ± 0.01</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_131">131</xref>]
							</td>
						</tr>
						<tr>
							<td>GIP</td>
							<td>YAEGTFIS-</td>
							<td>5–7</td>
							<td>0.14 ± 0.01</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_132">132</xref>]
							</td>
						</tr>
						<tr>
							<td>PACAP
								<sub>38</sub>
							</td>
							<td>HSDGIFTD-</td>
							<td>3.5</td>
							<td>0.73 ± 0.04</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_133">133</xref>]
							</td>
						</tr>
						<tr>
							<td>PACAP
								<sub>27</sub>
							</td>
							<td>HSDGIFTD-</td>
							<td>&lt;5</td>
							<td>0.05 ± 0.01</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_134">134</xref>]
							</td>
						</tr>
						<tr>
							<td>Oxyntomodulin</td>
							<td>HSQGTFTS-</td>
							<td>12</td>
							<td>0.15 ± 0.02</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_135">135</xref>]
							</td>
						</tr>
						<tr>
							<td>Secretin</td>
							<td>HSDGTFTS-</td>
							<td>4</td>
							<td>0.1</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_136">136</xref>]
							</td>
						</tr>
						<tr>
							<td>VIP</td>
							<td>HSDAVFTD-</td>
							<td>&lt;3</td>
							<td>Not reported</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_137">137</xref>]
							</td>
						</tr>
						<tr>
							<td>PHM</td>
							<td>HADGVFTS-</td>
							<td>Not reported</td>
							<td>0.25 ± 0.01</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>]
							</td>
						</tr>
						<tr>
							<td>GHRH</td>
							<td>YADAIFTN-</td>
							<td>7</td>
							<td>2.98 ± 0.3</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_138">138</xref>]
							</td>
						</tr>
						<tr>
							<td>GRP</td>
							<td>VPLPAGGG-</td>
							<td>1.5</td>
							<td>0.92 ± 0.12</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_139">139</xref>]
							</td>
						</tr>
						<tr>
							<td>SP</td>
							<td>RPKPQQFF-</td>
							<td>&lt;1–10</td>
							<td>Not reported</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_140">140</xref>]
							</td>
						</tr>
						<tr>
							<td>NPY</td>
							<td>YPSKPDNPG-</td>
							<td>39</td>
							<td>Not reported</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_141">141</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_142">142</xref>]
							</td>
						</tr>
						<tr>
							<td>PYY</td>
							<td>YPAKPEAPG-</td>
							<td>9.1</td>
							<td>Not reported</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_143">143</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_144">144</xref>]
							</td>
						</tr>
						<tr>
							<td>hCG</td>
							<td>SKEPLNCNP-</td>
							<td>1440</td>
							<td>Not reported</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_145">145</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_146">146</xref>]
							</td>
						</tr>
						<tr>
							<td>hPP</td>
							<td>APLEPVYPG-</td>
							<td>7</td>
							<td>Not reported</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_147">147</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_148">148</xref>]
							</td>
						</tr>
						<tr>
							<td>CLIP</td>
							<td>RPVKVYPNG-</td>
							<td>22</td>
							<td>Not reported</td>
							<td align="right">[
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_149">149</xref>,
								<xref ref-type="bibr" rid="j_psr-2022-0288_ref_150">150</xref>]
							</td>
						</tr>
					</tbody>
				</table>
			</table-wrap>
			<sec id="j_psr-2022-0288_s_003_s_001">
				<label>3.1</label>
				<title>DPP-IV and metabolism: an old and well-documented story</title>
				<p>Among the natural DPP-IV substrates, there are two incretine
					<?index value="incretine"?> hormones especially relevant the glucose metabolism in mammalian: GLP-1 and GIP [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_127">127</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_128">128</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_129">129</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_130">130</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_151">151</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_152">152</xref>] (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_003">Table 3</xref>). 85 % of the secreted GLP-1 never reaches the systemic circulation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_153">153</xref>] because it is rapidly degraded, with DPP-IV being the major responsible for its degradation (&gt;95 %) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_066">66</xref>]. Currently, one of the most recent and promising methods to treat T2DM is to use DPP-IV inhibitors, which are also called gliptins [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_022">22</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_023">23</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_024">24</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_025">25</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_026">26</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_027">27</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_028">28</xref>].
					<xref ref-type="table" rid="j_psr-2022-0288_tab_004">Table 4</xref> summarizes relevant aspects of most extensively commercialized gliptins worldwide, including several benefits beyond T2DM reported in animal models. In patients with T2DM, gliptins increase the half-life of GL-1 and GIP, thereby decreasing appetite, increasing feelings of fullness by decreasing gastric motility, inhibiting glucagon secretion, and, in longer terms, they reduce body weight and may even reverse some damage to the beta cells of the pancreas [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_022">22</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_023">23</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_024">24</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_025">25</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_026">26</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_027">27</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_028">28</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_029">29</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_177">177</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_178">178</xref>]. Recently, a direct correlation between glycosylated hemoglobin (HbA1c) and soluble DPP-IV levels has been observed [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_179">179</xref>]. Pérez-Macedonio et al. (2022) have found that DPP-IV from serum exosomes is higher in diabetic than in normal individuals; those exosomes also were smaller in T2DM patients [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_180">180</xref>]. More studies are required to know how relevant this particular finding may be for T2DM management.
				</p>
				<table-wrap id="j_psr-2022-0288_tab_004">
					<label>Table 4:</label>
					<caption>
						<p>Relevant aspects of the main marketed gliptins: molecular weight, 2D structure, main chemical interactions versus hDPP-IV, half-life time in humans, IC
							<sub>50</sub> versus hDPP-IV and benefits reported in animal models beyond T2DM benefits.
						</p>
					</caption>
					<table frame="hsides">
						<colgroup>
							<col align="left"/>
							<col align="right"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="right"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">DPP-IV inhibitor</th>
								<th align="right">Molecular weight (Da)</th>
								<th align="left">Chemical nature</th>
								<th align="left">2D structure</th>
								<th align="left">Inhibitor interacting functional groups</th>
								<th align="left">hDPP-IV interacting residues</th>
								<th align="right">Half-life time (h) (in humans)</th>
								<th align="right">IC
									<sub>50</sub> versus hDPP-IV (nM)
								</th>
								<th align="right">
									<italic>K</italic>
									<sub>i</sub> versus hDPP-IV (nM)
								</th>
								<th align="left">Benefits reported in animal models beyond T2DM benefits</th>
								<th align="right">References</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Sitagliptin</td>
								<td>407.3136</td>
								<td>β-amino acid based</td>
								<td>
									<inline-graphic xlink:href="graphic/j_psr-2022-0288_ingr_001.jpg"/>
								</td>
								<td>Trifluorophenyl
									<break/>Triazolopyrazine
									<break/>Trifluoromethyl
								</td>
								<td>Y
									<sup>631</sup> V
									<sup>656</sup> W
									<sup>659</sup> Y
									<sup>662</sup> Y
									<sup>666</sup> V
									<sup>711</sup>
									<break/>V
									<sup>207</sup> S
									<sup>209</sup> F
									<sup>357</sup> R
									<sup>358</sup>
									<break/>V
									<sup>207</sup> S
									<sup>209</sup> F
									<sup>357</sup> R
									<sup>358</sup>
								</td>
								<td align="right">12.4</td>
								<td>10.3</td>
								<td align="right">3.31</td>
								<td>Ameliorates fatty liver inflammation
									<break/>Attenuates oxidative and nitrative stress
									<break/>Inhibits adipose tissue inflammation
									<break/>Reduces atherosclerosis
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_024">24</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_154">154</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_155">155</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_156">156</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_157">157</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_180">180</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_405">405</xref>]
								</td>
							</tr>
							<tr>
								<td>Alogliptin</td>
								<td>339.3916</td>
								<td>Modified pyrimidinedione</td>
								<td>
									<inline-graphic xlink:href="graphic/j_psr-2022-0288_ingr_002.jpg"/>
								</td>
								<td>Cyanobenzyl
									<break/>Uracil ring
									<break/>Aminopiperidine
									<break/>Others
								</td>
								<td>Y
									<sup>631</sup> V
									<sup>656</sup> W
									<sup>659</sup> Y
									<sup>662</sup> Y
									<sup>666</sup> V
									<sup>711</sup>
									<break/>Y
									<sup>547</sup>
									<break/>E
									<sup>205</sup> E
									<sup>206</sup>
									<break/>Q
									<sup>553</sup> Y
									<sup>585</sup>
								</td>
								<td align="right">12.4–21.4</td>
								<td>4.9</td>
								<td align="right">–</td>
								<td>Ameliorates lipopolysaccharide-induced neuroinflammation
									<break/>Ameliorates chemical-induced nephrotoxicity
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_158">158</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_159">159</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_160">160</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_161">161</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_162">162</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>]
								</td>
							</tr>
							<tr>
								<td>Vildaliptin</td>
								<td>303.3993</td>
								<td>Cyanopyrrolidine</td>
								<td>
									<inline-graphic xlink:href="graphic/j_psr-2022-0288_ingr_003.jpg"/>
								</td>
								<td>OH
									<break/>NH
									<break/>Imidate
									<break/>CN
									<break/>CO
								</td>
								<td>H
									<sup>126</sup> S
									<sup>209</sup>
									<break/>E
									<sup>205</sup> E
									<sup>206</sup>
									<break/>Y
									<sup>547</sup>
									<break/>S
									<sup>630</sup>
									<break/>N
									<sup>710</sup>
								</td>
								<td align="right">2</td>
								<td>29.2</td>
								<td align="right">2.18</td>
								<td>Ameliorates chemical-induced liver fibrosis
									<break/>Atenuates inflammation during myocardial injury
									<break/>Ameliorates chemical-induced pulmonary fibrosis
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_163">163</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_164">164</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_165">165</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_166">166</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_167">167</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_405">405</xref>]
								</td>
							</tr>
							<tr>
								<td>Saxagliptin</td>
								<td>315.4100</td>
								<td>Cyanopyrrolidine</td>
								<td>
									<inline-graphic xlink:href="graphic/j_psr-2022-0288_ingr_004.jpg"/>
								</td>
								<td>NH
									<break/>OH
									<break/>CN
									<break/>Cyclopropane
									<break/>CO
								</td>
								<td>E
									<sup>205</sup> E
									<sup>206</sup>
									<break/>Y
									<sup>547</sup>
									<break/>Y
									<sup>666</sup>
									<break/>S
									<sup>630</sup>
									<break/>N
									<sup>710</sup>
								</td>
								<td align="right">4–6</td>
								<td>6.3</td>
								<td align="right">0.907</td>
								<td>Ameliorates endotelial senescence</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_168">168</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_169">169</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_170">170</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_405">405</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_406">406</xref>]
								</td>
							</tr>
							<tr>
								<td>Linagliptin</td>
								<td>472.5422</td>
								<td>Xanthine based</td>
								<td>
									<inline-graphic xlink:href="graphic/j_psr-2022-0288_ingr_005.jpg"/>
								</td>
								<td>Butinyl
									<break/>Uracil ring
									<break/>NH
									<sub>2</sub>
									<break/>Xanthine
									<break/>Quinazoline
								</td>
								<td>Y
									<sup>631</sup> V
									<sup>656</sup> W
									<sup>659</sup> Y
									<sup>662</sup> Y
									<sup>666</sup> V
									<sup>711</sup>
									<break/>Y
									<sup>547</sup>
									<break/>E
									<sup>205</sup> E
									<sup>206</sup> Y
									<sup>662</sup>
									<break/>Y
									<sup>547</sup>
									<break/>W
									<sup>629</sup>
								</td>
								<td align="right">12</td>
								<td>0.6</td>
								<td align="right">0.0098</td>
								<td>Reduces oxidative stress in autoimmune myocarditis
									<break/>Improves healing after antibody-induced nephritis
									<break/>Exerts neuroprotective effect after stroke
									<break/>Reduces inflammatory mediators, and collagen depositions in liver fibrosis with T2DM
								</td>
								<td align="right">[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_171">171</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_172">172</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_173">173</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_174">174</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_175">175</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_176">176</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_405">405</xref>]
								</td>
							</tr>
						</tbody>
					</table>
				</table-wrap>
				<p>Bo et al. (2021) have shown that, in diabetic mice deficient in apolipoprotein E, inhibition of DPP-IV via sitagliptin (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_004">Table 4</xref>) reduces apoptosis of the vascular musculature and, therefore, attenuates arteriosclerosis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_181">181</xref>]. It is also known that DPP-IV knockout mice do not develop fatty liver or insulin resistance after being subjected to hyperlipid diets. Even administrating normal diets, mice and rats lacking DPP-IV develop less body weight than normal ones during the 20 first weeks after the birth [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_182">182</xref>]. In humans, the administration of sitagliptin decreased the plasmatic levels of triglyceride and those of apolipoprotein B in patients with T2DM [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_183">183</xref>]. Rohman et al. (2021) have found higher levels of soluble DPP-IV in obese than in healthy people [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_184">184</xref>]. This trend was also observed in patients with non-alcoholic fatty liver disease [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_185">185</xref>]. These findings suggest some role (direct or indirect) of DPP-IV in regulating lipid metabolism. However, the possible mechanisms remain unclear.
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_003_s_002">
				<label>3.2</label>
				<title>DPP-IV and the immune system: a story of a dual role and multiple effects</title>
				<p>DPP-IV
					<?index value="DPP-IV"?> is identical to CD26
					<?index value="CD26"?> molecule, a surface marker in B and T lymphocytes. DPP-IV/CD26 has a double influence on the immune system due to the degradation of certain cytokines (including several chemokines) and due to its costimulatory effect via protein–protein interactions [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_016">16</xref>]. One of this relevant cytokines hydrolyzed by DPP-IV/CD26 is CXCL12 (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_003">Table 3</xref>), which is an important a chemoattractant for hematopoietic stem cells (HSC) and hematopoietic progenitor cells (HPC). CXCL12 can be truncated
					<italic>in vitro</italic> by DPP-IV/CD26. Once truncated, CXCL12 loses the ability to induce migration in purified mouse hematopoietic cells. Additionally, DPP-IV inhibition reduced the number of HPCs mobilized in mice treated with granulocyte colony-stimulating factor (G-CSF) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_186">186</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_187">187</xref>].
				</p>
				<p>Among the immune cellular lineages
					<?index value="lineages"?>, DPP-IV/CD26 is preferentially expressed on the subset of CD4
					<sup>+</sup> memory T cells, where it is up-regulated after T cell activation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_188">188</xref>], while naive CD4
					<sup>+</sup>CD45RA
					<sup>+</sup>, CD8
					<sup>+</sup>CD45RA
					<sup>+</sup> and CD4
					<sup>+</sup>CD25
					<sup>+</sup> T
					<sub>reg</sub> have low to moderate levels [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_189">189</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_190">190</xref>]. Besides being a marker of T cells activation, DPP-IV/CD26 is also associated with T cell signal transduction processes as a costimulatory molecule [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_191">191</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_192">192</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_193">193</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_194">194</xref>].
				</p>
				<p>DPP-IV/CD26 is able to interact with more than one isoform of CD45, which is a tyrosine phosphatase with critical role during T lymphocytes signal transduction. In peripheral blood T lymphocytes, DPP-IV/CD26 is associated with CD45RO isoform [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_195">195</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_196">196</xref>]. However, outside of lipid rafts in cord blood T cells, there is strong physical linkage of DPP-IV/CD26 and CD45RA isoform. According to Kobayashi et al. (2004), this interaction may be responsible for the attenuation of cord blood T-cell activation signaling through DPP-IV/CD26 axis, which may cause immature immune responses [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_197">197</xref>].
				</p>
				<p>Among protein-protein interactions involving DPP-IV, the best characterized is its interaction with ADA and the proliferation of T lymphocytes that this promotes [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_198">198</xref>]. ADA catalyzes the deamination of adenosine, a molecule whose high concentrations inhibit the proliferation of T lymphocytes [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_199">199</xref>]. ADA is only catalytically active when is associated with DPP-IV/CD26, hence the association of both proteins in considered a necessary condition to reduce extracellular concentrations of adenosine and thus facilitate T lymphocyte proliferation. This idea is reinforced by the fact that CD4
					<sup>+</sup> T lymphocytes, which are capable of migrating
					<italic>in vitro</italic>, express large amounts of DPP-IV/CD26 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_200">200</xref>].
				</p>
				<p>It is also known that Th1 subpopulation of CD4
					<sup>+</sup>
					<?index value="CD4+"?> lymphocytes expresses high amounts of DPP-IV/CD26, something that does not occur in the Th2 subpopulation. In addition, DPP-IV/CD26 is correlated with high levels of Th1-type cytokines: interleukin 6 (IL6), tumour necrosis factor α (TNF-α), and interferon γ (INF-γ) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_201">201</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_202">202</xref>]. Similarly, it has been observed that knockout mice for DPP-IV/CD26 display a poor Th1-type response, but have an upregulation of cytokines from Th2-type response, such as interleukins 4 (IL-4), 5 (IL-5), and 13 (IL-13). These findings suggest the importance of DPP-IV/CD26 during the regulation of Th1/Th2 balance. DPP-IV/CD26 also seems to be linked to the proliferation of the Th17 subpopulation, where it appears in 90 % of cells; hence the enzyme activity is considerably higher within this subpopulation compared to the Th1, Th2 and Th
					<sub>reg</sub> subpopulations [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_203">203</xref>]. Indeed, in DPP-IV/CD26 knockout mice, Yamada et al. (2016) have observed a considerable reduction in interleukins 17 (IL-17) and 21 (IL-21), which are typical of the Th17 response [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_204">204</xref>]. In addition, treatment with sitagliptin is capable of inhibiting the Th1/Th17 transition
					<italic>in vitro</italic> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_205">205</xref>].
				</p>
				<p>DPP-IV/CD26 is also expressed by dendritic cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_016">16</xref>], mobilized hematopoietic stem cells, macrophages, natural killer cells (NK) and B-lymphocytes [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_206">206</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_207">207</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_208">208</xref>]. However, in all these cases its possible regulatory functions remain poorly characterized [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_016">16</xref>, 
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_206">206</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_207">207</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_208">208</xref>]. According to Lee et al. (2016) inflammation might be stimulated by some unclear upregulation of toll-like receptors induced by DPP-IV [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_209">209</xref>]. Wronkowitz et al. (2016) have sugested that DPP-IV may be able to promote the upregulation of proinflammatory cytokines, such as monocyte chemoattractant protein-1 (MCP-1), interleukin 6 (IL-6) and 8 (IL-8), so inhibiting DPP-IV
					<italic>in vitro</italic> could prevent inflammation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_210">210</xref>]. Decreased serum DPP-IV activity and reduced production of proinflammatory cytokines have been observed after using sitagliptin during the lipopolysaccharide (LPS) induced lung in mice model [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_211">211</xref>].
				</p>
				<p>Recent studies suggest that DPP-IV/CD26 may have some relevance in the acceptance of allogeneic skin transplantation in mice because DPP-IV/CD26 knockout mice were much less vulnerable to transplant-associated necrosis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_212">212</xref>]. This decrease took place in a context of significantly low levels of IL-2, IL3, IL-6, IL-17 and INF-α. Low levels of Th17 and T(CD8
					<sup>+</sup>) cells, indicating that DPP-IV/CD26 deficiency compromises host cell activation and proliferation in the context of allogenic transplantation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_016">16</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_212">212</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_003_s_003">
				<label>3.3</label>
				<title>DPP-IV and viral infections: the deadly MERS-CoV and SARS-Cov-2</title>
				<p>Dysregulations of aminopeptidases
					<?index value="aminopeptidases"?> often arise during viral infections [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_213">213</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_214">214</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_215">215</xref>]. DPP-IV is not an exception.
				</p>
				<p>DPP-IV can mediate the entry of the Middle East respiratory syndrome virus (MERSCoV) into cell due to its junction to S1 domain from MERSCoV spike proteins [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_214">214</xref>]. However, DPP-IV active site and the binding site to MERS-CoV are in different positions within the 3D structure protein. For this reason, gliptins such as vildagliptin and sitagliptin have been ineffective to prevent MERS-CoV infection [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_216">216</xref>]. Anti-DPP-IV antibodies targeting the binding site of DPP-IV did block the virus access [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_217">217</xref>]. Soluble DPP-IV levels were higher in healthy people than in MERS patients [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_218">218</xref>]. This was correlated with stronger resistance to infection
					<italic>in vitro</italic>. Moreover, a recombinant soluble hDPP-IV could reduce the infection in mice [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_219">219</xref>]. These effects could be explained considering that a soluble DPP-IV can bind to MERS-CoV in plasma competitively via its binding site and thus preventing the virus access to healthy cells. Zhang et al. (2020) have propose that recombinant soluble DPP-IV could be a valuable tool in future MERS treatment [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_021">21</xref>], but more evidence is needed.
				</p>
				<p>Not a little has been discussed about the hypothetic role of DPP-IV during SARS-Cov-2 infection. When Vankadari and Wilce (2020) proposed that SARS-Cov-2 might interact with DPP-IV due to its S1 domain from spike glycoprotein, DPP-IV was postulated as a promissory therapeutic target [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_220">220</xref>]. However ulterior binding experiments did not show any interaction between RBD and DPP-IV. Instead of that, it was found that RBD could bind to angiotensin-converting enzyme 2 (ACE2) in bats or humans [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_221">221</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_222">222</xref>]. DPP-IV inhibition may help to reduce lung damage in general by improving glucose homeostasis and, in particular, by decreasing levels of inflammatory cytokines such as TNF-α, interleukin 1β (IL-1β) and IL-6 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_211">211</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_222">222</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_223">223</xref>]. Some authors report good results by inhibiting DPP-IV in patients with COVID-19 and T2DM [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_224">224</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_225">225</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_226">226</xref>]. Other authors, however, reported that there was no beneficial outcome after DPP-IV inhibition treatments [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_227">227</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_228">228</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_229">229</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_230">230</xref>]. As we see, these results are controversial; therefore, more rigorous studies are needed to achieve strong conclusions. During clinical trials, inclusion criteria and baseline characteristics (comorbidities, inflammation levels, etc.) must be meticulously observed to achieve fully comparable results.
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_003_s_004">
				<label>3.4</label>
				<title>DPP-IV and asthma: promising evidences (but in mice)</title>
				<p>DPP-IV is upregulated in airway from asthma patients.
					<italic>In vitro</italic> assays have strongly suggested that DPP-IV stimulates the proliferation of smooth muscle cells (SMCs), bronchial endothelial cells, and lung fibroblasts [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_231">231</xref>]. On the other hand, studies carried out in asthmatic children indicate that there is a positive correlation between IL-13 mRNA and DPP-IV mRNA levels [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_232">232</xref>]. In fact, IL-13 was found to be capable of inducing DPP-IV mRNA. IL-13 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_233">233</xref>] has been found to be strongly associated with the allergy and inflammation characteristic of asthma. Considering that IL-13 is produced by Th2 cells, these findings suggest that DPP-IV is not only capable of influencing asthma through SMC and fibroblast proliferation, but via T cell dysregulation. DPP-IV inhibitors have been tested against asthma in mice model. By decreasing the production of IL-13 and/or fibrotic-related factors such as TGF-β [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_234">234</xref>], TLR4 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_236">236</xref>] and NF-κB, they can ameliorate airway remodelling [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_235">235</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_236">236</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_003_s_005">
				<label>3.5</label>
				<title>DPP-IV and pulmonary hypertension: a field not very explored</title>
				<p>An abnormal proliferation of SMCs characterizes pulmonary hypertension [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_237">237</xref>]. In that context, DPP-IV is overexpressed in pulmonary arterial SMCs. DPP-IV inhibition have given protective effects during the arterial remodeling in some models of pulmonary hypertension
					<?index value="hypertension"?>. Since NF-κB andAkt/mTORC1 pathways were demonstrated to mediate the hypoxia-induced pulmonary hypertension and the development of pulmonary arterial SMCs [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_238">238</xref>], it has been proposed that a possible modulation of Akt pathway by DPP-IV inhibition might be implied [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_239">239</xref>]. Other authors suggest that the extended half-live time of GLP-1 may be the main responsible of those protective effects [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_240">240</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_003_s_006">
				<label>3.6</label>
				<title>DPP-IV and pulmonary fibrosis: is this a story of inflammation, senescence or both?</title>
				<p>Increased activity and soluble levels of DPP-IV have been associated with chronic low-grade inflammation in both experimental and clinical situations [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_240">240</xref>]. DPP-IV was found to be a marker of activated fibroblasts. Several studies strongly suggest that DPP-IV inhibition attenuated liver fibrosis, dermal fibrosis and kidney fibrosis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_241">241</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_242">242</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_243">243</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_244">244</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_245">245</xref>].
				</p>
				<p>In several models of pulmonary fibrosis, vasculature endothelial cells (VECs) have been observed to upregulate DPP-IV [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_246">246</xref>]. Recently, the inhibition of DPP-IV with vildagliptin (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_003">Table 3</xref>) has been successful in attenuating the disease in a murine model of pulmonary fibrosis. This is probably due to a decrease in the inflammatory environment that is obtained by inhibiting DPP-IV, as well as a possible decrease in extracellular matrix protein (ECM) secretion [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_247">247</xref>]. Another DPP-IV inhibitor (vildagliptin) has given promising results in murine model of pulmonary fibrosis. Evidence suggests that vildagliptin inhibits the endothelial/mesenchymal transition both
					<italic>in vitro</italic> and
					<italic>in vivo</italic> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_246">246</xref>], thereby alleviating fibrosis. The cause may be related not only to the fact that DPP-IV is an important marker of endothelial senescence [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_248">248</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_249">249</xref>], but also to the correlation that has been observed between DPP-IV inhibition and decreased levels of other characteristic molecules of senescence such as p21 and p53 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_250">250</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_251">251</xref>]. However, even in animal models it is still not clear whether the decrease in fibrosis necessarily goes through an anti-senescence mechanism. Effects of DPP-IV inhibition in patients with pulmonary fibrosis are unclear nowadays and new experiments are needed to achieve more refined conclusions [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_021">21</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_003_s_007">
				<label>3.7</label>
				<title>DPP-IV and cardiovascular system: cardio-protector effects of its inhibitions and possible causes</title>
				<p>Several studies have suggested some roll to DPP-IV during the pathogenesis of left ventricular dysfunction, as well as during the heart failure [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_252">252</xref>]. Kadoglou et al. (2021) reports that, regardless the presence of TDM2, soluble DPP-IV is higher in individuals with coronary artery disease [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_253">253</xref>]. Interestingly, linagliptin (but not other gliptins like saxagliptin, alogliptin or sitaglipti) facilitate the recovery after ischemia reperfusion, most likely by promoting the endothelial activation of Akt/eNOS way, and, as a consequence, leading to the pivotal regulator of myocardial contractility: the cyclic guanosine monophosphate (cGMP)-mediated activation of phospholamban [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_254">254</xref>]. Several evidences support that inhibition DPP-IV can give cardiovascular protection via a double system of implications. By inhibiting GLP-1 degradation, DPP-IV inhibitors carry out metabolic improvements that indirectly preserve cardiovascular
					<?index value="cardiovascular"?> system. By preventing the hydrolysis of SDF-1α, DPP-IV inhibitors causes endothelial repair and promotes an anti-inflammatory response to ischemia
					<?index value="ischemia"?> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_255">255</xref>].
				</p>
			</sec>
		</sec>
		<sec id="j_psr-2022-0288_s_004">
			<label>4</label>
			<title>DPP- IV and cancer: friend or foe?</title>
			<p>As we mentioned earlier, carcinogenesis
				<?index value="carcinogenesis"?> and tumour
				<?index value="tumour"?> evolution are strongly influenced by the abundance of extracellular regulatory peptides, which depends on the proteolytic rate [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>]. During carcinogenesis, a tumour microenvironment (defined by and specific for the tissue in which the tumourigenic process was initiated) is established and contributes to the tumour development and growth [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_256">256</xref>]. The recruitment of immune and other cell types into this microenvironment and their interactions within it are dependent upon a complex display of cytokines
				<?index value="cytokines"?> and other signaling mediators [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_257">257</xref>]. Proteolysis mediated by DPP-IV could have strong effects on the availability of growth promoting or inhibitory factors in some microenvironments [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_003">3</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_090">90</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_258">258</xref>]. In addition, DPP-IV can influence extracellular matrix interactions [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_041">41</xref>]. Therefore, the loss or lack of DPP-IV expression, and its expression or that of its ligands in the tumour neighboring cells can be crucial for the progression and metastasis
				<?index value="metastasis"?> in several tumour types. To date, evidences are multifactorial, and their interpretations depend on the properties of the carcinogenesis affected tissues.
			</p>
			<p>DPP-IV is downregulated in melanoma [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_259">259</xref>], as well as in several types of lung cancer [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_260">260</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_262">262</xref>], endometrial adenocarcinoma [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_263">263</xref>], and prostate cancer [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_264">264</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_265">265</xref>], [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_266">266</xref>]. Soluble DPP-IV is found to be lower in patients with oral [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_267">267</xref>] and colorectal cancers [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_268">268</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_269">269</xref>]. By contrast, DPP-IV is upregulated in several prostate
				<?index value="prostate"?> cancers [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_263">263</xref>], various primary lung
				<?index value="lung"?> tumours [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_270">270</xref>], thyroid
				<?index value="thyroid"?> carcinoma [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_271">271</xref>], dermal basal cell carcinoma [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_272">272</xref>], esophageal adenocarcinoma [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_273">273</xref>], ovarian
				<?index value="ovarian"?> carcinoma [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_274">274</xref>], gastric cancer [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_275">275</xref>], B-cells chronic leukemia [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_276">276</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_277">277</xref>] and certain types of T cell cancers (T-cell lymphoblastic lymphoma
				<?index value="lymphoma"?>, anaplastic large cell lymphomas and T-cell acute lymphoblastic leukemia
				<?index value="leukemia"?>) [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_041">41</xref>,
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_278">278</xref>].
			</p>
			<p>In general, these differences in DPP-IV effects might be attributed to the tumour microenvironment as well as to the complex and multiple functions of DPP-IV [
				<xref ref-type="bibr" rid="j_psr-2022-0288_ref_272">272</xref>].
			</p>
			<sec id="j_psr-2022-0288_s_004_s_001">
				<label>4.1</label>
				<title>DPP-IV and leukemia: a protein often linked to worst prognosis</title>
				<p>The upregulation of DPP-IV/CD26 protein, have been reported on B-chronic lymphocytic leukemia cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_276">276</xref>]. However, are the pathologies involving T cells were dysregulations of this enzyme/antigen have been more extensively documented. The expression of DPP-IV seems to be correlated with a worse prognosis in several subtypes of T-cell neoplasms
					<?index value="neoplasms"?>. This protein is upregulated in aggressive subtypes of non-Hodgkin’s lymphomas
					<?index value="lymphomas"?> (NHL) such as T-acute lymphoblastic leukemia (ALL), T-lymphoblastic lymphoma (LBL) and T-cell CD30
					<sup>+</sup> anaplastic large cell (ALC) lymphoma. Expression of DPP-IV/CD26 and expression of CD40L were mutually exclusive on cell surface; CD40L expression was found in gentler diseases. By contrast, the expression of DPP-IV/CD26 in T-cell LBL/ALL was associated with a significant worse survival [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_279">279</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_280">280</xref>]. Similarly, DPP-IV/CD26 expression causes a more aggressive course in T-cell large granular lymphocyte leukemia (T-LGLL), which is a clonal disorder characterized by infiltration of bone marrow, liver and spleen with large granular lymphocytes (LGL) (typically CD3
					<sup>+</sup>, CD16
					<sup>+</sup>, CD57
					<sup>+</sup>). DPP-IV/CD26
					<sup>+</sup> patients developed severe neutropenia, and were more expose to develop infections. In contrast, patients with low or absent DPP-IV/CD26 expression had a gentler clinical course [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_281">281</xref>]. These findings suggest that DPP-IV might be a promissory molecular marker of malignancy
					<?index value="malignancy"?> in patients affected by above-mentioned pathologies.
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_002">
				<label>4.2</label>
				<title>DPP-IV in skin malignancies: a protein that vanishes in melanoma and rises in keratinocyte tumours</title>
				<p>DPP-IV is expressed by melanocytes both
					<italic>in vitro</italic> and
					<italic>in vivo</italic>, but not by the melanoma itself. The loss of expression seems to occur at a very early stage during melanocyte
					<?index value="melanocyte"?> transformation into melanoma. Wesley et al. [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_259">259</xref>] demonstrated that DPP-IV transfected melanoma cells displayed neither tumourigenicity nor anchorage-independent growth. Both observations depended on the enzymatic activity. Additionally, the protein re-expression led to the reacquisition of growth dependency on exogenously provided growth factors [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_041">41</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_259">259</xref>]. Tumour growth was reduced and a relationship was observed between levels of expression and grade of inhibition. Cells expressing DPP-IV showed a more organized growth and sheet-like appearance as opposed to parental melanoma cells. No change was observed in the logarithmic phase. However, cells re-expressing DPP-IV had a longer lag period before entering the logarithmic growth phase, and the growth was inhibited when cells reached a confluent state. Congruent results were obtained by Pethiyagoda et al. (2001). They reported that DPP-IV restitution inhibits cellular invasion of malignant melanoma cell lines [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_282">282</xref>]. These evidences suggest that DPP-IV might be act as a tumour suppressor in melanoma. Interestingly, Rivera et al. (2020) have detected activity of extracellular DPP-IV on the surface of MEWO melanoma cell line. This finding is the first time that DPP-IV expression in melanoma cell lines is reported. Furthermore, they proved that bestatin and bacitracin inhibits DPP-IV through non-competitive and competitive mechanisms, respectively. Treatments with bestatin or bacitracin were assayed on MEWO cells and they reduced the cellular viability via DNA fragmentation. More studies in more melanoma cell lines are required to know if this is a unique exception or is not [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_035">35</xref>].
				</p>
				<p>DPP-IV is upregulated in human psoriasis
					<?index value="psoriasis"?> plaques and has been associated with inflammatory infiltrates in neoplasic skin. Novelli et al. (1996) have proposed that DPP-IV play a role as antigen for keratinocyte
					<?index value="keratinocyte"?> activation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_283">283</xref>]. Additionally, several gliptins have been tested for the treatment of psoriasis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_284">284</xref>]. However, most of the melanomas are DPP-IV-.
				</p>
				<p>Experiments in InvEE transgenic mice, bearing keratinocytes with constitutively activated MAP kinase 1 (MEK-1), evidenced the upregulation of DPP-IV in epithelial tumour of keratinocytes. This is particularly notorious at the edge of intercellular contact. Noteworthy, although dermal fibroblasts associated to tissue damage also shown upregulated DPP-IV, DPP-IV was downregulated in the tumour stroma. Interestingly, DPP-IV upregulation in dermal fibroblasts was promoted by addition of interleukin-1α (IL-1α). DPP-IV inhibition reduced tumour growth. In addition, tumour incidence was decreased by blocking IL1α activity in healthy individuals; tumour delayed appearance also was reported [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_028">28</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_003">
				<label>4.3</label>
				<title>DPP-IV in lung cancer: a voluble expression pattern</title>
				<p>DPP-IV was demonstrated to be broadly distributed in the lung parenchyma and the surface of the epithelium, vascular endothelium, and fibroblasts of human bronchi, indicating that DPP-IV may play a significant role in regulating physiological and pathological functions in the lung [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_285">285</xref>].
				</p>
				<p>Lung cancer development relies on the confluence of different growth factors, such as the NPY and SP, which are DPP-IV substrates. The excision and subsequent inactivation of NPY abrogate its growth promoting effects [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_041">41</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_286">286</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_287">287</xref>]. This suggests that the loss of the DPP-IV proteolytic activity would promote growth of certain lung tumour cells. Nevertheless, DPP-IV could be acting not only enzymatically, but regulating other processes or signaling pathways independent of its enzyme activity. In addition, other surface molecules such as the fibroblasts activation protein (FAP), which its stromal abundance correlates with increased tumour cell survival, could be involved [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>]. DPP-IV overexpression has been reported in lung squamous cells carcinoma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_270">270</xref>] as well as in lung adenocarcinoma cells from human (H460) and mouse (LLC) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_288">288</xref>]. By contrast, marginal DPP-IV expression has been measured in other lung adenocarcinoma line (A549) as well as in a cell line from squamous cells carcinoma (SK-MES-1) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_262">262</xref>]. In this last case, some variations arose from the history of the carcinogenic process. A549 exhibited an 8–10 times decrease in the overall DPP-IV activity, with a 93 % of surface relative activity. This indicates a fast externalization of the recently synthesized protein (probably due to preserved secretory activities inherent to alveolar type II pneumocytes, the original cell type from this cell line). The proteolytic activity of DPP-IV on SKMES-1 decreased, following a granular intracellular deposition pattern with a 35 % surface relative activity; this is consistent with the low secretory potential of SKMES-1 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_262">262</xref>]. These observations suggest that the distribution of the enzyme during carcinogenesis correlates with alterations that may originate in the intracellular membrane trafficking system.
				</p>
				<p>Literature reports large-cells and small-cells carcinomas with null or marginal DPP-IV expression [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_260">260</xref>]. In non-small lung cell carcinoma, such lack occurs both at mRNA and protein expression levels [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>], due to frequent losses of chromosome 2q, which, as we mentioned above, bears the DPP-IV loci [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_289">289</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_290">290</xref>]. Similarly, Dimitrova et al. (2012) have found that DPP-IV activity is lower in human adenocarcinoma
					<?index value="adenocarcinoma"?> cells and in squamous cells from carcinoma than in normal fetal lung-derived P cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_291">291</xref>].
				</p>
				<p>Wesley et al. (2004) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>] have reported that the human non-small cells lung cancer cell lines H28, H226, H441, SK-LUC-8, SK-LUC-17, SK-LUC-13, SK-LUC-9 and SW-900 show diminished DPP-IV expression. The restitution of DPP-IV in SK-LUC-8, particularly attractive by its undetectable expression of the enzyme, significantly reverted the malign phenotype
					<italic>in vitro</italic>, independent of the enzyme activity. Cells loss their long and slightly dendritic cells to adopt cylindrical or flat epithelial shape. Growth in culture is inhibited, with a lag for the entry in the logarithm phase, and there is inhibition of anchoring-dependent growth measurable by a decreased ability (about 50–70 %) to form colonies in soft agar. These changes induced by DPP-IV restitution reduced
					<italic>in vitro</italic> migration and cell confluence (probably due to the appearance of density inhibition at a confluence higher than 50 %). This was also related to the increased expression of p21, a drastic cell cycle arrest on G1 and apoptosis induction (possibly due to the inactivation of unknown peptides). Simultaneously, there was a high expression of CD44 and FAP [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>], two cell surface proteins associated to suppressed growth and suppressed metastasis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_292">292</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_293">293</xref>]. The subsequent implantation of these cells on athymic mice allowed to corroborate tumour growth (as expected) compared to the control, which was implanted with tumour cells from the same line but untransfected with DPP-IV [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_004">
				<label>4.4</label>
				<title>DPP-IV and endometrial adenocarcinoma: an unsolved question</title>
				<p>Khin et al. (2003) have reported that the correlation between endometrial carcinoma and the expression/activity of DPP-IV stage is negative, suggesting possible anti-proliferative effects due to DPP-IV hydrolysis of local proproliferative peptides from microenvironment such as the chemokine RANTES (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_003">Table 3</xref>), which is one of the natural ligands of CCL5 receptor [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_263">263</xref>]. However, Yang et al. (2017) have described a positive correlation between DPP-IV levels and tumour cell proliferation, invasion, and malignancy. DPP-IV upregulation
					<italic>in vitro</italic> leaded to activated HIF-1alpha/VEGF signaling and stimulated the expression of pro-proliferative IGF-1. Growth was decreased in DPP-IV knockdown tumour cells; the use of DPP-IV inhibitors also result in less proliferation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_294">294</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_005">
				<label>4.5</label>
				<title>DPP-IV in ovarian cancer: the importance of fibronectin</title>
				<p>Kikkawa et al. (2003) demonstrated
					<italic>in vitro</italic> the presence of DPP-IV in ovarian carcinoma and its influence on tumour adhesion to the mesothelium. They showed that SKOV-3 cells (a DPP-IV-knockout line) attached more efficiently to mesothelial cells when DPP-IV expression was restituted. Adhesion was dose-dependent
					<italic>in vitro</italic>. This suggests that DPP-IV is a key protein during the processes of tumour cell adhesion to the mesothelium, proliferation and invasion. Ovarian carcinoma and the peritoneal mesothelium (where this tumour spreads out) also express DPP-IV, and high amounts of soluble FN [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_274">274</xref>]. Notice that ascites and the malignant serum from ovarian tumours have high levels of FN. This leads to assume that DPP-IV captures high amounts of FN from these fluids. As a result, carcinoma cells would develop an easy adhesion capacity to either endothelium or mesothelium, once displaying FN in amounts enough to bind the DPP-IV molecules on these two layers [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_274">274</xref>].
				</p>
				<p>Surprisingly, nude mice inoculated with SKOV-3 tumour cells reconstituted with DPP-IV showed lower peritoneal dissemination and longer survival than those receiving the non-reconstituted cell line [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_295">295</xref>]. Although the causes for such a phenomenon is not completely understood, it would be possible that high DPP-IV levels would promote a tight cell to cell adhesion, which may limit the ability of the carcinoma cells to detach from the tumour and spread away from it. Nevertheless, when they detach, DPP-IV expressed by the tumour and the mesothelium facilitate the invasion into the peritoneum [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_274">274</xref>].
				</p>
				<p>Taking into account the evidence in both humans and mice cells, we can hypothesize that dissemination might depend on the tumour possessing sufficient amounts of DPP-IV to bind FN, but not enough to promote strong cell adhesion. In addition, it could be predicted that the sustained and increased activity of the enzyme could influence indirectly that event, in spite of its unapparent involvement in cell adhesion. Further experiments
					<italic>in vitro</italic> and
					<italic>in vivo</italic> are needed to accept or reject those assumptions.
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_006">
				<label>4.6</label>
				<title>DPP-IV in prostate cancer: a possible dependency on DPP-IV levels</title>
				<p>Some evidences suggest that prostate cancer metastasis is associated to the loss of DPP-IV (above 50 % in most of the cases) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_264">264</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_265">265</xref>] and to the increase of the activity of basic fibroblast growth factor (bFGF), which is a potent mitogen and pro-angiogenic factor [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_296">296</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_297">297</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_298">298</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_299">299</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_300">300</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_301">301</xref>]. bFGF is expressed as two isoforms: one cytoplasmic of low molecular weight and another one nuclear of high molecular weight. bFGF transduces through the extracellular signal-regulated ERK1/2 pathway, promoting cell cancer progression and migration [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_302">302</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_303">303</xref>]. Besides, ERK1/2 activation by bFGF during cell migration and angiogenesis increases the production of urokinase-type collagen activator (uPA), a serine peptidase catalyzing the conversion of plasminogen into plasmin, and further promoting metastasis through the destruction of the extracellular matrix [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_304">304</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_305">305</xref>]. It has been reported that DPP-IV restitution in the DU-145 cell line blocks the nuclear translocation of bFGF and the expression of both isoforms, abrogating the stimulation through the MAP-ERK1/2 pathways. This leads to a decrease in uPA mRNA levels, the acquisition of flat and cube-like cell shapes, the loss of contact and anchoring-dependent growth and tumour migration. Although the mechanism by which DPP-IV affects bFGF production remains to be elucidated, it is speculated that in a normal cell, DPP-IV excises its amino terminal region, causing its confinement within the nucleus. That excision could be the first step for bFGF degradation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_266">266</xref>]. Similarly, a direct association may occur with bFGF. This may interfere in post-transcriptional modification such as the methylation of the amino terminal region, which is required for its nuclear confinement [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_306">306</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_307">307</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_308">308</xref>]. The expression of DPP-IV in DU-145 cells also stimulated transcription of the p27 gene, an inhibitor of cyclin-dependent kinases, halting the cell cycle at the G2/M transition and increasing apoptosis from 24 to 34 % [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>].
				</p>
				<p>Other authors reported a DPP-IV increased expression in human prostate cancer tissue and, to lesser extent, in adjacent benign hyperplastic glands [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_309">309</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_310">310</xref>]. A small study demonstrated a positive correlation between DPP-IV expression and prostatic specific antigen (PSA) levels and cancer stage, suggesting that DPP-IV may represent a negative prognostic marker in prostate cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_309">309</xref>].
				</p>
				<p>As we can see, in the case of prostate cancer, evidences lead to a complex and contradictory picture when we are talking about DPP-IV implications. Different authors use cellular lines, animal models or human studies, so output information is difficult to compare most of the tie. However, we can prudently presume that DPP-IV upregulation might help the tumour itself but not the metastasis. Benign prostate tumours often progresses to a fatal hormone
					<?index value="hormone"?> refractory stage through a process considered to be mediated by the overexpression of peptide growth factors that trigger alternative mitogenic signals [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_296">296</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_297">297</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_298">298</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_299">299</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_300">300</xref>]. As described, under normal physiological conditions, DPP-IV participates in cell growth regulation and differentiation by regulating some of those growth factors [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_311">311</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_312">312</xref>] (e.g., the factor 1-derived stromal chemokine (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_003">Table 3</xref>)). Therefore, it overregulation might promote carcinogenesis process. However, since bFGF is a DPP-IV substrate that promotes angiogenesis, DPP-IV upregulation leads to its hydrolysis and, therefore, to the loss of an important source of angiogenesis, which is a crucial during metastasis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_002">2</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_007">
				<label>4.7</label>
				<title>DPP-IV and thyroid gland: a very useful tool to discriminate among neoplasias, papillary and follicular carcinomas</title>
				<p>Papillary and follicle thyroid
					<?index value="thyroid"?> carcinomas are characterized by a high expression of DPP-IV. This contrasts to benign neoplasias, which are markedly negative to this protein [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_271">271</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_313">313</xref>]. Furthermore, in papillary thyroid carcinomas, the association of high DPP-IV expression with BRAF gene mutation, cancer cell invasion, and a more aggressive course of the disease has been reported [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_314">314</xref>].
				</p>
				<p>DPP-IV expression increases during benign adenoma
					<?index value="adenoma"?> progression to malignancy, a fact demonstrated by its higher expression in follicle adenoma displaying incomplete capsule invasion compared to that without capsular invasion [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_315">315</xref>]. The expression of the enzyme is so distinctive at both stages. Therefore, currently DPP-IV levels are considered the most effective molecular marker to discriminate between follicle carcinoma
					<?index value="carcinoma"?> and follicle adenoma. Results are even more precise that those obtained via canonical variables such as the patient age, lesion size, ultrasound images and serum thyroglobulin levels [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_316">316</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_008">
				<label>4.8</label>
				<title>DPP-IV and neural tissue: gliomas, meningiomas and neuroblastomas</title>
				<p>Healthy human brain tissues have a DPP-IV-like activity mostly from DPP8 and DPP9. Otherwise, in glioma (which is the most significant tumour type in the central nervous system, with more than 50 % of the tumours) this enzyme activity has been correlated not only with decreased DPP8
					<?index value="DPP8"?> and DPP9
					<?index value="DPP9"?> activities, but with an increased DPP-IV and FAP
					<?index value="FAP"?> expression in parenchymal and vascularized areas. At the same time, a high expression of CXCR4, receptor for CXCL12, has been found [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_317">317</xref>]. As we mentioned, CXCL12 is one of the endogenous substrates of DPP-IV (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_003">Table 3</xref>). While it remains non-hydrolyzed by DPP-IV, it is the main chemokine that mediates the survival of glioma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_318">318</xref>]. Once is hydrolyzed, CXCL12 loses its chemotactic properties and could even act as CXCR4 antagonist [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_319">319</xref>]. The notorious CXCR4 upregulation seen in glioma would seem to compensate DPP-IV overexpression, suggesting a potential cross-regulation between both molecules [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_317">317</xref>]. Similarly, there is DPP-IV upregulation in high-grade astrocytic tumours [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_278">278</xref>].
				</p>
				<p>Type I and atypical type II of WHO meningiomas express DPP-IV at very low levels. In contrast, they have increased DPP8 and DPP9 activities. The differential DPP-IV expression in meningiomas and gliomas
					<?index value="gliomas"?> could be caused by their embryonic origin and, paradoxically, could be one of the underlying causes for the lowest aggressiveness of meningiomas compared to gliomas. In fact, meningiomas express normal levels of CXCR4 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_320">320</xref>]. Thus, the putative ‘compensatory effect’ does not seem to be activated due to insufficient DPP-IV activity, a mechanism that, as we mentioned earlier, is found in glioma through the CXCL12 activation pathway.
				</p>
				<p>Several human neuroblastoma cell lines have shown notoriously low DPP-IV expression.
					<italic>In vitro</italic> DPP-IV re-expression leads to the loss of the malignant phenotype: restitution of neuron-like or flat epithelium morphology; inhibition of proliferation; caspase-activated apoptosis
					<?index value="apoptosis"?>; decreased Akt phosphorylation; decreased de matrix metalloproteinase 9 (MMP9) activity and decreased cell migration. Low proliferation seems to be caused by the restitution of differentiation as evidenced by morphological changes. The loss of migration activity may be related to the simultaneous contribution of morphology recovery and the underregulation of MMP9, which is a proangiogenic factor displaying gelatinase activity on the extracellular matrix [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_321">321</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_009">
				<label>4.9</label>
				<title>DPP-IV and mesothelioma: a promising field to be explored</title>
				<p>Among the very well established highly aggressive cancers with poor prognosis we can find mesothelioma
					<?index value="mesothelioma"?>. This type of cancer is resistant to traditional therapies such as surgery, radiotherapy and chemotherapy [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_322">322</xref>]. Immunohistochemical studies reveal an overexpression of DPP-IV in mesothelioma tissues and cell lines [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_323">323</xref>]. Moreover, DPP-IV is expressed in mesothelioma cancer stem cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_324">324</xref>]. Experiments carried out by Ghani et al. (2011) suggest that DPP-IV protein is an important marker of mesothelioma capabilities [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_325">325</xref>]. As we can see, evidence points to DPP-IV as a possible biomarker and/or target. More studies are required to explore those possibilities.
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_010">
				<label>4.10</label>
				<title>DPP-IV and hepatocarcinoma: a rising not only in cancer, but precancerous pathologies</title>
				<p>DPP-IV is upregulated in hepatocellular carcinoma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_326">326</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_327">327</xref>] and high serum DPP-IV activity is associated with worse patient survival [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_031">31</xref>]. Increased DPP-IV expression might contribute to the cancer progression by converting NPY to the Y5 receptor agonist NPY (3–36) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_326">326</xref>]. DPP-IV levels often are associated with tumour size, stage, and proliferation capacity in hepatocellular cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_328">328</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_329">329</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_330">330</xref>].
				</p>
				<p>More than 20 years ago, it was reported that the inhibition of DPP-IV activity in human hepatoma cells suppressed tyrosine kinase activity and caused anti-apoptotic effects [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_331">331</xref>]. However, during the last decade, Yamamoto et al. (2012) described cases where, after four weeks of treatment with DPP-IV inhibitors, they observed a considerable regression of hepatocarcinoma
					<?index value="hepatocarcinoma"?> in patients with chronic viral hepatitis C (HCV). Although it is unknown whether inhibitors are directly involved in the regression of hepatocarcinoma, a large infiltration of CD8
					<sup>+</sup> T cells has been observed around tumour tissue [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_029">29</xref>], suggesting that the inhibition could have promoted the immune response, previously diminished by chronic HCV infection [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_332">332</xref>].
				</p>
				<p>In addition, studies in murine hepatocarcinoma models showed that DPP-IV downregulation (both genetic and catalytic) prevented tumour progression [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_328">328</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_329">329</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_330">330</xref>] due to eosinophil recruitment [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_328">328</xref>] and downregulation of angiogenesis and chymosin CCL2 [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_031">31</xref>]. Eosinophil recruitment was enabled by the increased half-life time of CCL11, which is a known-eosinophil chemo-attractant that is normally degradated by DPP-IV [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_328">328</xref>].
				</p>
				<p>Gliptins
					<?index value="Gliptins"?> also ameliorated chemically induced liver fibrosis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_166">166</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_333">333</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_334">334</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_335">335</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_336">336</xref>], a well-known risk factor for hepatocellular carcinoma, in animal models. Additionally, vildagliptin prevented diethylnitrosamine-induced carcinogenesis in liver of rats fed a high-fat diet. Increased vascularization and macrophage, but not the T-cell or NK-cell infiltration of hepatic nodules, together with lung metastases, were observed in animals fed a high-fat diet, and these effects were suppressed by vildagliptin. Interestingly, vildagliptin normalized the high-fat diet-induced elevation of plasma CCL2, a potential contributor to the proangiogenic effects [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_031">31</xref>].
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_011">
				<label>4.11</label>
				<title>DPP-IV and gastro-oesophageal junction adenocarcinoma (EGJA): a shortcut to early diagnosis</title>
				<p>As its name indicates, the adenocarcinoma of gastro-oesophageal junction (EGJA) develops in the transition zone between the oesophagus and the stomach. Its incidence has grown in recent decades within Western countries and in Japan; for both cases, a sustained increase is expected during the following years. Although the initial stages of EGJA can be removed via endoscopic sub-mucosal dissection with good results [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_337">337</xref>], the prognosis for adenocarcinomas in the esophagus area is very often quite poor for advanced stages [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_338">338</xref>], hence early detection is necessary to remove the tumour on time.
				</p>
				<p>Traditional imaging methods often fail to detect EGJA because tumour develops in a “borderline” area and it exhibits a similar morphology to that of surrounding healthy tissue. In addition, many times the tumour is below the squamous epithelium [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_339">339</xref>]. Fortunately, Yamamoto et al. (2020) created a procedure that takes advantage of the differential DDP-IV expression in the context of the EGJA (where it is sufficiently high) and in healthy tissue, which does not express it. They mark the entire doubtful area with a glutamyl-prolyl-hydroxymethyl-rodamine spray incorporated into the endoscope. Later, they monitor the possible increased fluorescence. Glutamyl-prolyl-hydroxymethyl-rodamine is a very sensitive and selective fluorophore agent that produces fluorescence after its cleavage/activation by DPP-IV [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_340">340</xref>]. It usually activates several minutes after its topical application [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_341">341</xref>]. Yamamoto et al. (2020) have reported that, in the case of EGJA, the fluorescence of glutamyl-prolyl-hydroxymethyl-rodamine has a time-dependent increase with sensitivity values and very high specificity. Indeed, subsequent histological analyzes confirmed that all the fluorescent areas corresponded to tumour areas, while those areas that did not fluorescence corresponded to healthy tissue. After 10 min, the background fluorescence of healthy tissue has disappeared, while a sustained increase occurs in the tissue compromised by the tumour [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_340">340</xref>]. Therefore, this evidence suggests that to employ DPP-IV as a diagnosis marker of EGJA is a strategy with good selectivity, specificity, little invasiveness, and reasonably short time to reach conclusions of clinical relevance.
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_012">
				<label>4.12</label>
				<title>DPP-IV and colorectal cancers: a protein that remains upregulated from early stages to metastasis</title>
				<p>DPP-IV is upregulated in premalignant adenomas
					<?index value="adenomas"?> and colorectal carcinomas
					<?index value="carcinomas"?> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_342">342</xref>]. A subpopulation of DPP-IV
					<sup>+</sup> colorectal cancer stem cells has been described in primary tumours, as well as in their liver metastases, suggesting that DPP-IV preservation might be important from early stages to final ones. These DPP-IV expressing cells seem to be critical for processes like tumour initiation, progression, and chemoresistance [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_343">343</xref>]. Amritha et al. (2015) reported that the gliptins sitagliptin and vildagliptin has anti-proliferative effects on human HT-29 cancer cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_344">344</xref>]. Further, Jang et al. (2015) demonstrated an enzyme activity-dependent role of DPP-IV during metastasis in a mouse model, in which DPP-IV inhibition blocked the growth of lung metastases from colon cancer cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_032">32</xref>]. Although more experiments are needed to further understand the function of DPP-IV enzyme in colon cancer, the above evidence suggests that DPP-IV could be a valuable target for future colon
					<?index value="colon"?> cancer therapies.
				</p>
				<p>
					<xref ref-type="table" rid="j_psr-2022-0288_tab_005">Table 5</xref> summarizes the upregulation or downregulation of DPP-IV in all of the aforementioned cancers. Possible relevance of DPP-IV in metastasis, immune disorders and as a molecular marker is also listed.
				</p>
				<table-wrap id="j_psr-2022-0288_tab_005">
					<label>Table 5:</label>
					<caption>
						<p>DPP-IV expression in various human cancer types and its possible relevance in metastasis, immune disorders and as a molecular marker.</p>
					</caption>
					<table frame="hsides">
						<colgroup>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
							<col align="left"/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">Cancer type</th>
								<th align="left">DPP-IV expression</th>
								<th align="left">Relevance in metastasis</th>
								<th align="left">Relevance in immune disorders</th>
								<th align="left">Utility as a molecular biomarker</th>
								<th align="left">References</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>B-cells chronic leukemia</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>High</td>
								<td>Potential</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_276">276</xref>]
								</td>
							</tr>
							<tr>
								<td>T-cell acute lymphoblastic leukemia</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>High</td>
								<td>Associated with less survival</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_279">279</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_280">280</xref>]
								</td>
							</tr>
							<tr>
								<td>T-cell lymphoblastic lymphoma</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>High</td>
								<td>Associated with less survival</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_279">279</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_280">280</xref>]
								</td>
							</tr>
							<tr>
								<td>Anaplastic large cell lymphomas</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>High</td>
								<td>Potential</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_279">279</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_280">280</xref>]
								</td>
							</tr>
							<tr>
								<td>T-cell large granular lymphocyte leukemia</td>
								<td>Upregulated</td>
								<td>Potential</td>
								<td>High</td>
								<td>Associated with less survival</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_281">281</xref>]
								</td>
							</tr>
							<tr>
								<td>Melanoma</td>
								<td>Downregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_259">259</xref>]
								</td>
							</tr>
							<tr>
								<td>Keratinocyte tumours</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Potential</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_028">28</xref>]
								</td>
							</tr>
							<tr>
								<td>Dermal basal cell carcinoma</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_272">272</xref>]
								</td>
							</tr>
							<tr>
								<td>Squamous-cells carcinoma</td>
								<td>Controversial</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Null</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_262">262</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_270">270</xref>]
								</td>
							</tr>
							<tr>
								<td>Lung adenocarcinoma</td>
								<td>Controversial</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_262">262</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_288">288</xref>]
								</td>
							</tr>
							<tr>
								<td>Small-cell lung carcinoma</td>
								<td>Downregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_260">260</xref>]
								</td>
							</tr>
							<tr>
								<td>Large-cell lung carcinoma</td>
								<td>Downregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_260">260</xref>]
								</td>
							</tr>
							<tr>
								<td>Non-small-cell lung carcinoma</td>
								<td>Extremely downregulated</td>
								<td>Potential suppressor</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_260">260</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_261">261</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_289">289</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_290">290</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_291">291</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_292">292</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_293">293</xref>]
								</td>
							</tr>
							<tr>
								<td>Endometrial adenocarcinoma</td>
								<td>Controversial</td>
								<td>Controversial</td>
								<td>Unidentified</td>
								<td>Null</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_263">263</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_294">294</xref>]
								</td>
							</tr>
							<tr>
								<td>Ovarian carcinoma</td>
								<td>Upregulated</td>
								<td>Potential promotor</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_274">274</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_295">295</xref>]
								</td>
							</tr>
							<tr>
								<td>Primary prostate carcinoma</td>
								<td>Upregulated</td>
								<td>Potential suppressor</td>
								<td>Unidentified</td>
								<td>Discriminate between primary and secondary tumour</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_309">309</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_310">310</xref>]
								</td>
							</tr>
							<tr>
								<td>Secondary prostate carcinoma</td>
								<td>Downregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Discriminate between secondary and primary tumour</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_264">264</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_265">265</xref>]
								</td>
							</tr>
							<tr>
								<td>Papillary thyroid carcinoma</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Discriminate between malignant tumour and benign neoplasia</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_271">271</xref>]
								</td>
							</tr>
							<tr>
								<td>Follicular thyroid carcinoma</td>
								<td>Upregulated</td>
								<td>Potential promotor</td>
								<td>Unidentified</td>
								<td>Discriminate between malignant tumour and benign neoplasia</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_313">313</xref>]
								</td>
							</tr>
							<tr>
								<td>Glioma</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Evaluate the tumour grade</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_317">317</xref>]
								</td>
							</tr>
							<tr>
								<td>Astrocyte tumour</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_278">278</xref>]
								</td>
							</tr>
							<tr>
								<td>Meningioma</td>
								<td>Downregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Discriminate between meningioma and glioma</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_320">320</xref>]
								</td>
							</tr>
							<tr>
								<td>Neuroblastoma</td>
								<td>Downregulated</td>
								<td>Potential promotor</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_321">321</xref>]
								</td>
							</tr>
							<tr>
								<td>Mesothelioma</td>
								<td>Upregulated</td>
								<td>Potential promotor</td>
								<td>Unidentified</td>
								<td>Evaluate aggressiveness</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_323">323</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_325">325</xref>]
								</td>
							</tr>
							<tr>
								<td>Hepatocellular carcinoma</td>
								<td>Upregulated</td>
								<td>Potential promotor</td>
								<td>Unidentified</td>
								<td>Evaluate tumour grade and survival of patients</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_031">31</xref>,
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_328">328</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_329">329</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_330">330</xref>]
								</td>
							</tr>
							<tr>
								<td>Esophageal adenocarcinoma</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Potential</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_273">273</xref>]
								</td>
							</tr>
							<tr>
								<td>Gastro-esophageal junction adenocarcinoma</td>
								<td>Upregulated</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>Discriminate the tumour</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_337">337</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_338">338</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_339">339</xref>], [
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_340">340</xref>]
								</td>
							</tr>
							<tr>
								<td>Colorectal carcinoma</td>
								<td>Upregulated</td>
								<td>Potential promotor</td>
								<td>Unidentified</td>
								<td>Unidentified</td>
								<td>[
									<xref ref-type="bibr" rid="j_psr-2022-0288_ref_342">342</xref>]
								</td>
							</tr>
						</tbody>
					</table>
				</table-wrap>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_013">
				<label>4.13</label>
				<title>DPP-IV and extracellular matrix proteins or cytoskeleton proteins: a possible way into metastasis</title>
				<p>The DPP-IV binding to a subset of extracellular matrix proteins (EMPs) is probably due to the β-propeller domain [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_345">345</xref>]. DPP-IV can bind at least three EMPs: type I collagen, FN, and type II plasminogen (Pg 2) [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_112">112</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_346">346</xref>].
				</p>
				<p>FN has consensus recognition sequences for DPP-IV from the endothelia [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_112">112</xref>]. FN is overexpressed in cells that can colonize the lung from several cancers in humans, rats and mice. Such metastatic potential relies not only on the ability of FN to self-polymerize on the surface of numerous lung cancers [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_347">347</xref>], but to assemble into long, fibrillar strands. Cheng et al. [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_112">112</xref>] demonstrated that, during the colonization of the lung by blood-derived cancer cells, the vascular arrest of metastatic cells was mediated by the adhesion of DPP-IV to FN on the surface of cancerous cells. Kikkawa et al. (2003) detected a significant increase in the adhesion to immobilized FN and collagen when DPP-IV expression was restituted in ovarian cancer SKOV-3 cells [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_274">274</xref>].
				</p>
				<p>DPP-IV have a weak binding activity to plasma soluble FN, suggesting that polymerized FN (poly-FN) acquires a conformation different from that of plasma FN [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_112">112</xref>]. More findings have confirmed the role of DPP-IV and poly-FN during metastasis. In humans and mice, large amounts of poly-FN are found to be associated to lung metastatic cells as well as to melanoma cell lines able to colonize the lung. The poly-FN expression in rhabdomyosarcoma correlates with lung metastasis. Interestingly, a soluble peptide mimicking the extracellular region of DPP-IV was able to suppress the adhesion of DPP-IV to breast metastatic cells in lung, preventing colonization; this could be caused by the peptide competing with cell surface DPP-IV for binding to poly-FN [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_348">348</xref>].
				</p>
				<p>Binding experiments with a peptide bearing the FN-III repeat 14 sequence (peptide FN-III14) and the native DPP-IV showed that this peptide was able to compete for the binding site of poly-FN to DPP-IV in the MTF-7 cell line. This led to remarkable anti-metastatic effects in lung: cellular adhesion was reduced to 50 % and there was decreased numbers and sizes of colonies. This behaviour was similar to that obtained through blocking DPP-IV extracellular domain by a specific antibody [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_112">112</xref>]. Another peptide bearing the FN-III14 sequence (22-mer peptide) has shown anti-metastatic effects in spleen and liver colonization in T cell lymphoma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_349">349</xref>]. Still remains to be elucidated if the vascular compromise during metastasis is only mediated by the DPP-IV to poly-FN interaction or their complexation with other adhesion molecules, such as proteoglycans, CD44 or heparin sulphate [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_112">112</xref>]. In fact, DPP-IV binding to Pg2 on the surface of the 1-LN prostate cancer cell line lead to increased intracellular Ca
					<sup>2+</sup> concentrations, with downstream activation of a transduction pathway ultimately resulting in increased cytosolic pH. That pathway may be triggered by phospholipase C activation, which promotes the synthesis of inositol 3,4,5-triphosphate, a well-known inducer of endoplasmic reticulum Ca
					<sup>2+</sup> release [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_089">89</xref>]. Moreover, it is possible that Pg2 may regulate pH though its association to NH3E, a member of the family Na
					<sup>+</sup>/H
					<sup>+</sup> exchanger (NHE), previously bound to DPP-IV. These suggest that the DPP-IV/Pg2 association may regulate simultaneously Ca
					<sup>2+</sup>, Na
					<sup>+</sup> and H
					<sup>+</sup> concentrations required for tumour proliferation and invasion [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_346">346</xref>].
				</p>
				<p>DPP-IV can also exert its tumour progressive effect through induction of epithelial-mesenchymal transition (EMT) and upregulation of EMT markers from cytoskeleton
					<?index value="cytoskeleton"?> such as N-cadherin and vimentin [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_350">350</xref>]. Mechanisms remains unclear, so more experiments are required to achieve a deeper understanding of the effects.
				</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_014">
				<label>4.14</label>
				<title>DPP-IV, GLP-1 and cancer: concerns about pancreas</title>
				<p>As previously said, currently gliptins are used in clinical practice worldwide [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_022">22</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_023">23</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_024">24</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_025">25</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_026">26</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_027">27</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_028">28</xref>]. The systemic DPP-IV inhibition with the ensuing increased bioavailability and signaling of various DPP-IV substrates, including those that may affect cell proliferation and migration, has raised concerns. This is the case of sustained levels of GLP-1
					<?index value="GLP-1"?> and its possible pro-carcinogenic effects via a sustained activation of GLP-1 receptor (GLP-1R
					<?index value="GLP-1R"?>) on pancreatic cells.
				</p>
				<p>GLP-1R presence was demonstrated in human pancreatic carcinoma Hs-7766T cell line as well as in human pancreatic duct adenocarcinoma CFPAC-1, PL45 and CAPAN-1 cell lines. However, there are differences in the GLP-1R stimulation mechanism, mediated either through ERK1/2 activation or through AMPc induction [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_351">351</xref>]. Since transduction pathways triggered by ERK1/2 and, to a lower extent those of AMPc, are relevant in events such as mitosis, meiosis and carcinogenesis, GLP-1 peptide mimetics or DPP-IV inhibitors might exert oncogenic effects [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_352">352</xref>]. Based on the lack of detection of GLP-1R isoforms in 21 human pancreatic adenocarcinomas, Korner et al. (2007) suggested that GLP-1R expression could be restricted to certain cell lines and, therefore, could be irrelevant in humans
					<italic>in vivo</italic> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_353">353</xref>]. In addition, exenatide, a GLP-1 analogue, neither modulated the growth of pancreatic cancer cells that expressed GLP-1R, nor rescued them from drug-induced death. Moreover, the sustained exenatide-mediated activation of GLP-1R did not stimulate tumour growth or progression in rats [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_354">354</xref>]. These observations suggested that the hypothetical appearance of pancreatic cancer by administering DPP-IV inhibitors or GLP-1 mimetics could be caused by collateral pancreatitis [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_352">352</xref>], a condition favoured by underlying diseases such as T2DM and obesity [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_355">355</xref>]. In fact, pancreatitis incidence in patients treated with GLP-1R agonists does not differ with that found in populations suffering T2DM [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_356">356</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_357">357</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_358">358</xref>]. Similarly, studies in monkeys and rats revealed that the induction of pancreatitis via the stimulation of the GLP-1R seems to be quite improbable [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_033">33</xref>]. Moreover, three different studies on rodents failed to reveal changes in ductal proliferation or evidence of pancreatitis, ductal metaplasia or neoplasia with gliptin treatment lasting for up to two years [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_359">359</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_360">360</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_361">361</xref>].
				</p>
				<p>Preclinical studies have shown an increased incidence of thyroid C-cell tumours in rodents treated with GLP-1 analogues. Nevertheless, the GLP-1R expression in this cell types is highly dependent on the species, implying that observations in rodents are not necessarily relevant in human [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_353">353</xref>] due to a differential GLP1R expression twenty two-times higher in rodents [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_362">362</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_363">363</xref>]. Furthermore, it was shown that rats are more susceptible to develop thyroid C-cell neoplasias, quite rare in humans [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_364">364</xref>].
				</p>
				<p>The rise in GLP-1 levels seems to originate more probably from premalignant lesions stimulation rather than the induction of new lesions, both in pancreas and the thyroid, based on the short duration of the studies and the evidences gathered so far. By contrast, it is believed that GLP-1R activation could inhibit tumour growth in two very common cancer types: colon and breast cancers [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_353">353</xref>].
				</p>
				<p>In the case of colon cancer, the CT26 murine colon cancer cell line expresses a functional GLP-1R. Its exposure to exenatide
					<italic>in vitro</italic> leads to morphological changes, inhibits proliferation and colony formation in solid agar and induces apoptosis. These effects were confirmed
					<italic>in vivo</italic> in CT26 cells implanted in mice, even when this did not affect tumour weight [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_365">365</xref>].
				</p>
				<p>Ligumsky et al. (2012) demonstrated
					<italic>in vitro</italic> that exenatide significantly reduced the number of colonies formed by the cell lines MCF-1 and MDA-MB-231, positive and negative to strogen receptors, respectively [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_034">34</xref>]. The non-cancer HB-2 cell line, used as a negative control, remained unaffected. A significant exenatide dose-dependent tumour reduction was seen in mice implanted with MDA-MB-231 cells, when the drug was administrated via intraperitoneal [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_133">133</xref>].
				</p>
				<p>All these results indicate that the increase in the half-life time of GLP-1 does not seem to be linked to the induction and/or growth of tumours in pancreas. Although colon and breast cells lines have shown promissory effects after being treated with the GLP-1 analogue exenatide, more and deeper experiments are necessary due to the pleiotropic effects of DPP-IV.</p>
			</sec>
			<sec id="j_psr-2022-0288_s_004_s_015">
				<label>4.15</label>
				<title>DPP-IV inhibitors and cancer: a tenue light at the end of the tunnel</title>
				<p>As we have seen, due to its implications in several pathologies including cancer, DPP-IV is an important target to develop new tools against those pathologies. Currently, most of the drugs used to treat cancer are cytotoxic, so they are not highly specific to cancer cells but also affect normal cells as a collateral damage [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_344">344</xref>]. Therefore, it is necessary to discovery or design newer drugs that are more specific to cancer cells. Potent, stable and selective DPP-IV inhibitors could be valuable tools for the treatments of those cancer types where DPP-IV is upregulated.
				</p>
				<p>Until now, a great number of molecules capable of inhibit DPP-IV have been developed searching for possible future therapeutic applications, although not all have had the same fortune.</p>
				<p>Two main strategies are followed during the search of new inhibitors for peptidases in general and for DPP-IV in particular [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_366">366</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_367">367</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_368">368</xref>]. Searching for inhibitory activity from different natural sources is the first and older strategy. Among these sources are plant extracts [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_369">369</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_370">370</xref>], and marine organisms [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_371">371</xref>]. Several inhibitors are derived from plants [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_372">372</xref>], like quercetin and coumarin [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_373">373</xref>], while low molecular weight compounds such as bestatin
					<?index value="bestatin"?> and bacitracin
					<?index value="bacitracin"?>, are obtained from microorganisms [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_035">35</xref>]. Additionally, some enzymatic hydrolysates from food are characterized by hypoglycemic activity due to DPP-IV inhibitory activity [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_374">374</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_375">375</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_376">376</xref>]. So far, among the natural sources, scientists have preferred to search DPP-IV inhibitors in marine fauna. They seem to be particularly attracted by the wide diversity of different biomolecules and low molecular weight compounds that those organisms usually contain [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_368">368</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_377">377</xref>].
				</p>
				<p>The second and more recent strategy is the rational prediction and
					<italic>in silico</italic> design of putative inhibitors that latter are synthetized and assayed. To date, these inhibitors are of a varied chemical nature. There are substrate analogs, product analogs [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_378">378</xref>], transition state analogs [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_379">379</xref>], piridopirimidindionas [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_380">380</xref>], fenetilfenilftalimida derivates [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_381">381</xref>], etc. Interestingly, it has been reported that rat and porcine DPP-IVs are inhibited by divalent cations such as zinc and calcium [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_382">382</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_383">383</xref>]. The prediction of the binding sites to these ions and the presence of several residues from active site involved in the observed inhibition suggest the possibility of designing new inhibitors that take advantage of this susceptibility of DPP-IV to zinc and/or calcium [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_383">383</xref>].
				</p>
				<p>Some of these new inhibitors have been assayed with promissory results versus DPP-IV
					<sup>+</sup> tumour cell lines. Pascual et al. (2022) have reported four new low molecular weight inhibitors of porcine DPP-IV that are hydrophobic molecules (labeled as BTB11079, JFD00064, BTB07018 and HTS08762) identified by
					<italic>in silico</italic> approach screening in the HitFinder database from Maybridge ThermoFisher. These molecules reduced the cell viability/metabolism of DPP-IV
					<sup>+</sup> HL-60 (from acute promyelocytic leukemia) and MDA-MDB-231 (from breast adenocarcinoma). All are tight-binding competitive inhibitors of DPP-IV and they have proven to reach pancreas, liver, and brain in rat model.
					<italic>In silico</italic> predictions suggested that the blood–brain barrier crossing of theses inhibitors could be explained by their binding to serum albumin [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_384">384</xref>].
				</p>
				<p>Due to their long use in the pharmaceutical market, the possible tumour/anti-tumour effects of gliptins (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_004">Table 4</xref>) have been extensively studied. Although some authors suggest a possible induction of carcinogenesis and/or metastasis via long-term use of gliptins [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_385">385</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_386">386</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_387">387</xref>], [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_388">388</xref>], a large number of studies reach different conclusions. DPP-IV inhibition has been reported to improve progression-free survival in advanced airway and colorectal cancer patients with T2DM [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_389">389</xref>]. Bishnoi et al. (2019) found that the combined use of DPP-IV inhibitors and metformin can significantly increase the survival of lung cancer patients [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_390">390</xref>]. Several epidemiological studies suggest that gliptin use is associated with a reduced risk of breast [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_391">391</xref>], prostate [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_392">392</xref>], and HCV infection-associated hepatocellular cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_393">393</xref>]. In addition, a small study reported improved outcomes in tyrosine-kinase-inhibitor-treated patients with renal cell cancer using gliptins [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_394">394</xref>]. An observational German study with a 3–4 year follow-up did not reveal an increased risk of metastases in DPP-IV-inhibitor treated patients with breast, prostate or digestive-organ cancers [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_036">36</xref>]. Similarly, a study with a 5–6 year follow-up in diabetic patients from South Korea with preexisting primary cancer did not reveal an association between the use of DPP-IV inhibitors and new metastatic disease. A possible exception was a subgroup of patients with thyroid cancer, but the overall frequency of metastatic disease in this small subgroup was low [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_037">37</xref>]. A study using a model of chemically induced renal cell carcinoma showed that, probably by improving the defense against oxidative stress and ameliorating inflammation, sitagliptin decreased the occurrence of neoplastic foci in the kidney cortex and improved renal functions [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_395">395</xref>]. Sitagliptin further reduced tumour growth in transgenic mice that expressed oncogenically activated MAPK kinase one in non-dividing, differentiating epidermal cells, in which skin wounding induced tumour formation. Nevertheless, the onset, formation and number of tumours were similar, and there was no effect of sitagliptin on angiogenesis or cancer cell proliferation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_396">396</xref>].
				</p>
				<p>Sitagliptin has been successfully assayed
					<italic>in vitro</italic> versus several tumour cell lines. It has promoted anti-tumour and/or anti-proliferative effects in cellular cultures of breast cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_397">397</xref>], thyroid cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_314">314</xref>], gastric cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_398">398</xref>], endometrial cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_294">294</xref>], hepatocellular carcinoma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_399">399</xref>], cervical carcinoma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_400">400</xref>] and chronic myeloid leukemia [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_401">401</xref>].
				</p>
				<p>In human and mouse lung adenocarcinoma cell lines, vildagliptin can exhibit anti-tumour effects, possibly due to regulating macrophage and NK cell activity. It was also shown to suppress the pulmonary metastasis of colorectal cancer in mice [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_032">32</xref>]. Vildagliptin has promoted anti-tumour and/or anti-proliferative effects in cellular cultures of colorectal cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_032">32</xref>], thyroid cancer [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_314">314</xref>], acute myeloid leukemia, chronic myeloid leukemia [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_401">401</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_402">402</xref>] and multiple myeloma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_403">403</xref>]. On the other hand, saxagliptin had cytotoxic effects in cellular cultures of multiple myeloma [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_403">403</xref>], and reduced mobilization of leukemic stem cells from a stroma cell layer in chronic myeloid leukemia [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_401">401</xref>].
				</p>
				<p>Due to the proven efficacy of gliptins, complexes between DPP-IV and various gliptins may be quite useful for the design and/or improvement of potent and selective inhibitors of DPP-IV. From the analysis of these complexes, several regularities should be looked for in order to guarantee a strong binding with the enzyme. Although not all of them are mandatory, the evidence suggests that the more of these given, the greater the effectiveness of the union. Gliptins demonstrate that access to certain sites (S1, S2 and S′2) and residues (Y
					<sup>547</sup>, E
					<sup>205</sup>, E
					<sup>206</sup> and S
					<sup>630</sup>) of the enzyme are critical to achieve potent inhibition. As we said, Y547 stabilizes the intermediate tetrahedral oxyanion of the reaction [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_066">66</xref>], S630 is part of the catalytic triad, and the E
					<sup>205</sup>, E
					<sup>206</sup> pair form salt bridges with the amino end of the substrate, facilitating its fixation and orientation [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_068">68</xref>,
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_069">69</xref>]. On the other hand, the S1 hydrophobic pocket (formed by Y
					<sup>662</sup>, Y
					<sup>666</sup>, Y
					<sup>631</sup>, V
					<sup>711</sup>, V
					<sup>656</sup> and W
					<sup>659</sup>) determines the substrate specificity, since its particular narrowness allows only residues with small side chains such as proline, alanine or glycine in the second position; they can fit inside [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_066">66</xref>]. Access to the S1 site is therefore quite promising for inhibition [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>]. The access of inhibitors to the S2 subsite (where E
					<sup>205</sup> and E
					<sup>206</sup> belong) has been reported as vital for the inhibitory effect versus DPP-IV [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>]. This behaviour is clearly seen in
					<xref ref-type="table" rid="j_psr-2022-0288_tab_004">Table 4</xref>, where almost all gliptins exhibit a functional group in their structure (amino, for example) that guarantees interaction with these residues. Since DPP-IV is a dipeptidase enzyme, in principle it would not make sense to refer to sites beyond S2 in DPP-IV. This is valid for substrates, but not for inhibitors, which can find anchors beyond the S2 site, in the so-called extensive S2 site (S2-ex) and thus increase their inhibitory activity [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_405">405</xref>]. It is composed of V
					<sup>207</sup>, S
					<sup>20</sup>9, F
					<sup>357</sup> and R
					<sup>358</sup>. It has been verified that S2-ex is not clearly defined in other proteins of the family such as DPP8/9 (which do not establish sufficient hydrophobic interactions with their inhibitors beyond S2) and FAP (which has no binding sites beyond S2). Thus, binding with S2-ex could not only improve inhibitory potency, but also selectivity [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>].
				</p>
				<p>For clarity, it would be useful to briefly review how the particular structure of the main gliptines manages to satisfy most of the regularities mentioned above.</p>
				<p>Vildagliptin
					<?index value="Vildagliptin"?> and saxagliptin
					<?index value="saxagliptin"?> (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_004">Table 4</xref>) are peptide mimetics whose design mimics the P1 and P2 sites of the substrate. Both share a cyanopyrrolidine region that binds to the S1 site, forming a covalent bond between the nitrile group and S
					<sup>630</sup> in addition, its hydroxyadamantyl groups bind to the S2 subsite [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>]. In vildagliptin, the imidate nitrogen hydrogen bonds with the hydroxyl on the Y
					<sup>547</sup> side chain. The remaining part, including the adamantane, binds to the S2 subsite, where the carbonyl group forms a hydrogen bond with N
					<sup>710</sup> and the amino group forms salt bridges with E
					<sup>205</sup> and E
					<sup>206</sup>. The hydroxyl group of adamantyl also forms hydrogen bonds with H
					<sup>126</sup> and S
					<sup>209</sup> via water molecules [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>]. Although its mode of binding is very similar to that of vildagliptin, saxagliptin has a five-fold higher inhibitory potency (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_004">Table 4</xref>). This has been attributed to its cyclopropanated cyanopyrrolidine, which provides an additional hydrophobic interaction with the Y
					<sup>666</sup> side chain at the S1 subsite. In addition, direct hydrogen bonding between the saxagliptin hydroxyl and the Y
					<sup>547</sup> side chain may also contribute to its higher potency [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>].
				</p>
				<p>Alogliptin
					<?index value="Alogliptin"?> and Linagliptin
					<?index value="Linagliptin"?> have a substituted uracil ring (
					<xref ref-type="table" rid="j_psr-2022-0288_tab_004">Table 4</xref>). Both bind to S1: alogliptin does so via its cyanobenzyl group and linagliptin does so through its butynyl group. In both cases, the uracil ring establishes p-p interactions with Y
					<sup>547</sup>, which induces a conformational change in S′1 and facilitates inhibition. In addition to binding to S1, alogliptin also occupies the S2 pocket. It does so through its aminopiperidine group. Three hydrogen bonds are established between the inhibitor and the residues Y
					<sup>547</sup>, Q
					<sup>553</sup> and Y
					<sup>585</sup> [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>].
				</p>
				<p>Linagliptin, whose structure is based on a xanthine skeleton, has proven to be highly potent and selective as a DPP-IV inhibitor. The X-ray crystallographic structure of linagliptin in complex with hDPP-IV showed that the aminopiperidine at C-8 of the xanthine backbone occupied the S2 site. Its primary amine formed a network of hydrogen bonds with E
					<sup>205</sup>, E
					<sup>206</sup> and Y
					<sup>662</sup>, residues that constitute the recognition site for the amino terminus. The butynyl substituent on N-7 occupied the S1 hydrophobic pocket of the enzyme. On the other hand, it has been seen that the xanthine structure and the quinazoline substituent in N-1 interacted through their aromatic π clouds with some residues of the enzyme: Y
					<sup>547</sup> and W
					<sup>629</sup>, respectively. These particularities in the mode of binding with the enzyme are the reasons why this compound is 8-times more potent than alogliptin [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>].
				</p>
				<p>In the case of sitagliptin, the presence of a trifluorophenyl group allows it to bind to S1. On the other hand, triazolopyrazine and the trifluoromethyl substituent facilitate S2-ex anchoring, thereby increasing selectivity for DPP-IV for the reasons already explained [
					<xref ref-type="bibr" rid="j_psr-2022-0288_ref_404">404</xref>].
				</p>
			</sec>
		</sec>
		<sec id="j_psr-2022-0288_s_005">
			<label>5</label>
			<title>Conclusions</title>
			<p>Due to its multiple functions, DPP-IV has a great influence on important physiological and pathological processes. Therefore, it is very attractive as a possible therapeutic target. However, its versatility makes such expectations very difficult. Until now, the most remarkable advances are those obtained by gliptins in T2DM patients.</p>
			<p>DPP-IV role in cancer seems to depend on specific location, histologic type of tumour, tumour microenvironment, and presence/absence of molecules able to interact with DPP-IV. Because of DPP-IV controversial effects, generalizations are difficult and most of the time the role of DPP-IV must be analyzed case by case, but literature suggests that it seems to be some correlation between the DPP-IV exposure and metastasis via ECMPs and/or cytoskeletal proteins. New evidences in cell lines, animal model and clinical studies suggest that DPP-IV inhibitors open a promissory window through new therapeutic strategies against some cancers, but much of the road remains to be explored.</p>
		</sec>
	</body>
	<back>
		<ack id="j_psr-2022-0288_ack_001">
			<title>Acknowledgements</title>
			<p>The authors would like to thank the editors for their guidance and review of this article before its publication.</p>
		</ack>
		<fn-group>
			<fn fn-type="con" id="j_psr-2022-0288_fn_002">
				<p>
					<bold>Author contributions:</bold> All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
				</p>
			</fn>
			<fn fn-type="financial-disclosure" id="j_psr-2022-0288_fn_003">
				<p>
					<bold>Research funding:</bold> Results of the group included in the review were partially supported by a University Laboratory in Nanotechnology and Cancer (NaNoCancer) project: “New inhibitors of aminopeptidases with potential applications in cancer” (2016-2022), and a grant from the “Oficina de Gestión de Fondos y Proyectos Internacionales del Ministerio de Ciencia, Tecnología y Medio Ambiente de la República de Cuba” (code PN223LH010-010 2021-2023).
				</p>
			</fn>
			<fn fn-type="other" id="j_psr-2022-0288_fn_004">
				<p>
					<bold>Conflict of interest statement:</bold> The authors declare no conflicts of interest regarding this article.
				</p>
			</fn>
		</fn-group>
		<ref-list id="j_psr-2022-0288_reflist_001">
			<title>References</title>
			<ref id="j_psr-2022-0288_ref_001">
				<label>1.</label>
				<mixed-citation>Bray, F, Soerjomataram, I. Chapter 01: global burden of cancer: current and future. In: Minghui, R, editor
					<italic>WHO report on cancer: setting priorities, investing wisely and providing care for all</italic>. Geneva, Switzerland: World Health Organization; 2020. pp. 23–37.
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Bray</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Soerjomataram</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<article-title>Chapter 01: global burden of cancer: current and future</article-title>
					<person-group person-group-type="editor">
						<name>
							<surname>Minghui</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<source>WHO report on cancer: setting priorities, investing wisely and providing care for all</source>
					<publisher-loc>Geneva, Switzerland</publisher-loc>
					<publisher-name>World Health Organization</publisher-name>
					<year>2020</year>
					<fpage>23</fpage>
					<lpage>37</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_002">
				<label>2.</label>
				<mixed-citation>Hanahan, D. Hallmarks of cancer: new dimensions.
					<italic>Cancer Discov</italic> 2022;12:31–46.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hanahan</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Hallmarks of cancer: new dimensions</article-title>
					<source>Cancer Discov</source>
					<year>2022</year>
					<volume>12</volume>
					<fpage>31</fpage>
					<lpage>46</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_003">
				<label>3.</label>
				<mixed-citation>Carl-McGrath, S, Lendeckel, U, Ebert, M, Rocken, C. Ectopeptidases in tumour biology: a review.
					<italic>Histol Histopathol</italic> 2006;21:1339–53.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Carl-McGrath</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Lendeckel</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Ebert</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Rocken</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Ectopeptidases in tumour biology: a review</article-title>
					<source>Histol Histopathol</source>
					<year>2006</year>
					<volume>21</volume>
					<fpage>1339</fpage>
					<lpage>53</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_004">
				<label>4.</label>
				<mixed-citation>Barnieh, FM, Loadman, PM, Falconer, RA. Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?
					<italic>Biochim Biophys Acta Rev Cancer</italic> 2021, 1876:188641.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barnieh</surname>
							<given-names>FM</given-names>
						</name>
						<name>
							<surname>Loadman</surname>
							<given-names>PM</given-names>
						</name>
						<name>
							<surname>Falconer</surname>
							<given-names>RA</given-names>
						</name>
					</person-group>
					<article-title>Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?</article-title>
					<source>Biochim Biophys Acta Rev Cancer</source>
					<year>2021</year>
					<volume>1876</volume>
					<elocation-id>188641</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_005">
				<label>5.</label>
				<mixed-citation>Drinkwater, N, Lee, J, Yang, W, Malcolm, TR, McGowan, S. M1 aminopeptidases as drug targets: broad applications or therapeutic niche?
					<italic>FEBS J</italic> 2017;284:1473–88.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Drinkwater</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Malcolm</surname>
							<given-names>TR</given-names>
						</name>
						<name>
							<surname>McGowan</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>M1 aminopeptidases as drug targets: broad applications or therapeutic niche?</article-title>
					<source>FEBS J</source>
					<year>2017</year>
					<volume>284</volume>
					<fpage>1473</fpage>
					<lpage>88</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_006">
				<label>6.</label>
				<mixed-citation>Amin, M, Adhikari, N, Jha, T. Design of aminopeptidase N (APN) inhibitors as anticancer agents.
					<italic>J Med Chem</italic> 2018;61:6468–90.
					<ext-link ext-link-type="doi" xlink:href="https://doi.org/10.1021/acs.jmedchem.7b00782">https://doi.org/10.1021/acs.jmedchem.7b00782</ext-link>.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Amin</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Adhikari</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Jha</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Design of aminopeptidase N (APN) inhibitors as anticancer agents</article-title>
					<source>J Med Chem</source>
					<year>2018</year>
					<volume>61</volume>
					<fpage>6468</fpage>
					<lpage>90</lpage>
					<ext-link ext-link-type="doi" xlink:href="https://doi.org/10.1021/acs.jmedchem.7b00782">https://doi.org/10.1021/acs.jmedchem.7b00782</ext-link>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_007">
				<label>7.</label>
				<mixed-citation>Li, FJ, Hu, JH, Ren, X, Zhou, CM, Liu, Q, Zhang, YQ. Toad venom: a comprehensive review of chemical constituents, anticancer activities, and mechanisms.
					<italic>Arch Pharmazie</italic> 2021;354:2100060.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Li</surname>
							<given-names>FJ</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Ren</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Zhou</surname>
							<given-names>CM</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>YQ</given-names>
						</name>
					</person-group>
					<article-title>Toad venom: a comprehensive review of chemical constituents, anticancer activities, and mechanisms</article-title>
					<source>Arch Pharmazie</source>
					<year>2021</year>
					<volume>354</volume>
					<elocation-id>2100060</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_008">
				<label>8.</label>
				<mixed-citation>Turk, B. Targeting proteases: successes, failures and future prospects.
					<italic>Nat Rev Drug Discov</italic> 2006;5:785–99.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Turk</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>Targeting proteases: successes, failures and future prospects</article-title>
					<source>Nat Rev Drug Discov</source>
					<year>2006</year>
					<volume>5</volume>
					<fpage>785</fpage>
					<lpage>99</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_009">
				<label>9.</label>
				<mixed-citation>Leung, D, Abbenante, G, Fairlie, DP. Protease inhibitors: current status and future prospects.
					<italic>J Med Chem</italic> 2000;43:305–41.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Leung</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Abbenante</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Fairlie</surname>
							<given-names>DP</given-names>
						</name>
					</person-group>
					<article-title>Protease inhibitors: current status and future prospects</article-title>
					<source>J Med Chem</source>
					<year>2000</year>
					<volume>43</volume>
					<fpage>305</fpage>
					<lpage>41</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_010">
				<label>10.</label>
				<mixed-citation>Abbenante, G, Fairlie, DP. Protease inhibitors in the clinic.
					<italic>Med Chem</italic> 2005;1:71–104.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Abbenante</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Fairlie</surname>
							<given-names>DP</given-names>
						</name>
					</person-group>
					<article-title>Protease inhibitors in the clinic</article-title>
					<source>Med Chem</source>
					<year>2005</year>
					<volume>1</volume>
					<fpage>71</fpage>
					<lpage>104</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_011">
				<label>11.</label>
				<mixed-citation>Pascual, I, Valiente, PA, García, G, Valdés, ME, Arrebola, Y, Díaz, L, et al.. Discovery of novel non-competitive inhibitors of mammalian neutral M1 aminopeptidase (APN).
					<italic>Biochimie</italic> 2017;142:216–25.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Valiente</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>García</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Valdés</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Arrebola</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Díaz</surname>
							<given-names>L</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Discovery of novel non-competitive inhibitors of mammalian neutral M1 aminopeptidase (APN)</article-title>
					<source>Biochimie</source>
					<year>2017</year>
					<volume>142</volume>
					<fpage>216</fpage>
					<lpage>25</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_012">
				<label>12.</label>
				<mixed-citation>Rawlings, ND, Barrett, JA, Thomas, PD, Huang, X. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database.
					<italic>Nucleic Acids Res</italic> 2018;46:624–32.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rawlings</surname>
							<given-names>ND</given-names>
						</name>
						<name>
							<surname>Barrett</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Thomas</surname>
							<given-names>PD</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>X</given-names>
						</name>
					</person-group>
					<article-title>The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database</article-title>
					<source>Nucleic Acids Res</source>
					<year>2018</year>
					<volume>46</volume>
					<fpage>624</fpage>
					<lpage>32</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_013">
				<label>13.</label>
				<mixed-citation>Kameoka, J, Tanaka, T, Nojima, Y, Schlossman, SF, Morimoto, C. Direct association of adenosine deaminase with a T cell activation antigen, CD26.
					<italic>Science</italic> 1993;261:466–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kameoka</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Tanaka</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Nojima</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Schlossman</surname>
							<given-names>SF</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Direct association of adenosine deaminase with a T cell activation antigen, CD26</article-title>
					<source>Science</source>
					<year>1993</year>
					<volume>261</volume>
					<fpage>466</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_014">
				<label>14.</label>
				<mixed-citation>Wagner, L, Klemann, C, Stephan, M, von Horsten, S. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH)proteins.
					<italic>Clin Exp Imm</italic> 2016;184:265–83.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wagner</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Klemann</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Stephan</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>von Horsten</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH)proteins</article-title>
					<source>Clin Exp Imm</source>
					<year>2016</year>
					<volume>184</volume>
					<fpage>265</fpage>
					<lpage>83</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_015">
				<label>15.</label>
				<mixed-citation>Klemann, C, Wagner, L, Stephan, M, von Horsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4′s (DPP4) entanglement in the immune system.
					<italic>Clin Exp Imm</italic> 2016;185:1–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Klemann</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Wagner</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Stephan</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>von Horsten</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Cut to the chase: a review of CD26/dipeptidyl peptidase-4′s (DPP4) entanglement in the immune system</article-title>
					<source>Clin Exp Imm</source>
					<year>2016</year>
					<volume>185</volume>
					<fpage>1</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_016">
				<label>16.</label>
				<mixed-citation>Shao, S, Xu, Q, Yu, X, Pan, R, Chen, Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
					<italic>Pharmacol Ther</italic> 2020;209:107503.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Shao</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Xu</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Pan</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions</article-title>
					<source>Pharmacol Ther</source>
					<year>2020</year>
					<volume>209</volume>
					<elocation-id>107503</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_017">
				<label>17.</label>
				<mixed-citation>Arrebola, YM, Gómez, H, Valiente, PA, Chávez, MA, Pascual, I.
					<italic>Biotecnol Apl</italic> 2014;31:102–10.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Arrebola</surname>
							<given-names>YM</given-names>
						</name>
						<name>
							<surname>Gómez</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Valiente</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Chávez</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<source>Biotecnol Apl</source>
					<year>2014</year>
					<volume>31</volume>
					<fpage>102</fpage>
					<lpage>10</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_018">
				<label>18.</label>
				<mixed-citation>Schuetz, CA, Ong, SH, Blüher, M. Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.
					<italic>Clinicoecon Outcomes Res</italic> 2015;7:313–23.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Schuetz</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>Ong</surname>
							<given-names>SH</given-names>
						</name>
						<name>
							<surname>Blüher</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease</article-title>
					<source>Clinicoecon Outcomes Res</source>
					<year>2015</year>
					<volume>7</volume>
					<fpage>313</fpage>
					<lpage>23</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_019">
				<label>19.</label>
				<mixed-citation>Klemann, C, Wagner, L, Stephan, M, von Hörsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system.
					<italic>Clin Exp Immunol</italic> 2016;185:1–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Klemann</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Wagner</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Stephan</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>von Hörsten</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system</article-title>
					<source>Clin Exp Immunol</source>
					<year>2016</year>
					<volume>185</volume>
					<fpage>1</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_020">
				<label>20.</label>
				<mixed-citation>Florentin, M, Kostapanos, MS, Papazafiropoulou, AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.
					<italic>World J Diabetes</italic> 2022;13:85–96.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Florentin</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kostapanos</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Papazafiropoulou</surname>
							<given-names>AK</given-names>
						</name>
					</person-group>
					<article-title>Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment</article-title>
					<source>World J Diabetes</source>
					<year>2022</year>
					<volume>13</volume>
					<fpage>85</fpage>
					<lpage>96</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_021">
				<label>21.</label>
				<mixed-citation>Zhang, T, Tong, X, Zhang, S, Wang, D, Wang, L, Wang, Q, et al.. The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence.
					<italic>Front Pharmacol</italic> 2021;12:731453.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhang</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Tong</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Q</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence</article-title>
					<source>Front Pharmacol</source>
					<year>2021</year>
					<volume>12</volume>
					<elocation-id>731453</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_022">
				<label>22.</label>
				<mixed-citation>Green, BD, Flatt, PR, Bailey, CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes.
					<italic>Diab Vasc. Dis Res</italic> 2006;3:159–65.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Green</surname>
							<given-names>BD</given-names>
						</name>
						<name>
							<surname>Flatt</surname>
							<given-names>PR</given-names>
						</name>
						<name>
							<surname>Bailey</surname>
							<given-names>CJ</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes</article-title>
					<source>Diab Vasc. Dis Res</source>
					<year>2006</year>
					<volume>3</volume>
					<fpage>159</fpage>
					<lpage>65</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_023">
				<label>23.</label>
				<mixed-citation>Wu, D, Li, L, Liu, C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
					<italic>Diabetes Obes Metab</italic> 2014;16:30–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wu</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2014</year>
					<volume>16</volume>
					<fpage>30</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_024">
				<label>24.</label>
				<mixed-citation>Röhrborn, D, Wronkowitz, N, Eckel, J. DPP4 in diabetes.
					<italic>Front Immunol</italic> 2015;6:1–20.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Röhrborn</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Wronkowitz</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Eckel</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>DPP4 in diabetes</article-title>
					<source>Front Immunol</source>
					<year>2015</year>
					<volume>6</volume>
					<fpage>1</fpage>
					<lpage>20</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_025">
				<label>25.</label>
				<mixed-citation>Shimizu, S, Hosooka, T, Matsuda, T, Asahara, S, Koyanagi-Kimura, M, Kanno, A, et al.. DPP4 inhibitor vildagliptin preserves-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
					<italic>J Mol Endocrinol</italic> 2012;49:125–35.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Shimizu</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Hosooka</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Matsuda</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Asahara</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Koyanagi-Kimura</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kanno</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>DPP4 inhibitor vildagliptin preserves-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice</article-title>
					<source>J Mol Endocrinol</source>
					<year>2012</year>
					<volume>49</volume>
					<fpage>125</fpage>
					<lpage>35</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_026">
				<label>26.</label>
				<mixed-citation>De, S, Banerjee, S, Kumar, SK, Paira, P. Critical role of dipeptidyl peptidase IV: a therapeutic target for diabetes and cancer.
					<italic>Mini Rev Med Chem</italic> 2018;19:88–97.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>De</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Banerjee</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Kumar</surname>
							<given-names>SK</given-names>
						</name>
						<name>
							<surname>Paira</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Critical role of dipeptidyl peptidase IV: a therapeutic target for diabetes and cancer</article-title>
					<source>Mini Rev Med Chem</source>
					<year>2018</year>
					<volume>19</volume>
					<fpage>88</fpage>
					<lpage>97</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_027">
				<label>27.</label>
				<mixed-citation>Ahrén, B. DPP-4 inhibition and the path to clinical proof.
					<italic>Front Endocrinol</italic> 2019;10:1–18.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ahrén</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>DPP-4 inhibition and the path to clinical proof</article-title>
					<source>Front Endocrinol</source>
					<year>2019</year>
					<volume>10</volume>
					<fpage>1</fpage>
					<lpage>18</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_028">
				<label>28.</label>
				<mixed-citation>Arwert, EN, Mentink, RA, Driskell, RR, Hoste, E, Goldie, SJ, Quist, S. Upregulation of CD26 expression in epithelial cells and stromalcells during wound-induced skin tumour formation.
					<italic>Oncogene</italic> 2012;31:992–1000.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Arwert</surname>
							<given-names>EN</given-names>
						</name>
						<name>
							<surname>Mentink</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Driskell</surname>
							<given-names>RR</given-names>
						</name>
						<name>
							<surname>Hoste</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Goldie</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Quist</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Upregulation of CD26 expression in epithelial cells and stromalcells during wound-induced skin tumour formation</article-title>
					<source>Oncogene</source>
					<year>2012</year>
					<volume>31</volume>
					<fpage>992</fpage>
					<lpage>1000</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_029">
				<label>29.</label>
				<mixed-citation>Yamamoto, S, Tokuhara, T, Nishikawa, M, Nishizawa, S, Nishioka, T, Nozawa, A, et al.. Spontaneous regression of hepatocellular carcinoma after improving diabetes mellitus: possibly responsible for immune system.
					<italic>Kanzo</italic> 2012;53:164–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yamamoto</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tokuhara</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Nishikawa</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Nishizawa</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Nishioka</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Nozawa</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Spontaneous regression of hepatocellular carcinoma after improving diabetes mellitus: possibly responsible for immune system</article-title>
					<source>Kanzo</source>
					<year>2012</year>
					<volume>53</volume>
					<fpage>164</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_030">
				<label>30.</label>
				<mixed-citation>Abd Elhameed, AG, Helal, MG, Said, E, Salem, HA. Saxagliptin defers thioacetamide-induced hepatocarcinogenesis in rats: a novel suppressive impact on Wnt/Hedgehog/Notch1 signaling.
					<italic>Environ Toxicol Pharmacol</italic> 2021;86:103668.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Abd Elhameed</surname>
							<given-names>AG</given-names>
						</name>
						<name>
							<surname>Helal</surname>
							<given-names>MG</given-names>
						</name>
						<name>
							<surname>Said</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Salem</surname>
							<given-names>HA</given-names>
						</name>
					</person-group>
					<article-title>Saxagliptin defers thioacetamide-induced hepatocarcinogenesis in rats: a novel suppressive impact on Wnt/Hedgehog/Notch1 signaling</article-title>
					<source>Environ Toxicol Pharmacol</source>
					<year>2021</year>
					<volume>86</volume>
					<elocation-id>103668</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_031">
				<label>31.</label>
				<mixed-citation>Qin, CJ, Zhao, LH, Zhou, X, Zhang, HL, Wen, W, Tang, L, et al.. Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2.
					<italic>Cancer Lett</italic> 2018;420:26–37.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Qin</surname>
							<given-names>CJ</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>LH</given-names>
						</name>
						<name>
							<surname>Zhou</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>HL</given-names>
						</name>
						<name>
							<surname>Wen</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Tang</surname>
							<given-names>L</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2</article-title>
					<source>Cancer Lett</source>
					<year>2018</year>
					<volume>420</volume>
					<fpage>26</fpage>
					<lpage>37</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_032">
				<label>32.</label>
				<mixed-citation>Jang, JH, Baerts, L, Waumans, Y, De Meester, I, Yamada, Y, Limani, P, et al.. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice.
					<italic>Clin Exp Metastasis</italic> 2015;32:677–87.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jang</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Baerts</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Waumans</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>De Meester</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Yamada</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Limani</surname>
							<given-names>P</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice</article-title>
					<source>Clin Exp Metastasis</source>
					<year>2015</year>
					<volume>32</volume>
					<fpage>677</fpage>
					<lpage>87</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_033">
				<label>33.</label>
				<mixed-citation>Nyborg, NC, Molck, AM, Madsen, LW, Knudsen, LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
					<italic>Diabetes</italic> 2012;61:1243–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nyborg</surname>
							<given-names>NC</given-names>
						</name>
						<name>
							<surname>Molck</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Madsen</surname>
							<given-names>LW</given-names>
						</name>
						<name>
							<surname>Knudsen</surname>
							<given-names>LB</given-names>
						</name>
					</person-group>
					<article-title>The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species</article-title>
					<source>Diabetes</source>
					<year>2012</year>
					<volume>61</volume>
					<fpage>1243</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_034">
				<label>34.</label>
				<mixed-citation>Ligumsky, H, Wolf, I, Israeli, S, Haimsohn, M, Ferber, S, Karasik, A. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
					<italic>Breast Cancer Res Treat</italic> 2012;132:449–61.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ligumsky</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Wolf</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Israeli</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Haimsohn</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ferber</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Karasik</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells</article-title>
					<source>Breast Cancer Res Treat</source>
					<year>2012</year>
					<volume>132</volume>
					<fpage>449</fpage>
					<lpage>61</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_035">
				<label>35.</label>
				<mixed-citation>Rivera, L, Arrebola, Y, Valdés-Tresanco, ME, Díaz-Guevara, L, Bergado, G, Sánchez, B, et al.. Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability.
					<italic>Int J Biol Macromol</italic> 2020;164:2944–52.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rivera</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Arrebola</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Valdés-Tresanco</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Díaz-Guevara</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Bergado</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Sánchez</surname>
							<given-names>B</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability</article-title>
					<source>Int J Biol Macromol</source>
					<year>2020</year>
					<volume>164</volume>
					<fpage>2944</fpage>
					<lpage>52</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_036">
				<label>36.</label>
				<mixed-citation>Rathmann, W, Kostev, K. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
					<italic>J Diabetes Complicat</italic> 2017;31:687–92.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rathmann</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Kostev</surname>
							<given-names>K</given-names>
						</name>
					</person-group>
					<article-title>Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer</article-title>
					<source>J Diabetes Complicat</source>
					<year>2017</year>
					<volume>31</volume>
					<fpage>687</fpage>
					<lpage>92</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_037">
				<label>37.</label>
				<mixed-citation>Noh, Y, Jeon, SM, Shin, S. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
					<italic>Int J Cancer</italic> 2019;144:1530–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Noh</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Jeon</surname>
							<given-names>SM</given-names>
						</name>
						<name>
							<surname>Shin</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy</article-title>
					<source>Int J Cancer</source>
					<year>2019</year>
					<volume>144</volume>
					<fpage>1530</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_038">
				<label>38.</label>
				<mixed-citation>Matteucci, E, Giampietro, O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
					<italic>Curr Med Chem</italic> 2009;16:2943–51.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Matteucci</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Giampietro</surname>
							<given-names>O</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme</article-title>
					<source>Curr Med Chem</source>
					<year>2009</year>
					<volume>16</volume>
					<fpage>2943</fpage>
					<lpage>51</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_039">
				<label>39.</label>
				<mixed-citation>Klemann, C, Wagner, L, Stephan, M, von Hörsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system.
					<italic>Clin Exp Immunol</italic> 2016;185:1–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Klemann</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Wagner</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Stephan</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>von Hörsten</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system</article-title>
					<source>Clin Exp Immunol</source>
					<year>2016</year>
					<volume>185</volume>
					<fpage>1</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_040">
				<label>40.</label>
				<mixed-citation>Hopsu-Havu, VK, Glenner, GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide.
					<italic>Histochemie</italic> 1966;7:197–201.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hopsu-Havu</surname>
							<given-names>VK</given-names>
						</name>
						<name>
							<surname>Glenner</surname>
							<given-names>GG</given-names>
						</name>
					</person-group>
					<article-title>A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide</article-title>
					<source>Histochemie</source>
					<year>1966</year>
					<volume>7</volume>
					<fpage>197</fpage>
					<lpage>201</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_041">
				<label>41.</label>
				<mixed-citation>Yu, DM, Yao, TW, Chowdhury, S, Nadvi, NA, Osborne, B, Church, WB. The dipeptidyl peptidase IV family in cancer and cell biology.
					<italic>FEBS J</italic> 2010;277:1126–44.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yu</surname>
							<given-names>DM</given-names>
						</name>
						<name>
							<surname>Yao</surname>
							<given-names>TW</given-names>
						</name>
						<name>
							<surname>Chowdhury</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Nadvi</surname>
							<given-names>NA</given-names>
						</name>
						<name>
							<surname>Osborne</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Church</surname>
							<given-names>WB</given-names>
						</name>
					</person-group>
					<article-title>The dipeptidyl peptidase IV family in cancer and cell biology</article-title>
					<source>FEBS J</source>
					<year>2010</year>
					<volume>277</volume>
					<fpage>1126</fpage>
					<lpage>44</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_042">
				<label>42.</label>
				<mixed-citation>Mulvihill, EE, Drucker, DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
					<italic>Endocr Rev</italic> 2014;35:992–1019.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mulvihill</surname>
							<given-names>EE</given-names>
						</name>
						<name>
							<surname>Drucker</surname>
							<given-names>DJ</given-names>
						</name>
					</person-group>
					<article-title>Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors</article-title>
					<source>Endocr Rev</source>
					<year>2014</year>
					<volume>35</volume>
					<fpage>992</fpage>
					<lpage>1019</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_043">
				<label>43.</label>
				<mixed-citation>Klemann, C, Wagner, L, Stephan, M, von Horsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system.
					<italic>Clin Exp Immunol</italic> 2016;185:1–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Klemann</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Wagner</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Stephan</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>von Horsten</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system</article-title>
					<source>Clin Exp Immunol</source>
					<year>2016</year>
					<volume>185</volume>
					<fpage>1</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_044">
				<label>44.</label>
				<mixed-citation>Gutheil, WG, Subramanyam, M, Flentke, GR, Sanford, DG, Munoz, E, Huber, BT, et al.. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat’s immunosuppressive activity.
					<italic>Proc Natl Acad Sci USA</italic> 1994;91:6594–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gutheil</surname>
							<given-names>WG</given-names>
						</name>
						<name>
							<surname>Subramanyam</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Flentke</surname>
							<given-names>GR</given-names>
						</name>
						<name>
							<surname>Sanford</surname>
							<given-names>DG</given-names>
						</name>
						<name>
							<surname>Munoz</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Huber</surname>
							<given-names>BT</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat’s immunosuppressive activity</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>1994</year>
					<volume>91</volume>
					<fpage>6594</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_045">
				<label>45.</label>
				<mixed-citation>Blanco, J, Valenzuela, A, Herrera, C, Lluis, C, Hovanessian, AG, Franco, R. The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression.
					<italic>FEBS Lett</italic> 2000;477:123–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Blanco</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Valenzuela</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Herrera</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Lluis</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Hovanessian</surname>
							<given-names>AG</given-names>
						</name>
						<name>
							<surname>Franco</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression</article-title>
					<source>FEBS Lett</source>
					<year>2000</year>
					<volume>477</volume>
					<fpage>123</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_046">
				<label>46.</label>
				<mixed-citation>Lu, G, Hu, Y, Wang, Q, Qi, J, Gao, F, Li, Y, et al.. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26.
					<italic>Nature</italic> 2013;500:227–31.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lu</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Qi</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Gao</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>Y</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26</article-title>
					<source>Nature</source>
					<year>2013</year>
					<volume>500</volume>
					<fpage>227</fpage>
					<lpage>31</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_047">
				<label>47.</label>
				<mixed-citation>Bohm, SK, Gum, JR, Erickson, RH, Hicks, JW, Kim, YS. Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter.
					<italic>Biochem J</italic> 1995;311:835–43.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bohm</surname>
							<given-names>SK</given-names>
						</name>
						<name>
							<surname>Gum</surname>
							<given-names>JR</given-names>
						</name>
						<name>
							<surname>Erickson</surname>
							<given-names>RH</given-names>
						</name>
						<name>
							<surname>Hicks</surname>
							<given-names>JW</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>YS</given-names>
						</name>
					</person-group>
					<article-title>Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter</article-title>
					<source>Biochem J</source>
					<year>1995</year>
					<volume>311</volume>
					<fpage>835</fpage>
					<lpage>43</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_048">
				<label>48.</label>
				<mixed-citation>The Human Protein Atlas; 2003. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue">http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue</ext-link> [Accessed 11 Sep 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>The Human Protein Atlas</surname>
						</name>
					</person-group>
					<year>2003</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue">http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">11 Sep 2022</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_049">
				<label>49.</label>
				<mixed-citation>NLH National Library of Medicine, National Center for Biotechnology Information; 2023. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/gene?Db=gene&amp;Cmd=DetailsSearch&amp;Term=1803">http://www.ncbi.nlm.hih.gov/protein/gene?Db=gene&amp;Cmd=DetailsSearch&amp;Term=1803</ext-link> [Accessed 10 Feb 2023].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>NLH National Library of Medicine</surname>
						</name>
					</person-group>
					<publisher-name>National Center for Biotechnology Information</publisher-name>
					<year>2023</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/gene?Db=gene&amp;Cmd=DetailsSearch&amp;Term=1803">http://www.ncbi.nlm.hih.gov/protein/gene?Db=gene&amp;Cmd=DetailsSearch&amp;Term=1803</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">10 Feb 2023</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_050">
				<label>50.</label>
				<mixed-citation>NLH National Library of Medicine, National Center for Biotechnology Information; 2023. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1</ext-link> [Accessed 10 Feb 2023].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>NLH National Library of Medicine</surname>
						</name>
					</person-group>
					<publisher-name>National Center for Biotechnology Information</publisher-name>
					<year>2023</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">10 Feb 2023</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_051">
				<label>51.</label>
				<mixed-citation>NLH National Library of Medicine, National Center for Biotechnology Information; 2023. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001926.2">http://www.ncbi.nlm.hih.gov/protein/NP_001926.2</ext-link> [Accessed 10 Feb 2023].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>NLH National Library of Medicine</surname>
						</name>
					</person-group>
					<publisher-name>National Center for Biotechnology Information</publisher-name>
					<year>2023</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001926.2">http://www.ncbi.nlm.hih.gov/protein/NP_001926.2</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">10 Feb 2023</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_052">
				<label>52.</label>
				<mixed-citation>NLH National Library of Medicine, National Center for Biotechnology Information; 2023. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366533.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366533.1</ext-link> [Accessed 10 Feb 2023].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>NLH National Library of Medicine</surname>
						</name>
					</person-group>
					<publisher-name>National Center for Biotechnology Information</publisher-name>
					<year>2023</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366533.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366533.1</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">10 Feb 2023</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_053">
				<label>53.</label>
				<mixed-citation>NLH National Library of Medicine, National Center for Biotechnology Information; 2023. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366534.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366534.1</ext-link> [Accessed 10 Feb 2023].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>NLH National Library of Medicine</surname>
						</name>
					</person-group>
					<publisher-name>National Center for Biotechnology Information</publisher-name>
					<year>2023</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366534.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366534.1</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">10 Feb 2023</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_054">
				<label>54.</label>
				<mixed-citation>
					<collab>NLH National Library of Medicine</collab>. National Center for Biotechnology Information; 2023. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1</ext-link> [Accessed 10 Feb 2023].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<collab>NLH National Library of Medicine</collab>
					</person-group>
					<publisher-name>National Center for Biotechnology Information</publisher-name>
					<year>2023</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1">http://www.ncbi.nlm.hih.gov/protein/NP_001366535.1</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">10 Feb 2023</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_055">
				<label>55.</label>
				<mixed-citation>Kahne, T, Kroning, H, Thiel, U, Ulmer, AJ, Flad, HD, Ansorge, S. Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation.
					<italic>Cell Immunol</italic> 1996;170:63–70.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kahne</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kroning</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Thiel</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Ulmer</surname>
							<given-names>AJ</given-names>
						</name>
						<name>
							<surname>Flad</surname>
							<given-names>HD</given-names>
						</name>
						<name>
							<surname>Ansorge</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation</article-title>
					<source>Cell Immunol</source>
					<year>1996</year>
					<volume>170</volume>
					<fpage>63</fpage>
					<lpage>70</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_056">
				<label>56.</label>
				<mixed-citation>The Human Protein Atlas; 2003. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000197635-DPP4/mRNA">http://www.proteinatlas.org/ENSG00000197635-DPP4/mRNA</ext-link> [Accessed 10 Feb 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>The Human Protein Atlas</surname>
						</name>
					</person-group>
					<year>2003</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000197635-DPP4/mRNA">http://www.proteinatlas.org/ENSG00000197635-DPP4/mRNA</ext-link>
					<comment>[Accessed</comment>
					<date-in-citation content-type="access">10 Feb 2022</date-in-citation>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_057">
				<label>57.</label>
				<mixed-citation>Engel, M, Hoffmann, T, Wagner, L, Wermann, M, Heiser, U, Kiefersauer, R. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism.
					<italic>Proc Natl Acad Sci USA</italic> 2003;100:5063–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Engel</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Hoffmann</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Wagner</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Wermann</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Heiser</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Kiefersauer</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>2003</year>
					<volume>100</volume>
					<fpage>5063</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_058">
				<label>58.</label>
				<mixed-citation>Rasmussen, HB, Branner, S, Wiberg, FC, Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.
					<italic>Nat Struct Biol</italic> 2003;10:19–25.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rasmussen</surname>
							<given-names>HB</given-names>
						</name>
						<name>
							<surname>Branner</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Wiberg</surname>
							<given-names>FC</given-names>
						</name>
						<name>
							<surname>Wagtmann</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog</article-title>
					<source>Nat Struct Biol</source>
					<year>2003</year>
					<volume>10</volume>
					<fpage>19</fpage>
					<lpage>25</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_059">
				<label>59.</label>
				<mixed-citation>Duke-Cohan, JS, Morimoto, C, Rocker, JA, Schlossman, SF. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells.
					<italic>J Immunol</italic> 1996;156:1714–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Duke-Cohan</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Rocker</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Schlossman</surname>
							<given-names>SF</given-names>
						</name>
					</person-group>
					<article-title>Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells</article-title>
					<source>J Immunol</source>
					<year>1996</year>
					<volume>156</volume>
					<fpage>1714</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_060">
				<label>60.</label>
				<mixed-citation>Pascual, I, Gomez, H, Pons, T, Chappe, M, Vargas, MA, Valdes, G. Effect of divalent cations on the porcine kidney cortex membrane-bound form of dipeptidyl peptidase IV.
					<italic>Int J Biochem Cell Biol</italic> 2011;43:363–71.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Gomez</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Pons</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Chappe</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Vargas</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Valdes</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>Effect of divalent cations on the porcine kidney cortex membrane-bound form of dipeptidyl peptidase IV</article-title>
					<source>Int J Biochem Cell Biol</source>
					<year>2011</year>
					<volume>43</volume>
					<fpage>363</fpage>
					<lpage>71</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_061">
				<label>61.</label>
				<mixed-citation>Gomez, H, Chappe, M, Valiente, PA, Pons, T, Chavez, ML, Charli, JL. Effect of zinc and calcium ions on the rat kidney membrane-bound form of dipeptidyl peptidase IV.
					<italic>J Biosci</italic> 2013;38:461–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gomez</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Chappe</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Valiente</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Pons</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Chavez</surname>
							<given-names>ML</given-names>
						</name>
						<name>
							<surname>Charli</surname>
							<given-names>JL</given-names>
						</name>
					</person-group>
					<article-title>Effect of zinc and calcium ions on the rat kidney membrane-bound form of dipeptidyl peptidase IV</article-title>
					<source>J Biosci</source>
					<year>2013</year>
					<volume>38</volume>
					<fpage>461</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_062">
				<label>62.</label>
				<mixed-citation>Mentlein, R. Dipeptidyl-peptidase IV (CD26) Role in the inactivation of regulatory peptides.
					<italic>Regul Pept</italic> 1999;85:9–24.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mentlein</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl-peptidase IV (CD26) Role in the inactivation of regulatory peptides</article-title>
					<source>Regul Pept</source>
					<year>1999</year>
					<volume>85</volume>
					<fpage>9</fpage>
					<lpage>24</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_063">
				<label>63.</label>
				<mixed-citation>Lee, KN, Jackson, KW, Christiansen, VJ, Chung, KH, McKee, PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
					<italic>Blood</italic> 2004;103:3783–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lee</surname>
							<given-names>KN</given-names>
						</name>
						<name>
							<surname>Jackson</surname>
							<given-names>KW</given-names>
						</name>
						<name>
							<surname>Christiansen</surname>
							<given-names>VJ</given-names>
						</name>
						<name>
							<surname>Chung</surname>
							<given-names>KH</given-names>
						</name>
						<name>
							<surname>McKee</surname>
							<given-names>PA</given-names>
						</name>
					</person-group>
					<article-title>A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion</article-title>
					<source>Blood</source>
					<year>2004</year>
					<volume>103</volume>
					<fpage>3783</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_064">
				<label>64.</label>
				<mixed-citation>Ajami, K, Abbott, CA, McCaughan, GW, Gorrell, MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity.
					<italic>Biochim Biophys Acta</italic> 2004;1679:18–28.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ajami</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Abbott</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>McCaughan</surname>
							<given-names>GW</given-names>
						</name>
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity</article-title>
					<source>Biochim Biophys Acta</source>
					<year>2004</year>
					<volume>1679</volume>
					<fpage>18</fpage>
					<lpage>28</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_065">
				<label>65.</label>
				<mixed-citation>Delacour, D, Gouyer, V, Leteurtre, E, Ait-Slimane, T, Drobecq, H, Lenoir, C. 1-benzyl-2-acetamido-2-deoxy-alphaD-galactopyranoside blocks the apical biosynthetic pathway in polarized HT-29 cells.
					<italic>J Biol Chem</italic> 2003;278:37799–809.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Delacour</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Gouyer</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Leteurtre</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Ait-Slimane</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Drobecq</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Lenoir</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>1-benzyl-2-acetamido-2-deoxy-alphaD-galactopyranoside blocks the apical biosynthetic pathway in polarized HT-29 cells</article-title>
					<source>J Biol Chem</source>
					<year>2003</year>
					<volume>278</volume>
					<fpage>37799</fpage>
					<lpage>809</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_066">
				<label>66.</label>
				<mixed-citation>Thoma, R, Loffler, B, Stihle, M, Huber, W, Ruf, A, Hennig, M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV.
					<italic>Structure</italic> 2003;11:947–59.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Thoma</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Loffler</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Stihle</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Huber</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Ruf</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Hennig</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV</article-title>
					<source>Structure</source>
					<year>2003</year>
					<volume>11</volume>
					<fpage>947</fpage>
					<lpage>59</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_067">
				<label>67.</label>
				<mixed-citation>Aertgeerts, K, Ye, S, Tennant, MG, Kraus, ML, Rogers, J, Sang, BC. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation.
					<italic>Protein Sci</italic> 2004;13:412–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Aertgeerts</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Ye</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tennant</surname>
							<given-names>MG</given-names>
						</name>
						<name>
							<surname>Kraus</surname>
							<given-names>ML</given-names>
						</name>
						<name>
							<surname>Rogers</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Sang</surname>
							<given-names>BC</given-names>
						</name>
					</person-group>
					<article-title>Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation</article-title>
					<source>Protein Sci</source>
					<year>2004</year>
					<volume>13</volume>
					<fpage>412</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_068">
				<label>68.</label>
				<mixed-citation>Abbott, CA, McCaughan, GW, Gorrell, MD. Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity.
					<italic>FEBS Lett</italic> 1999;458:278–84.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Abbott</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>McCaughan</surname>
							<given-names>GW</given-names>
						</name>
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
					</person-group>
					<article-title>Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity</article-title>
					<source>FEBS Lett</source>
					<year>1999</year>
					<volume>458</volume>
					<fpage>278</fpage>
					<lpage>84</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_069">
				<label>69.</label>
				<mixed-citation>Ajami, K, Abbott, CA, Obradovic, M, Gysbers, V, Kahne, T, McCaughan, GW. Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family.
					<italic>Biochemistry</italic> 2003;42:694–701.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ajami</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Abbott</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>Obradovic</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Gysbers</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Kahne</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>McCaughan</surname>
							<given-names>GW</given-names>
						</name>
					</person-group>
					<article-title>Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family</article-title>
					<source>Biochemistry</source>
					<year>2003</year>
					<volume>42</volume>
					<fpage>694</fpage>
					<lpage>701</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_070">
				<label>70.</label>
				<mixed-citation>Chien, CH, Huang, LH, Chou, CY, Chen, YS, Han, YS, Chang, GG. One site mutation disrupts dimer formation in human DPP-IV proteins.
					<italic>J Biol Chem</italic> 2004;279:52338–45.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chien</surname>
							<given-names>CH</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>LH</given-names>
						</name>
						<name>
							<surname>Chou</surname>
							<given-names>CY</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>YS</given-names>
						</name>
						<name>
							<surname>Han</surname>
							<given-names>YS</given-names>
						</name>
						<name>
							<surname>Chang</surname>
							<given-names>GG</given-names>
						</name>
					</person-group>
					<article-title>One site mutation disrupts dimer formation in human DPP-IV proteins</article-title>
					<source>J Biol Chem</source>
					<year>2004</year>
					<volume>279</volume>
					<fpage>52338</fpage>
					<lpage>45</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_071">
				<label>71.</label>
				<mixed-citation>Varghese, JN, Laver, WG, Colman, PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution.
					<italic>Nature</italic> 1983;303:35–40.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Varghese</surname>
							<given-names>JN</given-names>
						</name>
						<name>
							<surname>Laver</surname>
							<given-names>WG</given-names>
						</name>
						<name>
							<surname>Colman</surname>
							<given-names>PM</given-names>
						</name>
					</person-group>
					<article-title>Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution</article-title>
					<source>Nature</source>
					<year>1983</year>
					<volume>303</volume>
					<fpage>35</fpage>
					<lpage>40</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_072">
				<label>72.</label>
				<mixed-citation>Vellieux, FM, Huitema, F, Groendijk, H, Kalk, KH, Jzn, JF, Jongejan, JA. Structure of quinoprotein methylamine dehydrogenase at 2.25 A resolution.
					<italic>EMBO J</italic> 1989;8:2171–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Vellieux</surname>
							<given-names>FM</given-names>
						</name>
						<name>
							<surname>Huitema</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Groendijk</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Kalk</surname>
							<given-names>KH</given-names>
						</name>
						<name>
							<surname>Jzn</surname>
							<given-names>JF</given-names>
						</name>
						<name>
							<surname>Jongejan</surname>
							<given-names>JA</given-names>
						</name>
					</person-group>
					<article-title>Structure of quinoprotein methylamine dehydrogenase at 2.25 A resolution</article-title>
					<source>EMBO J</source>
					<year>1989</year>
					<volume>8</volume>
					<fpage>2171</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_073">
				<label>73.</label>
				<mixed-citation>Ito, N, Phillips, SE, Stevens, C, Ogel, ZB, McPherson, MJ, Keen, JN. Novel thioether bond revealed by a 1.7 A crystal structure of galactose oxidase.
					<italic>Nature</italic> 1983;350:87–90.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ito</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Phillips</surname>
							<given-names>SE</given-names>
						</name>
						<name>
							<surname>Stevens</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Ogel</surname>
							<given-names>ZB</given-names>
						</name>
						<name>
							<surname>McPherson</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Keen</surname>
							<given-names>JN</given-names>
						</name>
					</person-group>
					<article-title>Novel thioether bond revealed by a 1.7 A crystal structure of galactose oxidase</article-title>
					<source>Nature</source>
					<year>1983</year>
					<volume>350</volume>
					<fpage>87</fpage>
					<lpage>90</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_074">
				<label>74.</label>
				<mixed-citation>Xia, ZX, Dai, WW, Xiong, JP, Hao, ZP, Davidson, VL, White, S. The three-dimensional structures of methanol dehydrogenase from two methylotrophic bacteria at 2.6-A resolution.
					<italic>J Biol Chem</italic> 1992;267:22289–97.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Xia</surname>
							<given-names>ZX</given-names>
						</name>
						<name>
							<surname>Dai</surname>
							<given-names>WW</given-names>
						</name>
						<name>
							<surname>Xiong</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>Hao</surname>
							<given-names>ZP</given-names>
						</name>
						<name>
							<surname>Davidson</surname>
							<given-names>VL</given-names>
						</name>
						<name>
							<surname>White</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>The three-dimensional structures of methanol dehydrogenase from two methylotrophic bacteria at 2.6-A resolution</article-title>
					<source>J Biol Chem</source>
					<year>1992</year>
					<volume>267</volume>
					<fpage>22289</fpage>
					<lpage>97</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_075">
				<label>75.</label>
				<mixed-citation>Murzin, AG. Structural principles for the propeller assembly of beta-sheets: the preference for seven-fold symmetry.
					<italic>Proteins</italic> 1992;14:191–201.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Murzin</surname>
							<given-names>AG</given-names>
						</name>
					</person-group>
					<article-title>Structural principles for the propeller assembly of beta-sheets: the preference for seven-fold symmetry</article-title>
					<source>Proteins</source>
					<year>1992</year>
					<volume>14</volume>
					<fpage>191</fpage>
					<lpage>201</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_076">
				<label>76.</label>
				<mixed-citation>Fülöp, V, Jones, DT. Beta propellers: structural rigidity and functional diversity.
					<italic>Curr Opin Struct Biol</italic> 1999;9:715–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fülöp</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Jones</surname>
							<given-names>DT</given-names>
						</name>
					</person-group>
					<article-title>Beta propellers: structural rigidity and functional diversity</article-title>
					<source>Curr Opin Struct Biol</source>
					<year>1999</year>
					<volume>9</volume>
					<fpage>715</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_077">
				<label>77.</label>
				<mixed-citation>Paoli, M. Protein folds propelled by diversity.
					<italic>Prog Biophys Mol Biol</italic> 2001;76:103–30.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Paoli</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Protein folds propelled by diversity</article-title>
					<source>Prog Biophys Mol Biol</source>
					<year>2001</year>
					<volume>76</volume>
					<fpage>103</fpage>
					<lpage>30</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_078">
				<label>78.</label>
				<mixed-citation>Jawad, Z, Paoli, M. Novel sequences propel familiar folds.
					<italic>Structure</italic> 2002;10:447–54.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jawad</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Paoli</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Novel sequences propel familiar folds</article-title>
					<source>Structure</source>
					<year>2002</year>
					<volume>10</volume>
					<fpage>447</fpage>
					<lpage>54</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_079">
				<label>79.</label>
				<mixed-citation>Adams, J, Kelso, R, Cooley, L. The kelch repeat superfamily of proteins: propellers of cell function.
					<italic>Trends Cell Biol</italic> 2000;10:17–24.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Adams</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Kelso</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Cooley</surname>
							<given-names>L</given-names>
						</name>
					</person-group>
					<article-title>The kelch repeat superfamily of proteins: propellers of cell function</article-title>
					<source>Trends Cell Biol</source>
					<year>2000</year>
					<volume>10</volume>
					<fpage>17</fpage>
					<lpage>24</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_080">
				<label>80.</label>
				<mixed-citation>Russell, RB, Sasieni, PD, Sternberg, MJ. Supersites within superfolds. Binding site similarity in the absence of homology.
					<italic>J Mol Biol</italic> 1998;282:903–18.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Russell</surname>
							<given-names>RB</given-names>
						</name>
						<name>
							<surname>Sasieni</surname>
							<given-names>PD</given-names>
						</name>
						<name>
							<surname>Sternberg</surname>
							<given-names>MJ</given-names>
						</name>
					</person-group>
					<article-title>Supersites within superfolds. Binding site similarity in the absence of homology</article-title>
					<source>J Mol Biol</source>
					<year>1998</year>
					<volume>282</volume>
					<fpage>903</fpage>
					<lpage>18</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_081">
				<label>81.</label>
				<mixed-citation>Todd, AE, Orengo, CA, Thornton, JM. Evolution of function in protein superfamilies, from a structural perspective.
					<italic>J Mol Biol</italic> 2001;307:1113–43.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Todd</surname>
							<given-names>AE</given-names>
						</name>
						<name>
							<surname>Orengo</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>Thornton</surname>
							<given-names>JM</given-names>
						</name>
					</person-group>
					<article-title>Evolution of function in protein superfamilies, from a structural perspective</article-title>
					<source>J Mol Biol</source>
					<year>2001</year>
					<volume>307</volume>
					<fpage>1113</fpage>
					<lpage>43</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_082">
				<label>82.</label>
				<mixed-citation>Pons, T, Gomez, R, Chinea, G, Valencia, A. Beta-propellers: associated functions and their role in human diseases.
					<italic>Curr Med Chem</italic> 2003;10:505–24.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pons</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Gomez</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Chinea</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Valencia</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Beta-propellers: associated functions and their role in human diseases</article-title>
					<source>Curr Med Chem</source>
					<year>2003</year>
					<volume>10</volume>
					<fpage>505</fpage>
					<lpage>24</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_083">
				<label>83.</label>
				<mixed-citation>Love, CA, Harlos, K, Mavaddat, N, Davis, SJ, Stuart, DI, Jones, EY. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D.
					<italic>Nat Struct Biol</italic> 2003;10:843–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Love</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>Harlos</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Mavaddat</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Davis</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Stuart</surname>
							<given-names>DI</given-names>
						</name>
						<name>
							<surname>Jones</surname>
							<given-names>EY</given-names>
						</name>
					</person-group>
					<article-title>The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D</article-title>
					<source>Nat Struct Biol</source>
					<year>2003</year>
					<volume>10</volume>
					<fpage>843</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_084">
				<label>84.</label>
				<mixed-citation>Xiong, JP, Stehle, T, Diefenbach, B, Zhang, R, Dunker, R, Scott, DL. Crystal structure of the extracellular segment of integrin alpha Vbeta3.
					<italic>Science</italic> 2001;294:339–45.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Xiong</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>Stehle</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Diefenbach</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Dunker</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Scott</surname>
							<given-names>DL</given-names>
						</name>
					</person-group>
					<article-title>Crystal structure of the extracellular segment of integrin alpha Vbeta3</article-title>
					<source>Science</source>
					<year>2001</year>
					<volume>294</volume>
					<fpage>339</fpage>
					<lpage>45</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_085">
				<label>85.</label>
				<mixed-citation>Gorrell, MD, Wang, XM, Park, J, Ajami, K, Yu, DM, Knott, H. Structure and function in dipeptidyl peptidase IV and related proteins.
					<italic>Adv Exp Med Biol</italic> 2006;575:45–54.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>XM</given-names>
						</name>
						<name>
							<surname>Park</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ajami</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>DM</given-names>
						</name>
						<name>
							<surname>Knott</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Structure and function in dipeptidyl peptidase IV and related proteins</article-title>
					<source>Adv Exp Med Biol</source>
					<year>2006</year>
					<volume>575</volume>
					<fpage>45</fpage>
					<lpage>54</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_086">
				<label>86.</label>
				<mixed-citation>Gorrell, MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders.
					<italic>Clin Sci (Lond)</italic> 2005;108:277–92.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders</article-title>
					<source>Clin Sci (Lond)</source>
					<year>2005</year>
					<volume>108</volume>
					<fpage>277</fpage>
					<lpage>92</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_087">
				<label>87.</label>
				<mixed-citation>Hiramatsu, H, Yamamoto, A, Kyono, K, Higashiyama, Y, Fukushima, C, Shima, H. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A.
					<italic>Biol Chem</italic> 2004;385:561–4.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hiramatsu</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Yamamoto</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kyono</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Higashiyama</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Fukushima</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Shima</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A</article-title>
					<source>Biol Chem</source>
					<year>2004</year>
					<volume>385</volume>
					<fpage>561</fpage>
					<lpage>4</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_088">
				<label>88.</label>
				<mixed-citation>Oefner, C, D’Arcy, A, Mac Sweeney, A, Pierau, S, Gardiner, R, Dale, GE. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine.
					<italic>Acta Crystallogr D Biol Crystallogr</italic> 2003;59:1206–12.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Oefner</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>D’Arcy</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Mac Sweeney</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Pierau</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Gardiner</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Dale</surname>
							<given-names>GE</given-names>
						</name>
					</person-group>
					<article-title>High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine</article-title>
					<source>Acta Crystallogr D Biol Crystallogr</source>
					<year>2003</year>
					<volume>59</volume>
					<fpage>1206</fpage>
					<lpage>12</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_089">
				<label>89.</label>
				<mixed-citation>Weihofen, WA, Liu, J, Reutter, W, Saenger, W, Fan, H. Crystal structure of CD26 dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface.
					<italic>J Biol Chem</italic> 2004;279:43330–5.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Weihofen</surname>
							<given-names>WA</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Reutter</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Saenger</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Fan</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Crystal structure of CD26 dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface</article-title>
					<source>J Biol Chem</source>
					<year>2004</year>
					<volume>279</volume>
					<fpage>43330</fpage>
					<lpage>5</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_090">
				<label>90.</label>
				<mixed-citation>Abbott, CA, Gorrell, MD. The family of CD26/DPP-IV and related ectopeptidases. In: Langner, J, Ansorge, S, editors.
					<italic>Ectopeptidases. CD13/aminopeptidase N and CD26/dipeptidylpeptidase IV in medicine and biology</italic>. New York: Kluwer Academic/Plenum Publishers; 2002. pp. 171–95.
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Abbott</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
					</person-group>
					<article-title>The family of CD26/DPP-IV and related ectopeptidases</article-title>
					<person-group person-group-type="editor">
						<name>
							<surname>Langner</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ansorge</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<source>Ectopeptidases. CD13/aminopeptidase N and CD26/dipeptidylpeptidase IV in medicine and biology</source>
					<publisher-loc>New York</publisher-loc>
					<publisher-name>Kluwer Academic/Plenum Publishers</publisher-name>
					<year>2002</year>
					<fpage>171</fpage>
					<lpage>95</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_091">
				<label>91.</label>
				<mixed-citation>Yoshimoto, T, Tsuru, D. Proline-specifc dipeptidyl aminopeptidase from Flavobacterium meningosepticum.
					<italic>J. Biochem</italic> 1982;91:1899–906.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yoshimoto</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Tsuru</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Proline-specifc dipeptidyl aminopeptidase from Flavobacterium meningosepticum</article-title>
					<source>J. Biochem</source>
					<year>1982</year>
					<volume>91</volume>
					<fpage>1899</fpage>
					<lpage>906</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_092">
				<label>92.</label>
				<mixed-citation>Cox, SW, Eley, BM. Detection of cathepsin B- and L-, elastase-, tryptase-, trypsin-, and dipeptidyl peptidase IV-like activities in crevicular fuid from gingivitis and periodontitis patients with peptidyl derivatives of 7-amino-4-trifuoromethyl coumarin.
					<italic>J Periodontal Res</italic> 1989;24:353–61.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cox</surname>
							<given-names>SW</given-names>
						</name>
						<name>
							<surname>Eley</surname>
							<given-names>BM</given-names>
						</name>
					</person-group>
					<article-title>Detection of cathepsin B- and L-, elastase-, tryptase-, trypsin-, and dipeptidyl peptidase IV-like activities in crevicular fuid from gingivitis and periodontitis patients with peptidyl derivatives of 7-amino-4-trifuoromethyl coumarin</article-title>
					<source>J Periodontal Res</source>
					<year>1989</year>
					<volume>24</volume>
					<fpage>353</fpage>
					<lpage>61</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_093">
				<label>93.</label>
				<mixed-citation>Mayo, B. Molecular cloning and sequence analysis of the X-prolyl dipeptidyl aminopeptidase gene from Lactococcus lactis subsp. cremoris.
					<italic>Appl Environ Microbiol</italic> 1991;57:38–44.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mayo</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>Molecular cloning and sequence analysis of the X-prolyl dipeptidyl aminopeptidase gene from Lactococcus lactis subsp. cremoris</article-title>
					<source>Appl Environ Microbiol</source>
					<year>1991</year>
					<volume>57</volume>
					<fpage>38</fpage>
					<lpage>44</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_094">
				<label>94.</label>
				<mixed-citation>Kabashima, T, Ito, K, Yoshimoto, T. Dipeptidyl peptidase IV from Xanthomonas maltophilia: sequencing and expression of the enzyme gene and characterization of the expressed enzyme.
					<italic>J Biochem</italic> 1996;120:1111–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kabashima</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Ito</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yoshimoto</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV from Xanthomonas maltophilia: sequencing and expression of the enzyme gene and characterization of the expressed enzyme</article-title>
					<source>J Biochem</source>
					<year>1996</year>
					<volume>120</volume>
					<fpage>1111</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_095">
				<label>95.</label>
				<mixed-citation>Ogasawara, W, Ogawa, Y, Yano, K, Okada, H, Morikawa, Y. Dipeptidyl aminopeptidase IV from Pseudomonas sp. WO24.
					<italic>Biosci. Biotechnol. Biochem</italic> 1996;60:2032–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ogasawara</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Ogawa</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Yano</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Okada</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Morikawa</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl aminopeptidase IV from Pseudomonas sp. WO24</article-title>
					<source>Biosci. Biotechnol. Biochem</source>
					<year>1996</year>
					<volume>60</volume>
					<fpage>2032</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_096">
				<label>96.</label>
				<mixed-citation>Shibata, Y, Miwa, Y, Hirai, K, Fujimura, S. Purification and partial characterization of a dipeptidyl peptidase from Prevotella intermedia.
					<italic>Oral Microbiol Immunol</italic> 2003;18:196–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Shibata</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Miwa</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Hirai</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Fujimura</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Purification and partial characterization of a dipeptidyl peptidase from Prevotella intermedia</article-title>
					<source>Oral Microbiol Immunol</source>
					<year>2003</year>
					<volume>18</volume>
					<fpage>196</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_097">
				<label>97.</label>
				<mixed-citation>Kuwahara, T. Genomic analysis of Bacteroides fragilisreveals extensive DNA inversions regulating cell surface adaptation.
					<italic>Proc Natl Acad Sci USA</italic> 2004;101:14919–24.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kuwahara</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Genomic analysis of Bacteroides fragilisreveals extensive DNA inversions regulating cell surface adaptation</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>2004</year>
					<volume>101</volume>
					<fpage>14919</fpage>
					<lpage>24</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_098">
				<label>98.</label>
				<mixed-citation>Monod, M. Aminopeptidases and dipeptidyl-peptidases secreted by the dermatophyte Trichophyton rubrum.
					<italic>Microbiology</italic> 2005;151:145–55.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Monod</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Aminopeptidases and dipeptidyl-peptidases secreted by the dermatophyte Trichophyton rubrum</article-title>
					<source>Microbiology</source>
					<year>2005</year>
					<volume>151</volume>
					<fpage>145</fpage>
					<lpage>55</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_099">
				<label>99.</label>
				<mixed-citation>Ogasawara, W. Isoforms of dipeptidyl aminopeptidase IV from Pseudomonassp. WO24: role of the signal sequence and overexpression in Escherichia coli.
					<italic>Protein Expr Purif</italic> 2005;41:241–51.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ogasawara</surname>
							<given-names>W</given-names>
						</name>
					</person-group>
					<article-title>Isoforms of dipeptidyl aminopeptidase IV from Pseudomonassp. WO24: role of the signal sequence and overexpression in
						<italic>Escherichia coli</italic>
					</article-title>
					<source>Protein Expr Purif</source>
					<year>2005</year>
					<volume>41</volume>
					<fpage>241</fpage>
					<lpage>51</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_100">
				<label>100.</label>
				<mixed-citation>Tachi, H, Ito, H, Ichishima, E. An X-prolyl dipeptidyl-aminopeptidase from Aspergillus oryzae.
					<italic>Phytochemistry</italic> 1992;31:3707–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tachi</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Ito</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Ichishima</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<article-title>An X-prolyl dipeptidyl-aminopeptidase from Aspergillus oryzae</article-title>
					<source>Phytochemistry</source>
					<year>1992</year>
					<volume>31</volume>
					<fpage>3707</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_101">
				<label>101.</label>
				<mixed-citation>Beauvais, A. Dipeptidylpeptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans.
					<italic>Infect Immun</italic> 1997;65:3042–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Beauvais</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidylpeptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans</article-title>
					<source>Infect Immun</source>
					<year>1997</year>
					<volume>65</volume>
					<fpage>3042</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_102">
				<label>102.</label>
				<mixed-citation>Oya, H, Nagatsu, I, Nagatsu, T. Purifcation and properties ofglycylprolyl-b-naphthylamidase in human submaxillary gland.
					<italic>Biochim Biophys Acta</italic> 1972;258:591–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Oya</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Nagatsu</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Nagatsu</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Purifcation and properties ofglycylprolyl-b-naphthylamidase in human submaxillary gland</article-title>
					<source>Biochim Biophys Acta</source>
					<year>1972</year>
					<volume>258</volume>
					<fpage>591</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_103">
				<label>103.</label>
				<mixed-citation>Barth, A, Schulz, H, Neubert, K. Studies on the purifcation and characterization of dipeptidyl aminopeptidase IV.
					<italic>Acta Biol Med Ger</italic> 1974;32:157–74.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barth</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Schulz</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Neubert</surname>
							<given-names>K</given-names>
						</name>
					</person-group>
					<article-title>Studies on the purifcation and characterization of dipeptidyl aminopeptidase IV</article-title>
					<source>Acta Biol Med Ger</source>
					<year>1974</year>
					<volume>32</volume>
					<fpage>157</fpage>
					<lpage>74</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_104">
				<label>104.</label>
				<mixed-citation>Yoshimoto, T, Walter, R. Post-proline dipeptidyl aminopeptidase (dipeptidyl aminopeptidase IV) from lamb kidney.
					<italic>Biochim Biophys Acta</italic> 1977;485:391–401.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yoshimoto</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Walter</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Post-proline dipeptidyl aminopeptidase (dipeptidyl aminopeptidase IV) from lamb kidney</article-title>
					<source>Biochim Biophys Acta</source>
					<year>1977</year>
					<volume>485</volume>
					<fpage>391</fpage>
					<lpage>401</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_105">
				<label>105.</label>
				<mixed-citation>Yoshimoto, T, Kita, T, Ichinose, M, Tsuru, D. Dipeptidyl aminopeptidase IV from porcine pancreas.
					<italic>J Biochem</italic> 1982;92:275–82.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yoshimoto</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kita</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Ichinose</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Tsuru</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl aminopeptidase IV from porcine pancreas</article-title>
					<source>J Biochem</source>
					<year>1982</year>
					<volume>92</volume>
					<fpage>275</fpage>
					<lpage>82</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_106">
				<label>106.</label>
				<mixed-citation>Wilson, MJ, Ruhland, AR, Pryor, JL. Prostate specific origin of dipeptidylpeptidase IV (CD26) in human malignant phenotype of melanocytic cells.
					<italic>J Exp Med</italic> 1998;190:311–22.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wilson</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Ruhland</surname>
							<given-names>AR</given-names>
						</name>
						<name>
							<surname>Pryor</surname>
							<given-names>JL</given-names>
						</name>
					</person-group>
					<article-title>Prostate specific origin of dipeptidylpeptidase IV (CD26) in human malignant phenotype of melanocytic cells</article-title>
					<source>J Exp Med</source>
					<year>1998</year>
					<volume>190</volume>
					<fpage>311</fpage>
					<lpage>22</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_107">
				<label>107.</label>
				<mixed-citation>The Human Protein Atlas; 2003. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue+cell+type">http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue+cell+type</ext-link> [Accessed Sep 11 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>The Human Protein Atlas</surname>
						</name>
					</person-group>
					<year>2003</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue+cell+type">http://www.proteinatlas.org/ENSG00000197635-DPP4/tissue+cell+type</ext-link>
					<comment>[Accessed</comment>
					<comment>Sep</comment>
					<volume>11</volume>
					<fpage>2022</fpage>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_108">
				<label>108.</label>
				<mixed-citation>Savino, W, Villa-Verde, DM, Lannes-Vieira, J. Extracellular matrix proteins in intrathymic T-cell migration and differentiation?
					<italic>Immunol Today</italic> 1993;14:158–61.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Savino</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Villa-Verde</surname>
							<given-names>DM</given-names>
						</name>
						<name>
							<surname>Lannes-Vieira</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Extracellular matrix proteins in intrathymic T-cell migration and differentiation?</article-title>
					<source>Immunol Today</source>
					<year>1993</year>
					<volume>14</volume>
					<fpage>158</fpage>
					<lpage>61</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_109">
				<label>109.</label>
				<mixed-citation>Zhong, J, Maiseyeu, A, Davis, SN, Rajagopalan, S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
					<italic>Circ Res</italic> 2015;116:1491–504.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhong</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Maiseyeu</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Davis</surname>
							<given-names>SN</given-names>
						</name>
						<name>
							<surname>Rajagopalan</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition</article-title>
					<source>Circ Res</source>
					<year>2015</year>
					<volume>116</volume>
					<fpage>1491</fpage>
					<lpage>504</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_110">
				<label>110.</label>
				<mixed-citation>Gorrell, MD, Gysbers, V, McCaughan, GW. CD26: a multifunctional integral membrane and secreted protein glucagon-like peptide-1 secretion from the GLUTag cell line.
					<italic>Diabetes</italic> 2011;52:1147–54.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
						<name>
							<surname>Gysbers</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>McCaughan</surname>
							<given-names>GW</given-names>
						</name>
					</person-group>
					<article-title>CD26: a multifunctional integral membrane and secreted protein glucagon-like peptide-1 secretion from the GLUTag cell line</article-title>
					<source>Diabetes</source>
					<year>2011</year>
					<volume>52</volume>
					<fpage>1147</fpage>
					<lpage>54</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_111">
				<label>111.</label>
				<mixed-citation>Girardi, ACC, Degray, BC, Nagy, T, Biemesderfer, D, Aronson, PS. Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule.
					<italic>J Biol Chem</italic> 2001;276:46671–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Girardi</surname>
							<given-names>ACC</given-names>
						</name>
						<name>
							<surname>Degray</surname>
							<given-names>BC</given-names>
						</name>
						<name>
							<surname>Nagy</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Biemesderfer</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Aronson</surname>
							<given-names>PS</given-names>
						</name>
					</person-group>
					<article-title>Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule</article-title>
					<source>J Biol Chem</source>
					<year>2001</year>
					<volume>276</volume>
					<fpage>46671</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_112">
				<label>112.</label>
				<mixed-citation>Cheng, HC, Abdel-Ghany, M, Pauli, BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis.
					<italic>J Biol Chem</italic> 2003;278:24600–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cheng</surname>
							<given-names>HC</given-names>
						</name>
						<name>
							<surname>Abdel-Ghany</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Pauli</surname>
							<given-names>BU</given-names>
						</name>
					</person-group>
					<article-title>A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis</article-title>
					<source>J Biol Chem</source>
					<year>2003</year>
					<volume>278</volume>
					<fpage>24600</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_113">
				<label>113.</label>
				<mixed-citation>Ohnuma, K, Yamochi, T, Uchiyama, M, Nishibashi, K, Yoshikawa, N, Shimizu, N, et al.. CD26 up-regulates expression of CD86 on antigenpresenting cells by means of caveolin-1.
					<italic>Proc Natl Acad Sci USA</italic> 2004;101:14186–91.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ohnuma</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yamochi</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Uchiyama</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Nishibashi</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yoshikawa</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Shimizu</surname>
							<given-names>N</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>CD26 up-regulates expression of CD86 on antigenpresenting cells by means of caveolin-1</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>2004</year>
					<volume>101</volume>
					<fpage>14186</fpage>
					<lpage>91</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_114">
				<label>114.</label>
				<mixed-citation>Pascual, I, López, A, Gómez, H, Chappé, M, Saroyán, A, Gonzáles, Y. Screening of inhibitors of porcine dipeptidyl peptidase IV activity in aqueous extracts from marine organisms.
					<italic>Enzym Microb Technol</italic> 2007;40:414–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>López</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Gómez</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Chappé</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Saroyán</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Gonzáles</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Screening of inhibitors of porcine dipeptidyl peptidase IV activity in aqueous extracts from marine organisms</article-title>
					<source>Enzym Microb Technol</source>
					<year>2007</year>
					<volume>40</volume>
					<fpage>414</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_115">
				<label>115.</label>
				<mixed-citation>González, L, Sánchez, RE, Rojas, L, Pascual, I, García-Fernández, R, Chávez, MA, et al.. Screening of protease inhibitory activity in aqueous extracts of marine invertebrates from Cuban coast.
					<italic>Am J Anal Chem</italic> 2016;7:319–31.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>González</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Sánchez</surname>
							<given-names>RE</given-names>
						</name>
						<name>
							<surname>Rojas</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>García-Fernández</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Chávez</surname>
							<given-names>MA</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Screening of protease inhibitory activity in aqueous extracts of marine invertebrates from Cuban coast</article-title>
					<source>Am J Anal Chem</source>
					<year>2016</year>
					<volume>7</volume>
					<fpage>319</fpage>
					<lpage>31</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_116">
				<label>116.</label>
				<mixed-citation>Pascual, I, Arrebola, Y, Almeida, F, Valdés, ME, Rivera, L, Hernández, A, et al.. Marine and coastal organisms: a source of biomedically relevant dipeptidyl peptidase IV inhibitors.
					<italic>Rev. Cuba Cienc biol</italic> 2020;8:1–16.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Arrebola</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Almeida</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Valdés</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Rivera</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Hernández</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Marine and coastal organisms: a source of biomedically relevant dipeptidyl peptidase IV inhibitors</article-title>
					<source>Rev. Cuba Cienc biol</source>
					<year>2020</year>
					<volume>8</volume>
					<fpage>1</fpage>
					<lpage>16</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_117">
				<label>117.</label>
				<mixed-citation>Maslov, I, Zinevich, TV, Kirichenko, OG, Trukhan, MV, Shorshnev, SV, Tuaeva, NO, et al.. Synthesis and Biological Evaluation of Neogliptin, a Novel 2 Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4).
					<italic>Pharmaceuticals (Basel)</italic> 2022;15:273.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Maslov</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Zinevich</surname>
							<given-names>TV</given-names>
						</name>
						<name>
							<surname>Kirichenko</surname>
							<given-names>OG</given-names>
						</name>
						<name>
							<surname>Trukhan</surname>
							<given-names>MV</given-names>
						</name>
						<name>
							<surname>Shorshnev</surname>
							<given-names>SV</given-names>
						</name>
						<name>
							<surname>Tuaeva</surname>
							<given-names>NO</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Synthesis and Biological Evaluation of Neogliptin, a Novel 2 Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)</article-title>
					<source>Pharmaceuticals (Basel)</source>
					<year>2022</year>
					<volume>15</volume>
					<fpage>273</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_118">
				<label>118.</label>
				<mixed-citation>Itou, M, Kawaguchi, T, Taniguchi, E, Sata, M. Dipeptidyl peptidase-4: a key player in chronic liver disease.
					<italic>World J Gastroenterol</italic> 2013;19:2298–306.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Itou</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kawaguchi</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Taniguchi</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Sata</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4: a key player in chronic liver disease</article-title>
					<source>World J Gastroenterol</source>
					<year>2013</year>
					<volume>19</volume>
					<fpage>2298</fpage>
					<lpage>306</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_119">
				<label>119.</label>
				<mixed-citation>Anderluh, M, Kocic, G, Tomovic, K, Kocic, R, Deljanin-Ilic, M, Smelcerovic, A. Cross-talk between the dipeptidyl peptidase-4 and stromal CellDerived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors.
					<italic>Pharmacol Ther</italic> 2016;167:100–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Anderluh</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kocic</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Tomovic</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Kocic</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Deljanin-Ilic</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Smelcerovic</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Cross-talk between the dipeptidyl peptidase-4 and stromal CellDerived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors</article-title>
					<source>Pharmacol Ther</source>
					<year>2016</year>
					<volume>167</volume>
					<fpage>100</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_120">
				<label>120.</label>
				<mixed-citation>Beckers, PAJ, Gielis, JF, Van Schil, PE, Adriaensen, D. Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition.
					<italic>Ann Transl Med</italic> 2017;5:129.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Beckers</surname>
							<given-names>PAJ</given-names>
						</name>
						<name>
							<surname>Gielis</surname>
							<given-names>JF</given-names>
						</name>
						<name>
							<surname>Van Schil</surname>
							<given-names>PE</given-names>
						</name>
						<name>
							<surname>Adriaensen</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition</article-title>
					<source>Ann Transl Med</source>
					<year>2017</year>
					<volume>5</volume>
					<fpage>129</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_121">
				<label>121.</label>
				<mixed-citation>Nausch, I, Mentlein, R, Heymann, E. The degradation of bioactive peptides and proteins by dipeptidil peptidase IV from human placenta.
					<italic>Biol Chem</italic> 1990;371:113–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nausch</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Mentlein</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Heymann</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<article-title>The degradation of bioactive peptides and proteins by dipeptidil peptidase IV from human placenta</article-title>
					<source>Biol Chem</source>
					<year>1990</year>
					<volume>371</volume>
					<fpage>113</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_122">
				<label>122.</label>
				<mixed-citation>Ahrén, B, Hughes, T. IInhibition of dipeptidil peptidase-4 augments insulin secretion in response to exogenously administrated glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, PItuitary adenylate cyclase-activating polipeptide, and gastrin-releasing peptide in mice.
					<italic>Endocrinology</italic> 2004;146:2055–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ahrén</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Hughes</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>IInhibition of dipeptidil peptidase-4 augments insulin secretion in response to exogenously administrated glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, PItuitary adenylate cyclase-activating polipeptide, and gastrin-releasing peptide in mice</article-title>
					<source>Endocrinology</source>
					<year>2004</year>
					<volume>146</volume>
					<fpage>2055</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_123">
				<label>123.</label>
				<mixed-citation>Hu, CX, Huang, H, Zhang, L, Huang, Y, Shen, ZF, Cheng, KD. A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors.
					<italic>Biotechnol Lett</italic> 2009;31:979–84.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hu</surname>
							<given-names>CX</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Shen</surname>
							<given-names>ZF</given-names>
						</name>
						<name>
							<surname>Cheng</surname>
							<given-names>KD</given-names>
						</name>
					</person-group>
					<article-title>A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors</article-title>
					<source>Biotechnol Lett</source>
					<year>2009</year>
					<volume>31</volume>
					<fpage>979</fpage>
					<lpage>84</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_124">
				<label>124.</label>
				<mixed-citation>Durinx, C, Lambeir, AM, Bosmans, E, Falmagne, JB, Berghmans, R, Haemers, A. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.
					<italic>Eur J Biochem</italic> 2000;267:5608–13.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Durinx</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Lambeir</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Bosmans</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Falmagne</surname>
							<given-names>JB</given-names>
						</name>
						<name>
							<surname>Berghmans</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Haemers</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides</article-title>
					<source>Eur J Biochem</source>
					<year>2000</year>
					<volume>267</volume>
					<fpage>5608</fpage>
					<lpage>13</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_125">
				<label>125.</label>
				<mixed-citation>Bermpohl, F, Loster, K, Reutter, W, Baum, O. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens.
					<italic>FEBS Lett</italic> 1998;428:152–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bermpohl</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Loster</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Reutter</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Baum</surname>
							<given-names>O</given-names>
						</name>
					</person-group>
					<article-title>Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens</article-title>
					<source>FEBS Lett</source>
					<year>1998</year>
					<volume>428</volume>
					<fpage>152</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_126">
				<label>126.</label>
				<mixed-citation>Lambeir, A, Paul, P, Durinx, C, Bal, G, Senten, K, Augustyns, K, et al.. Kinetic Investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.
					<italic>J Biol Chem</italic> 2001;276:29839–45.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lambeir</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Paul</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Durinx</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Bal</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Senten</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Augustyns</surname>
							<given-names>K</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Kinetic Investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family</article-title>
					<source>J Biol Chem</source>
					<year>2001</year>
					<volume>276</volume>
					<fpage>29839</fpage>
					<lpage>45</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_127">
				<label>127.</label>
				<mixed-citation>Orskov, C, Bersanis, M, Johnsen, AH, Hajrupll, P, Holst, J. Complete sequences of glucagon-like peptide-1 from human and pig small intestine.
					<italic>J Biol Chem</italic> 1989;264:12826–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Orskov</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Bersanis</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Johnsen</surname>
							<given-names>AH</given-names>
						</name>
						<name>
							<surname>Hajrupll</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Holst</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Complete sequences of glucagon-like peptide-1 from human and pig small intestine</article-title>
					<source>J Biol Chem</source>
					<year>1989</year>
					<volume>264</volume>
					<fpage>12826</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_128">
				<label>128.</label>
				<mixed-citation>Pauly, R, Rosche, F, Wermann, M, McIntosh, CHS, Pederson, RA, Demuth, HU. Investigation of glucose-dependent insulinotropic polypeptide-(1– 42) and glucagon-like peptide-1-(7–36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry.
					<italic>J Biol Chem</italic> 1996;271:23222–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pauly</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Rosche</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Wermann</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>McIntosh</surname>
							<given-names>CHS</given-names>
						</name>
						<name>
							<surname>Pederson</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Demuth</surname>
							<given-names>HU</given-names>
						</name>
					</person-group>
					<article-title>Investigation of glucose-dependent insulinotropic polypeptide-(1– 42) and glucagon-like peptide-1-(7–36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry</article-title>
					<source>J Biol Chem</source>
					<year>1996</year>
					<volume>271</volume>
					<fpage>23222</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_129">
				<label>129.</label>
				<mixed-citation>Hui, H, Farilla, L, Merkel, P, Perfetti, R. The short half-life of glucagón-like paptide-1 in plasma does not reflect its long-lasting beneficial effects.
					<italic>Eur J Endocrinol</italic> 2002;146:863–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hui</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Farilla</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Merkel</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Perfetti</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>The short half-life of glucagón-like paptide-1 in plasma does not reflect its long-lasting beneficial effects</article-title>
					<source>Eur J Endocrinol</source>
					<year>2002</year>
					<volume>146</volume>
					<fpage>863</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_130">
				<label>130.</label>
				<mixed-citation>Zhu, L, Tamvakopoulos, C, Xie, D, Dragovic, J, Shen, X, Fenyk-Melody, JE, et al.. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides.
					<italic>J Biol Chem</italic> 2003;278:22418–23.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhu</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Tamvakopoulos</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Xie</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Dragovic</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Shen</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Fenyk-Melody</surname>
							<given-names>JE</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides</article-title>
					<source>J Biol Chem</source>
					<year>2003</year>
					<volume>278</volume>
					<fpage>22418</fpage>
					<lpage>23</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_131">
				<label>131.</label>
				<mixed-citation>Alters, S, McLaughlin, B, Spink, B, Lachiyan, T, Wang, C, Podust, V, et al.. Correction: GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in rats Crohn’s disease model.
					<italic>PLoS One</italic> 2013;8:1371.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Alters</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>McLaughlin</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Spink</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Lachiyan</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Podust</surname>
							<given-names>V</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Correction: GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in rats Crohn’s disease model</article-title>
					<source>PLoS One</source>
					<year>2013</year>
					<volume>8</volume>
					<fpage>1371</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_132">
				<label>132.</label>
				<mixed-citation>Irwin, N, Flatt, P. Chapter gastric inhibitory polipeptide. In:
					<italic>Williams Textbook of Endocrinology</italic>, 12th ed. Philadelphia, United States: Saunders; 2012. pp. 1697–716.
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Irwin</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Flatt</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Chapter gastric inhibitory polipeptide</article-title>
					<source>Williams Textbook of Endocrinology</source>
					<edition>12th ed.</edition>
					<publisher-loc>Philadelphia, United States</publisher-loc>
					<publisher-name>Saunders</publisher-name>
					<year>2012</year>
					<fpage>1697</fpage>
					<lpage>716</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_133">
				<label>133.</label>
				<mixed-citation>Birk, S, Sitarz, J, Petersen, K, Oturai, P, Kruuse, C, Fahrenkrug, J, et al.. The effect of interavenous PACAP38 on cerebral hemodynamics in healthy volunteers.
					<italic>Regul Pept</italic> 2007;140:185–91.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Birk</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Sitarz</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Petersen</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Oturai</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Kruuse</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Fahrenkrug</surname>
							<given-names>J</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The effect of interavenous PACAP38 on cerebral hemodynamics in healthy volunteers</article-title>
					<source>Regul Pept</source>
					<year>2007</year>
					<volume>140</volume>
					<fpage>185</fpage>
					<lpage>91</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_134">
				<label>134.</label>
				<mixed-citation>Bourgault, S, Vaudry, D, Botia, B, Couvineau, A, Laburthe, M, Vaudry, H, et al.. Nobel stable PACAP analogs with potent activity towards the PAC1 receptor.
					<italic>Peptides</italic> 2008;29:919–32.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bourgault</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Vaudry</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Botia</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Couvineau</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Laburthe</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Vaudry</surname>
							<given-names>H</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Nobel stable PACAP analogs with potent activity towards the PAC1 receptor</article-title>
					<source>Peptides</source>
					<year>2008</year>
					<volume>29</volume>
					<fpage>919</fpage>
					<lpage>32</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_135">
				<label>135.</label>
				<mixed-citation>Pocai, A. Action and therapeutic potential of oxytomodulin.
					<italic>Mol Metab</italic> 2013;3:241–51.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pocai</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Action and therapeutic potential of oxytomodulin</article-title>
					<source>Mol Metab</source>
					<year>2013</year>
					<volume>3</volume>
					<fpage>241</fpage>
					<lpage>51</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_136">
				<label>136.</label>
				<mixed-citation>Kolts, B, McGuian, J. Radioimmunoassay measurement of secretin half-life time in man.
					<italic>Gastroenterology</italic> 1977;72:55–70.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kolts</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>McGuian</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Radioimmunoassay measurement of secretin half-life time in man</article-title>
					<source>Gastroenterology</source>
					<year>1977</year>
					<volume>72</volume>
					<fpage>55</fpage>
					<lpage>70</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_137">
				<label>137.</label>
				<mixed-citation>Boissard, C, Marie, J, Hejblum, G, Gespach, C, Rosselin, G. Vasoactive intestinal peptide receptor regulation and reversible desensibilization in human colonic carcinoma cells in culture.
					<italic>Cancer Res</italic> 1986;46:4406–13.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Boissard</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Marie</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Hejblum</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Gespach</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Rosselin</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>Vasoactive intestinal peptide receptor regulation and reversible desensibilization in human colonic carcinoma cells in culture</article-title>
					<source>Cancer Res</source>
					<year>1986</year>
					<volume>46</volume>
					<fpage>4406</fpage>
					<lpage>13</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_138">
				<label>138.</label>
				<mixed-citation>Frohman, L, Downs, T, Williams, T, Heimer, E, Pan, Y, Felix, A. Rapid enzymatic degradation of growth hormone-relasing hormone by plasma in vitro and in vivo to a biologically inactive, N-terminally cleaved product.
					<italic>J Clin Invest</italic> 1986;78:906–13.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Frohman</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Downs</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Williams</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Heimer</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Pan</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Felix</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Rapid enzymatic degradation of growth hormone-relasing hormone by plasma in vitro and in vivo to a biologically inactive, N-terminally cleaved product</article-title>
					<source>J Clin Invest</source>
					<year>1986</year>
					<volume>78</volume>
					<fpage>906</fpage>
					<lpage>13</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_139">
				<label>139.</label>
				<mixed-citation>Wojcik, E, Kulpa, J. Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response.
					<italic>Lung Cancer</italic> 2017;8:231–40.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wojcik</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Kulpa</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response</article-title>
					<source>Lung Cancer</source>
					<year>2017</year>
					<volume>8</volume>
					<fpage>231</fpage>
					<lpage>40</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_140">
				<label>140.</label>
				<mixed-citation>Mashaghi, A, Marmalidou, A, Mohsen, T, Grace, P, Pothoulakis, C, Dana, R. Neuropeptide substance P and the immune response.
					<italic>Cell Mol Life Sci</italic> 2016;73:4249–64.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mashaghi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Marmalidou</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Mohsen</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Grace</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Pothoulakis</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Dana</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Neuropeptide substance P and the immune response</article-title>
					<source>Cell Mol Life Sci</source>
					<year>2016</year>
					<volume>73</volume>
					<fpage>4249</fpage>
					<lpage>64</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_141">
				<label>141.</label>
				<mixed-citation>Takemoto, K, Neuropeptide, Y. Complete amino acid sequence of the brain peptide.
					<italic>Proc Natl Acad Sci USA</italic> 1982;79:5485–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Takemoto</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Neuropeptide</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Complete amino acid sequence of the brain peptide</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>1982</year>
					<volume>79</volume>
					<fpage>5485</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_142">
				<label>142.</label>
				<mixed-citation>Ahlborg, G, Weitzberg, E, Sollevi, A, Lundberg, J. Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man.
					<italic>Acta Physiol Scand</italic> 1992;145:139–49.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ahlborg</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Weitzberg</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Sollevi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Lundberg</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man</article-title>
					<source>Acta Physiol Scand</source>
					<year>1992</year>
					<volume>145</volume>
					<fpage>139</fpage>
					<lpage>49</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_143">
				<label>143.</label>
				<mixed-citation>Takemoto, K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion.
					<italic>Proc Natl Acad Sci USA</italic> 1982;79:2514–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Takemoto</surname>
							<given-names>K</given-names>
						</name>
					</person-group>
					<article-title>Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>1982</year>
					<volume>79</volume>
					<fpage>2514</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_144">
				<label>144.</label>
				<mixed-citation>Adrian, T, Sagor, G, Savage, A, Bacarese-Hamilton, A, Hall, G, Bloom, S. Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man.
					<italic>J Clin Endocrinol Metab</italic> 1986;63:803–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Adrian</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Sagor</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Savage</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Bacarese-Hamilton</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Hall</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Bloom</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man</article-title>
					<source>J Clin Endocrinol Metab</source>
					<year>1986</year>
					<volume>63</volume>
					<fpage>803</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_145">
				<label>145.</label>
				<mixed-citation>
					<collab>Uniprot</collab>.
					<italic>The amino acid sequence of human chorionic gonadotropin the alpha subunit and the beta subunit</italic>; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://uniprot.org/citations/1150658">http://uniprot.org/citations/1150658</ext-link> [Accessed 14 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<collab>Uniprot</collab>
					</person-group>
					<source>The amino acid sequence of human chorionic gonadotropin the alpha subunit and the beta subunit</source>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://uniprot.org/citations/1150658">http://uniprot.org/citations/1150658</ext-link>
					<comment>[Accessed 14</comment>
					<comment>Oct 2022]</comment>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_146">
				<label>146.</label>
				<mixed-citation>Tan, E, Hershman, J. Chapter hyperthyroidism and trophoblastic disease. In: Frederic, E, Radovick, S, editors.
					<italic>Clinical management of thyroid disease</italic>. Amsterdam, Netherlands: Elsevier B.V; 2009. pp. 407–23.
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Tan</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Hershman</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Chapter hyperthyroidism and trophoblastic disease</article-title>
					<person-group person-group-type="editor">
						<name>
							<surname>Frederic</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Radovick</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<source>Clinical management of thyroid disease</source>
					<publisher-loc>Amsterdam, Netherlands</publisher-loc>
					<publisher-name>Elsevier B.V</publisher-name>
					<year>2009</year>
					<fpage>407</fpage>
					<lpage>23</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_147">
				<label>147.</label>
				<mixed-citation>Genscript. Human pancreatic polipeptide; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://www.genscript.com/peptide/RP10398-Pancreatic_Polypeptide_human.html">http://www.genscript.com/peptide/RP10398-Pancreatic_Polypeptide_human.html</ext-link> [Accessed 14 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="book">
					<comment>Genscript. Human pancreatic polipeptide; 2022. Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://www.genscript.com/peptide/RP10398-Pancreatic_Polypeptide_human.html">http://www.genscript.com/peptide/RP10398-Pancreatic_Polypeptide_human.html</ext-link>
					<comment>[Accessed 14</comment>
					<year>Oct 2022]</year>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_148">
				<label>148.</label>
				<mixed-citation>Cuenco, J, Minnion, J, Tan, T, Scott, R, Germain, N, Ling, Y, et al.. Degradation paradigm of the gut hormone, pancreatic polipetide, by hepatic and renal peptidases.
					<italic>Endocrinology</italic> 2017;158:1755–65.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cuenco</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Minnion</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Tan</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Scott</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Germain</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Ling</surname>
							<given-names>Y</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Degradation paradigm of the gut hormone, pancreatic polipetide, by hepatic and renal peptidases</article-title>
					<source>Endocrinology</source>
					<year>2017</year>
					<volume>158</volume>
					<fpage>1755</fpage>
					<lpage>65</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_149">
				<label>149.</label>
				<mixed-citation>Gianoulakis, C, Seidah, N, Routhier, R, Chrétien, M. Biosynthesis and characterization of adenocorticotropic hormone, alpha-melanocite-stimulating hormone, and NH2-terminal fragment of the adenocorticotropic hormone/beta-lipoprotein precursor from rats pars intermedia.
					<italic>J Biol Chem</italic> 1979;254:1903–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gianoulakis</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Seidah</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Routhier</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Chrétien</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Biosynthesis and characterization of adenocorticotropic hormone, alpha-melanocite-stimulating hormone, and NH2-terminal fragment of the adenocorticotropic hormone/beta-lipoprotein precursor from rats pars intermedia</article-title>
					<source>J Biol Chem</source>
					<year>1979</year>
					<volume>254</volume>
					<fpage>1903</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_150">
				<label>150.</label>
				<mixed-citation>Veldhuis, J, Iranmanesh, A, Naftolowitz, D, Tathan, N, Cassidy, F, Carroll, B. Corticotropin secretory dynamics in humans under low glucocorticoid feedbac.
					<italic>J Clin Endocrinol Metab</italic> 2001;86:5554–63.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Veldhuis</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Iranmanesh</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Naftolowitz</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Tathan</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Cassidy</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Carroll</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>Corticotropin secretory dynamics in humans under low glucocorticoid feedbac</article-title>
					<source>J Clin Endocrinol Metab</source>
					<year>2001</year>
					<volume>86</volume>
					<fpage>5554</fpage>
					<lpage>63</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_151">
				<label>151.</label>
				<mixed-citation>Mentlein, R, Gallwits, B, Schmidt, WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
					<italic>Eur J Biochem</italic> 1993;213:829–35.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mentlein</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Gallwits</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Schmidt</surname>
							<given-names>WE</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum</article-title>
					<source>Eur J Biochem</source>
					<year>1993</year>
					<volume>213</volume>
					<fpage>829</fpage>
					<lpage>35</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_152">
				<label>152.</label>
				<mixed-citation>Kiefer, TJ, McIntosh, CH, Pederson, RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagons-like peptide 1 in vitroand in vivoby dipeptidyl peptidase IV.
					<italic>Endocrinology</italic> 1995;136:3585–96.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kiefer</surname>
							<given-names>TJ</given-names>
						</name>
						<name>
							<surname>McIntosh</surname>
							<given-names>CH</given-names>
						</name>
						<name>
							<surname>Pederson</surname>
							<given-names>RA</given-names>
						</name>
					</person-group>
					<article-title>Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagons-like peptide 1 in vitroand in vivoby dipeptidyl peptidase IV</article-title>
					<source>Endocrinology</source>
					<year>1995</year>
					<volume>136</volume>
					<fpage>3585</fpage>
					<lpage>96</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_153">
				<label>153.</label>
				<mixed-citation>Combettes, M. GLP-1 and type 2 diabetes: physiology and new clinical advances.
					<italic>Curr Opin Pharmacol</italic> 2006;6:598–605.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Combettes</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>GLP-1 and type 2 diabetes: physiology and new clinical advances</article-title>
					<source>Curr Opin Pharmacol</source>
					<year>2006</year>
					<volume>6</volume>
					<fpage>598</fpage>
					<lpage>605</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_154">
				<label>154.</label>
				<mixed-citation>ChemSpider; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.sitagliptin.html">http://chemispider.com/Chemical-Structure.sitagliptin.html</ext-link> [Accessed 14 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>ChemSpider</surname>
						</name>
					</person-group>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.sitagliptin.html">http://chemispider.com/Chemical-Structure.sitagliptin.html</ext-link>
					<comment>[Accessed 14</comment>
					<comment>Oct 2022]</comment>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_155">
				<label>155.</label>
				<mixed-citation>Zhou, ST, Cui, W, Kong, L, Yang, X. Efficacy of sitagliptin on Nonalcoholic fatty liver disease in high-fat-diet-fed diabetic mice.
					<italic>Curr Med Sci</italic> 2022;42:513–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhou</surname>
							<given-names>ST</given-names>
						</name>
						<name>
							<surname>Cui</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Kong</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>X</given-names>
						</name>
					</person-group>
					<article-title>Efficacy of sitagliptin on Nonalcoholic fatty liver disease in high-fat-diet-fed diabetic mice</article-title>
					<source>Curr Med Sci</source>
					<year>2022</year>
					<volume>42</volume>
					<fpage>513</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_156">
				<label>156.</label>
				<mixed-citation>Trocha, M, Fleszar, MG, Fortuna, P, Lewandowski, L, Gostomska-Pampuch, K, Sozanski, T, et al.. Sitagliptin modulates oxidative, nitrative and halogenative stress and inflammatory response in rat model of hepatic ischemia-reperfusion.
					<italic>Antioxidants</italic> 2021;10:1168.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Trocha</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Fleszar</surname>
							<given-names>MG</given-names>
						</name>
						<name>
							<surname>Fortuna</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Lewandowski</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Gostomska-Pampuch</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Sozanski</surname>
							<given-names>T</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Sitagliptin modulates oxidative, nitrative and halogenative stress and inflammatory response in rat model of hepatic ischemia-reperfusion</article-title>
					<source>Antioxidants</source>
					<year>2021</year>
					<volume>10</volume>
					<fpage>1168</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_157">
				<label>157.</label>
				<mixed-citation>Prakash, S, Rai, U, Kosuru, R, Tiwari, V, Singh, S. Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice.
					<italic>Biochimie</italic> 2020;168:198–209.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Prakash</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Rai</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Kosuru</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Tiwari</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Singh</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice</article-title>
					<source>Biochimie</source>
					<year>2020</year>
					<volume>168</volume>
					<fpage>198</fpage>
					<lpage>209</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_158">
				<label>158.</label>
				<mixed-citation>ChemSpider; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.alogliptin.html">http://chemispider.com/Chemical-Structure.alogliptin.html</ext-link> [Accessed 14 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>ChemSpider</surname>
						</name>
					</person-group>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.alogliptin.html">http://chemispider.com/Chemical-Structure.alogliptin.html</ext-link>
					<comment>[Accessed 14</comment>
					<comment>Oct 2022]</comment>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_159">
				<label>159.</label>
				<mixed-citation>White, JR. Alogliptin for the treatment of type 2 diabetes.
					<italic>Drugs Today</italic> 2011;47:99–107.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>White</surname>
							<given-names>JR</given-names>
						</name>
					</person-group>
					<article-title>Alogliptin for the treatment of type 2 diabetes</article-title>
					<source>Drugs Today</source>
					<year>2011</year>
					<volume>47</volume>
					<fpage>99</fpage>
					<lpage>107</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_160">
				<label>160.</label>
				<mixed-citation>Agency, E.M.:
					<italic>summary of product characteristics</italic>; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/productinformation/vipidia-eparproductinformation.en.pdf">https://www.ema.europa.eu/en/documents/productinformation/vipidia-eparproductinformation.en.pdf</ext-link> [Accessed 10 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Agency</surname>
							<given-names>E.M.</given-names>
						</name>
					</person-group>
					<source>summary of product characteristics</source>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/productinformation/vipidia-eparproductinformation.en.pdf">https://www.ema.europa.eu/en/documents/productinformation/vipidia-eparproductinformation.en.pdf</ext-link>
					<comment>[Accessed 10</comment>
					<comment>Oct</comment>
					<comment>2022]</comment>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_161">
				<label>161.</label>
				<mixed-citation>El-Sahar, AE, Shiha, NA, El Sayed, NS, Ahmed, LA. Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4/MYD88/NF-kappaB and miRNA-155/SOCS-1 signaling pathways.
					<italic>Int J Neuropsychopharmacol</italic> 2021;24:158–69.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>El-Sahar</surname>
							<given-names>AE</given-names>
						</name>
						<name>
							<surname>Shiha</surname>
							<given-names>NA</given-names>
						</name>
						<name>
							<surname>El Sayed</surname>
							<given-names>NS</given-names>
						</name>
						<name>
							<surname>Ahmed</surname>
							<given-names>LA</given-names>
						</name>
					</person-group>
					<article-title>Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4/MYD88/NF-kappaB and miRNA-155/SOCS-1 signaling pathways</article-title>
					<source>Int J Neuropsychopharmacol</source>
					<year>2021</year>
					<volume>24</volume>
					<fpage>158</fpage>
					<lpage>69</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_162">
				<label>162.</label>
				<mixed-citation>Salama, RM, Nasr, MM, Abdelhakeem, JI, Roshdy, OK, ElGamal, MA. Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade.
					<italic>Drug Chem Toxicol</italic> 2022;45:1254–63.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Salama</surname>
							<given-names>RM</given-names>
						</name>
						<name>
							<surname>Nasr</surname>
							<given-names>MM</given-names>
						</name>
						<name>
							<surname>Abdelhakeem</surname>
							<given-names>JI</given-names>
						</name>
						<name>
							<surname>Roshdy</surname>
							<given-names>OK</given-names>
						</name>
						<name>
							<surname>ElGamal</surname>
							<given-names>MA</given-names>
						</name>
					</person-group>
					<article-title>Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade</article-title>
					<source>Drug Chem Toxicol</source>
					<year>2022</year>
					<volume>45</volume>
					<fpage>1254</fpage>
					<lpage>63</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_163">
				<label>163.</label>
				<mixed-citation>ChemSpider; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.vildaliptin.html">http://chemispider.com/Chemical-Structure.vildaliptin.html</ext-link> [Accessed 14 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>ChemSpider</surname>
						</name>
					</person-group>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.vildaliptin.html">http://chemispider.com/Chemical-Structure.vildaliptin.html</ext-link>
					<comment>[Accessed 14</comment>
					<comment>Oct 2022]</comment>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_164">
				<label>164.</label>
				<mixed-citation>Agency, E.M.:
					<italic>summary of product characteristics</italic>; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/galvus-eparproduct-information_en.pdf">https://www.ema.europa.eu/en/documents/product-information/galvus-eparproduct-information_en.pdf</ext-link> [Accessed 10 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Agency</surname>
							<given-names>E.M.</given-names>
						</name>
					</person-group>
					<source>summary of product characteristics</source>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/galvus-eparproduct-information_en.pdf">https://www.ema.europa.eu/en/documents/product-information/galvus-eparproduct-information_en.pdf</ext-link>
					<comment>[Accessed 10</comment>
					<comment>Oct</comment>
					<comment>2022]</comment>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_165">
				<label>165.</label>
				<mixed-citation>Yang, M, Chen, X, Chen, X, Liu, H, Zhang, Z. Protective effect of vildagliptin on myocardial injury in septic rats by regulating TLR-4/NF-kappaB pathway.
					<italic>Minerva Med</italic> 2021;112:522–4.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yang</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>Z</given-names>
						</name>
					</person-group>
					<article-title>Protective effect of vildagliptin on myocardial injury in septic rats by regulating TLR-4/NF-kappaB pathway</article-title>
					<source>Minerva Med</source>
					<year>2021</year>
					<volume>112</volume>
					<fpage>522</fpage>
					<lpage>4</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_166">
				<label>166.</label>
				<mixed-citation>Khalil, R, Shata, A, Abd El-Kader, EM, Sharaf, H, Abdo, WS, Amin, NA, et al.. Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38alpha, and NF-kappaB signaling.
					<italic>Toxicol Appl Pharmacol</italic> 2020;407:115246.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Khalil</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Shata</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Abd El-Kader</surname>
							<given-names>EM</given-names>
						</name>
						<name>
							<surname>Sharaf</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Abdo</surname>
							<given-names>WS</given-names>
						</name>
						<name>
							<surname>Amin</surname>
							<given-names>NA</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38alpha, and NF-kappaB signaling</article-title>
					<source>Toxicol Appl Pharmacol</source>
					<year>2020</year>
					<volume>407</volume>
					<elocation-id>115246</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_167">
				<label>167.</label>
				<mixed-citation>Liu, Y, Qi, Y. Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.
					<italic>Int Immunopharmacol</italic> 2020;87:106774.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Qi</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix</article-title>
					<source>Int Immunopharmacol</source>
					<year>2020</year>
					<volume>87</volume>
					<elocation-id>106774</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_168">
				<label>168.</label>
				<mixed-citation>ChemSpider; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.saxagliptin.html">http://chemispider.com/Chemical-Structure.saxagliptin.html</ext-link> [Accessed 14 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>ChemSpider</surname>
						</name>
					</person-group>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.saxagliptin.html">http://chemispider.com/Chemical-Structure.saxagliptin.html</ext-link>
					<comment>[Accessed 14</comment>
					<comment>Oct 2022]</comment>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_169">
				<label>169.</label>
				<mixed-citation>Mulvihill, EE, Drucker, DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
					<italic>Endocr Rev</italic> 2014;35:992–1019.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mulvihill</surname>
							<given-names>EE</given-names>
						</name>
						<name>
							<surname>Drucker</surname>
							<given-names>DJ</given-names>
						</name>
					</person-group>
					<article-title>Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors</article-title>
					<source>Endocr Rev</source>
					<year>2014</year>
					<volume>35</volume>
					<fpage>992</fpage>
					<lpage>1019</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_170">
				<label>170.</label>
				<mixed-citation>Chen, Z, Yu, J, Fu, M, Dong, R, Yang, Y, Luo, J, et al.. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway.
					<italic>Biochem Pharmacol</italic> 2020;177:113951.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chen</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Fu</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Dong</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Luo</surname>
							<given-names>J</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway</article-title>
					<source>Biochem Pharmacol</source>
					<year>2020</year>
					<volume>177</volume>
					<elocation-id>113951</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_171">
				<label>171.</label>
				<mixed-citation>ChemSpider; 2022. Available from:
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.linagliptin.html">http://chemispider.com/Chemical-Structure.linagliptin.html</ext-link> [Accessed 14 Oct 2022].
				</mixed-citation>
				<element-citation publication-type="other">
					<person-group person-group-type="author">
						<name>
							<surname>ChemSpider</surname>
						</name>
					</person-group>
					<year>2022</year>
					<comment>Available from:</comment>
					<ext-link ext-link-type="uri" xlink:href="http://chemispider.com/Chemical-Structure.linagliptin.html">http://chemispider.com/Chemical-Structure.linagliptin.html</ext-link>
					<comment>[Accessed 14</comment>
					<comment>Oct 2022]</comment>
					<source>.</source>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_172">
				<label>172.</label>
				<mixed-citation>Graefe-Mody, U, Retlich, S, Friedrich, C. Clinical pharmacokinetics and pharmacodynamics of linagliptin.
					<italic>Clin Pharmacokinet</italic> 2012;51:411–27.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Graefe-Mody</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Retlich</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Friedrich</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Clinical pharmacokinetics and pharmacodynamics of linagliptin</article-title>
					<source>Clin Pharmacokinet</source>
					<year>2012</year>
					<volume>51</volume>
					<fpage>411</fpage>
					<lpage>27</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_173">
				<label>173.</label>
				<mixed-citation>Baranov, O, Kahle, M, Deacon, CF, Holst, JJ, Nauck, MA. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
					<italic>Diabetes Obes Metab</italic> 2016;18:1100–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Baranov</surname>
							<given-names>O</given-names>
						</name>
						<name>
							<surname>Kahle</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Deacon</surname>
							<given-names>CF</given-names>
						</name>
						<name>
							<surname>Holst</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>Nauck</surname>
							<given-names>MA</given-names>
						</name>
					</person-group>
					<article-title>Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2016</year>
					<volume>18</volume>
					<fpage>1100</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_174">
				<label>174.</label>
				<mixed-citation>Mayer, AL, Scheitacker, I, Ebert, N, Klein, T, Amann, K, Daniel, C. The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis.
					<italic>Br J Pharmacol</italic> 2021;178:878–95.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mayer</surname>
							<given-names>AL</given-names>
						</name>
						<name>
							<surname>Scheitacker</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Ebert</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Klein</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Amann</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Daniel</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis</article-title>
					<source>Br J Pharmacol</source>
					<year>2021</year>
					<volume>178</volume>
					<fpage>878</fpage>
					<lpage>95</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_175">
				<label>175.</label>
				<mixed-citation>Zhang, G, Kim, S, Gu, X, Yu, SP, Wei, L. DPP-4 inhibitor linagliptin is neuroprotective in hyperglycemic mice with stroke via the AKT/mTOR pathway and anti-apoptotic effects.
					<italic>Neurosci Bull</italic> 2020;36:407–18.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhang</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Gu</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>SP</given-names>
						</name>
						<name>
							<surname>Wei</surname>
							<given-names>L</given-names>
						</name>
					</person-group>
					<article-title>DPP-4 inhibitor linagliptin is neuroprotective in hyperglycemic mice with stroke via the AKT/mTOR pathway and anti-apoptotic effects</article-title>
					<source>Neurosci Bull</source>
					<year>2020</year>
					<volume>36</volume>
					<fpage>407</fpage>
					<lpage>18</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_176">
				<label>176.</label>
				<mixed-citation>Aboulmagd, YM, El-Bahy, AAZ, Menze, ET, Azab, SS, El-Demerdash, E. Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
					<italic>Eur J Pharmacol</italic> 2020;881:173224.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Aboulmagd</surname>
							<given-names>YM</given-names>
						</name>
						<name>
							<surname>El-Bahy</surname>
							<given-names>AAZ</given-names>
						</name>
						<name>
							<surname>Menze</surname>
							<given-names>ET</given-names>
						</name>
						<name>
							<surname>Azab</surname>
							<given-names>SS</given-names>
						</name>
						<name>
							<surname>El-Demerdash</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<article-title>Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats</article-title>
					<source>Eur J Pharmacol</source>
					<year>2020</year>
					<volume>881</volume>
					<elocation-id>173224</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_177">
				<label>177.</label>
				<mixed-citation>Schwehm, C, Li, J, Song, H, Hu, X, Kellam, B, Stocks, MJ. Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold.
					<italic>ACS Med Chem Lett</italic> 2015;6:324–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Schwehm</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Song</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Kellam</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Stocks</surname>
							<given-names>MJ</given-names>
						</name>
					</person-group>
					<article-title>Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold</article-title>
					<source>ACS Med Chem Lett</source>
					<year>2015</year>
					<volume>6</volume>
					<fpage>324</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_178">
				<label>178.</label>
				<mixed-citation>Berger, JP, SinhaRoy, R, Pocai, A, Kelly, TM, Scapin, G, Gao, YD, et al.. A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice.
					<italic>Endocrinol Diabetes Metab</italic> 2018;1:e00002.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Berger</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>SinhaRoy</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Pocai</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kelly</surname>
							<given-names>TM</given-names>
						</name>
						<name>
							<surname>Scapin</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Gao</surname>
							<given-names>YD</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice</article-title>
					<source>Endocrinol Diabetes Metab</source>
					<year>2018</year>
					<volume>1</volume>
					<elocation-id>e00002</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_179">
				<label>179.</label>
				<mixed-citation>Stano, J, Kovacs, P, Kakoniova, D, Kirilova, ND, Komov, VP. Activity of dipeptidyl peptidase IV in gingseng callus culture.
					<italic>Biologia</italic> 1994;49:353–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Stano</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Kovacs</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Kakoniova</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Kirilova</surname>
							<given-names>ND</given-names>
						</name>
						<name>
							<surname>Komov</surname>
							<given-names>VP</given-names>
						</name>
					</person-group>
					<article-title>Activity of dipeptidyl peptidase IV in gingseng callus culture</article-title>
					<source>Biologia</source>
					<year>1994</year>
					<volume>49</volume>
					<fpage>353</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_180">
				<label>180.</label>
				<mixed-citation>Pérez-Macedonio, CP, Flores-Alfaro, E, Alarcón-Romero, LC, Vences-Velázquez, A, Castro-Alarcón, N, MartínezMartínez, E, et al.. CD14 and CD26 from serum exosomes are associated with type 2 diabetes, exosomal Cystatin C and CD14 are associated with metabolic syndrome and atherogenic index of plasma.
					<italic>PeerJ</italic> 2022;10:e13656.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pérez-Macedonio</surname>
							<given-names>CP</given-names>
						</name>
						<name>
							<surname>Flores-Alfaro</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Alarcón-Romero</surname>
							<given-names>LC</given-names>
						</name>
						<name>
							<surname>Vences-Velázquez</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Castro-Alarcón</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>MartínezMartínez</surname>
							<given-names>E</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>CD14 and CD26 from serum exosomes are associated with type 2 diabetes, exosomal Cystatin C and CD14 are associated with metabolic syndrome and atherogenic index of plasma</article-title>
					<source>PeerJ</source>
					<year>2022</year>
					<volume>10</volume>
					<elocation-id>e13656</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_181">
				<label>181.</label>
				<mixed-citation>Bo, L, Yan, R, Quian, Z, Shi, H, Yun, D, Jing, W, et al.. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
					<italic>Vasc Pharmacol</italic> 2021;140:106854.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bo</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Yan</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Quian</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Shi</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Yun</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Jing</surname>
							<given-names>W</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice</article-title>
					<source>Vasc Pharmacol</source>
					<year>2021</year>
					<volume>140</volume>
					<elocation-id>106854</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_182">
				<label>182.</label>
				<mixed-citation>Conarello, S, Li, Z, Ronan, J. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
					<italic>Proc Natl Acad Sci USA</italic> 2003;100:6825–30.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Conarello</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Ronan</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>2003</year>
					<volume>100</volume>
					<fpage>6825</fpage>
					<lpage>30</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_183">
				<label>183.</label>
				<mixed-citation>Tremblay, AJ, Lamarche, B, Deacon, CF, Weisnagel, SJ, Couture, P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
					<italic>Diabetes Obes Metab</italic> 2011;13:366–73.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tremblay</surname>
							<given-names>AJ</given-names>
						</name>
						<name>
							<surname>Lamarche</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Deacon</surname>
							<given-names>CF</given-names>
						</name>
						<name>
							<surname>Weisnagel</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Couture</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2011</year>
					<volume>13</volume>
					<fpage>366</fpage>
					<lpage>73</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_184">
				<label>184.</label>
				<mixed-citation>Rohmann, N, Schlicht, K, Geisler, C, Hollstein, T, Knappe, C, Krause, L. Circulating sDPP-4 is increased in obesity and insulin resistance but is not related to systemic metabolic inflammation.
					<italic>J Clin Endocrinol Metab</italic> 2021;106:e592–e601.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rohmann</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Schlicht</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Geisler</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Hollstein</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Knappe</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Krause</surname>
							<given-names>L</given-names>
						</name>
					</person-group>
					<article-title>Circulating sDPP-4 is increased in obesity and insulin resistance but is not related to systemic metabolic inflammation</article-title>
					<source>J Clin Endocrinol Metab</source>
					<year>2021</year>
					<volume>106</volume>
					<fpage>e592</fpage>
					<lpage>e601</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_185">
				<label>185.</label>
				<mixed-citation>Barchetta, I, Ceccarelli, V, Cimini, FA, Barone, E, Sentinelli, F, Coluzzi, M. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.
					<italic>J Endocrinol Invest</italic> 2021;44:979–88.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barchetta</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Ceccarelli</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Cimini</surname>
							<given-names>FA</given-names>
						</name>
						<name>
							<surname>Barone</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Sentinelli</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Coluzzi</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease</article-title>
					<source>J Endocrinol Invest</source>
					<year>2021</year>
					<volume>44</volume>
					<fpage>979</fpage>
					<lpage>88</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_186">
				<label>186.</label>
				<mixed-citation>Christopherson, KW, Cooper, S, Broxmeyer, HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells.
					<italic>Blood</italic> 2003;101:4680–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Christopherson</surname>
							<given-names>KW</given-names>
						</name>
						<name>
							<surname>Cooper</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Broxmeyer</surname>
							<given-names>HE</given-names>
						</name>
					</person-group>
					<article-title>Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells</article-title>
					<source>Blood</source>
					<year>2003</year>
					<volume>101</volume>
					<fpage>4680</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_187">
				<label>187.</label>
				<mixed-citation>Chistopherson, KW, Cooper, S, Hangoc, G, Broxmeyer, HE. CD26 isessential for normal G-CSF-induced progenitor cell mobilization as determined by CD26−/− mice.
					<italic>Exp Hematol</italic> 2003;31:1126–34.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chistopherson</surname>
							<given-names>KW</given-names>
						</name>
						<name>
							<surname>Cooper</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Hangoc</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Broxmeyer</surname>
							<given-names>HE</given-names>
						</name>
					</person-group>
					<article-title>CD26 isessential for normal G-CSF-induced progenitor cell mobilization as determined by CD26−/− mice</article-title>
					<source>Exp Hematol</source>
					<year>2003</year>
					<volume>31</volume>
					<fpage>1126</fpage>
					<lpage>34</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_188">
				<label>188.</label>
				<mixed-citation>Morimoto, C, Torimoto, Y, Levinson, G, Rudd, CE, Schrieber, M, Dang, NH, et al.. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells.
					<italic>J Immunol</italic> 1989;143:3430–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Torimoto</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Levinson</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Rudd</surname>
							<given-names>CE</given-names>
						</name>
						<name>
							<surname>Schrieber</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>1F7, a novel cell surface molecule, involved in helper function of CD4 cells</article-title>
					<source>J Immunol</source>
					<year>1989</year>
					<volume>143</volume>
					<fpage>3430</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_189">
				<label>189.</label>
				<mixed-citation>Waumans, Y, Baerts, L, Kehoe, K, Lambeir, AM, De Meester, I. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis.
					<italic>Front Immunol</italic> 2015;6:387.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Waumans</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Baerts</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Kehoe</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Lambeir</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>De Meester</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<article-title>The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis</article-title>
					<source>Front Immunol</source>
					<year>2015</year>
					<volume>6</volume>
					<fpage>387</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_190">
				<label>190.</label>
				<mixed-citation>Bengsch, B, Seigel, B, Flecken, T, Wolanski, J, Blum, HE, Thimme, R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
					<italic>J Immunol</italic> 2012;188:5438–47.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bengsch</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Seigel</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Flecken</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Wolanski</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Blum</surname>
							<given-names>HE</given-names>
						</name>
						<name>
							<surname>Thimme</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)</article-title>
					<source>J Immunol</source>
					<year>2012</year>
					<volume>188</volume>
					<fpage>5438</fpage>
					<lpage>47</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_191">
				<label>191.</label>
				<mixed-citation>Dang, NH, Hafler, DA, Schlossman, SF, Breitmeyer, JB. FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation.
					<italic>Cell Immunol</italic> 1990;125:42–57.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<name>
							<surname>Hafler</surname>
							<given-names>DA</given-names>
						</name>
						<name>
							<surname>Schlossman</surname>
							<given-names>SF</given-names>
						</name>
						<name>
							<surname>Breitmeyer</surname>
							<given-names>JB</given-names>
						</name>
					</person-group>
					<article-title>FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation</article-title>
					<source>Cell Immunol</source>
					<year>1990</year>
					<volume>125</volume>
					<fpage>42</fpage>
					<lpage>57</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_192">
				<label>192.</label>
				<mixed-citation>Dang, NH, Torimoto, Y, Deusch, K, Schlossman, SF, Morimoto, C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways.
					<italic>J Immunol</italic> 1990;144:4092–100.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<name>
							<surname>Torimoto</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Deusch</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Schlossman</surname>
							<given-names>SF</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways</article-title>
					<source>J Immunol</source>
					<year>1990</year>
					<volume>144</volume>
					<fpage>4092</fpage>
					<lpage>100</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_193">
				<label>193.</label>
				<mixed-citation>Dang, NH, Torimoto, Y, Sugita, K, Daley, JF, Schow, P, Prado, C, et al.. Cell surface modulation of CD26 by anti-1F7 monclonal antibody: analysis of surface expression and human T cell activation.
					<italic>J Immunol</italic> 1990;145:3963–71.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<name>
							<surname>Torimoto</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Sugita</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Daley</surname>
							<given-names>JF</given-names>
						</name>
						<name>
							<surname>Schow</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Prado</surname>
							<given-names>C</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Cell surface modulation of CD26 by anti-1F7 monclonal antibody: analysis of surface expression and human T cell activation</article-title>
					<source>J Immunol</source>
					<year>1990</year>
					<volume>145</volume>
					<fpage>3963</fpage>
					<lpage>71</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_194">
				<label>194.</label>
				<mixed-citation>Torimoto, Y, Dang, NH, Tanaka, T, Prado, C, Schlossman, SF, Morimoto, C. Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies.
					<italic>Mol Immunol</italic> 1992;29:183–92.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Torimoto</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<name>
							<surname>Tanaka</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Prado</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Schlossman</surname>
							<given-names>SF</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies</article-title>
					<source>Mol Immunol</source>
					<year>1992</year>
					<volume>29</volume>
					<fpage>183</fpage>
					<lpage>92</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_195">
				<label>195.</label>
				<mixed-citation>Torimoto, Y, Dang, NH, Vivier, E, Tanaka, T, Schlossman, SF, Morimoto, C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes.
					<italic>J Immunol</italic> 1991;147:2514–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Torimoto</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<name>
							<surname>Vivier</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Tanaka</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Schlossman</surname>
							<given-names>SF</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes</article-title>
					<source>J Immunol</source>
					<year>1991</year>
					<volume>147</volume>
					<fpage>2514</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_196">
				<label>196.</label>
				<mixed-citation>Ishii, T, Ohnuma, K, Marakami, A, Takasawa, N, Kobayashi, S, Dang, NH, et al.. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.
					<italic>Proc Natl Acad Sci USA</italic> 2001;98:12138–43.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ishii</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Ohnuma</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Marakami</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Takasawa</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Kobayashi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>2001</year>
					<volume>98</volume>
					<fpage>12138</fpage>
					<lpage>43</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_197">
				<label>197.</label>
				<mixed-citation>Kobayashi, S, Ohnuma, K, Uchiyama, M, Iino, K, Iwata, S, Dang, NH, et al.. Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation.
					<italic>Blood</italic> 2004;103:1002–10.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kobayashi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Ohnuma</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Uchiyama</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Iino</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Iwata</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation</article-title>
					<source>Blood</source>
					<year>2004</year>
					<volume>103</volume>
					<fpage>1002</fpage>
					<lpage>10</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_198">
				<label>198.</label>
				<mixed-citation>Hatano, R, Ohnuma, K, Yamamoto, J, Dang, NH, Morimoto, C. CD26-mediated Co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.
					<italic>Immunology</italic> 2013;138:165–72.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hatano</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Ohnuma</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yamamoto</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>CD26-mediated Co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production</article-title>
					<source>Immunology</source>
					<year>2013</year>
					<volume>138</volume>
					<fpage>165</fpage>
					<lpage>72</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_199">
				<label>199.</label>
				<mixed-citation>Green, H, Chan, T. Pyrimidine starvation induced by adenosine infibroblasts and lymphoid cells: role of adenosine deaminase.
					<italic>Science</italic> 1973;182:836–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Green</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Chan</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Pyrimidine starvation induced by adenosine infibroblasts and lymphoid cells: role of adenosine deaminase</article-title>
					<source>Science</source>
					<year>1973</year>
					<volume>182</volume>
					<fpage>836</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_200">
				<label>200.</label>
				<mixed-citation>Brezinschek, RI, Lipsky, PE, Galea, P, Vita, R, Oppenheimer-Marks, N. Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity.
					<italic>J Immunol</italic> 1995;154:3062–77.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Brezinschek</surname>
							<given-names>RI</given-names>
						</name>
						<name>
							<surname>Lipsky</surname>
							<given-names>PE</given-names>
						</name>
						<name>
							<surname>Galea</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Vita</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Oppenheimer-Marks</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity</article-title>
					<source>J Immunol</source>
					<year>1995</year>
					<volume>154</volume>
					<fpage>3062</fpage>
					<lpage>77</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_201">
				<label>201.</label>
				<mixed-citation>Willheim, M, Ebner, C, Baier, K, Kern, W, Schrattbauer, K, Thien, R. Cell surface characterization of T lymphocytes and allergen-specific t cell clones: correlation of CD26 expression with T(H1) subsets.
					<italic>J Allergy Clin Immunol</italic> 1997;100:348–55.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Willheim</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ebner</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Baier</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Kern</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Schrattbauer</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Thien</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Cell surface characterization of T lymphocytes and allergen-specific t cell clones: correlation of CD26 expression with T(H1) subsets</article-title>
					<source>J Allergy Clin Immunol</source>
					<year>1997</year>
					<volume>100</volume>
					<fpage>348</fpage>
					<lpage>55</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_202">
				<label>202.</label>
				<mixed-citation>Pacheco, R, Martinez-Navio, JM, Lejeune, M, Climent, N, Oliva, H, Gatell, JM, et al.. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.
					<italic>Proc Natl Acad Sci USA</italic> 2005;102:9583–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pacheco</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Martinez-Navio</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Lejeune</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Climent</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Oliva</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Gatell</surname>
							<given-names>JM</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<year>2005</year>
					<volume>102</volume>
					<fpage>9583</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_203">
				<label>203.</label>
				<mixed-citation>Bengsch, B, Seigel, B, Flecken, T, Wolanski, J, Blum, HE, Thimme, R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
					<italic>J Immunol</italic> 2012;188:5438–47.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bengsch</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Seigel</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Flecken</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Wolanski</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Blum</surname>
							<given-names>HE</given-names>
						</name>
						<name>
							<surname>Thimme</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)</article-title>
					<source>J Immunol</source>
					<year>2012</year>
					<volume>188</volume>
					<fpage>5438</fpage>
					<lpage>47</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_204">
				<label>204.</label>
				<mixed-citation>Yamada, Y, Jang, JH, De Meester, I, Baerts, L, Vliegen, G, Inci, I, et al.. CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression.
					<italic>J Heart Lung Transplant</italic> 2016;35:508–17.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yamada</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Jang</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>De Meester</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Baerts</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Vliegen</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Inci</surname>
							<given-names>I</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression</article-title>
					<source>J Heart Lung Transplant</source>
					<year>2016</year>
					<volume>35</volume>
					<fpage>508</fpage>
					<lpage>17</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_205">
				<label>205.</label>
				<mixed-citation>Pinheiro, MM, Stoppa, CL, Valduga, CJ, Okuyama, CE, Gorjao, R, Pereira, RM, et al.. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
					<italic>Eur J Pharmaceut Sci</italic> 2017;100:17–24.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pinheiro</surname>
							<given-names>MM</given-names>
						</name>
						<name>
							<surname>Stoppa</surname>
							<given-names>CL</given-names>
						</name>
						<name>
							<surname>Valduga</surname>
							<given-names>CJ</given-names>
						</name>
						<name>
							<surname>Okuyama</surname>
							<given-names>CE</given-names>
						</name>
						<name>
							<surname>Gorjao</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Pereira</surname>
							<given-names>RM</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro</article-title>
					<source>Eur J Pharmaceut Sci</source>
					<year>2017</year>
					<volume>100</volume>
					<fpage>17</fpage>
					<lpage>24</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_206">
				<label>206.</label>
				<mixed-citation>Ghorpade, DS, Ozcan, L, Zheng, Z, Nicoloro, SM, Shen, Y, Chen, E, et al.. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
					<italic>Nature</italic> 2018;555:673–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ghorpade</surname>
							<given-names>DS</given-names>
						</name>
						<name>
							<surname>Ozcan</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zheng</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Nicoloro</surname>
							<given-names>SM</given-names>
						</name>
						<name>
							<surname>Shen</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>E</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance</article-title>
					<source>Nature</source>
					<year>2018</year>
					<volume>555</volume>
					<fpage>673</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_207">
				<label>207.</label>
				<mixed-citation>Nieto-Fontarigo, JJ, González-Barcala, FJ, San José, E, Arias, P, Nogueira, M, Salgado, FJ. CD26 and asthma: a comprehensive review.
					<italic>Clin Rev Allergy Immunol</italic> 2019;56:139–60.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nieto-Fontarigo</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>González-Barcala</surname>
							<given-names>FJ</given-names>
						</name>
						<name>
							<surname>San José</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Arias</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Nogueira</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Salgado</surname>
							<given-names>FJ</given-names>
						</name>
					</person-group>
					<article-title>CD26 and asthma: a comprehensive review</article-title>
					<source>Clin Rev Allergy Immunol</source>
					<year>2019</year>
					<volume>56</volume>
					<fpage>139</fpage>
					<lpage>60</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_208">
				<label>208.</label>
				<mixed-citation>Christopherson, KW, Hangoc, G, Mantel, CR, Broxmeyer, HE. Modulation of hematopoietic stem cell homing and engraftment by CD26.
					<italic>Science</italic> 2004;305:1000–3.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Christopherson</surname>
							<given-names>KW</given-names>
						</name>
						<name>
							<surname>Hangoc</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Mantel</surname>
							<given-names>CR</given-names>
						</name>
						<name>
							<surname>Broxmeyer</surname>
							<given-names>HE</given-names>
						</name>
					</person-group>
					<article-title>Modulation of hematopoietic stem cell homing and engraftment by CD26</article-title>
					<source>Science</source>
					<year>2004</year>
					<volume>305</volume>
					<fpage>1000</fpage>
					<lpage>3</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_209">
				<label>209.</label>
				<mixed-citation>Lee, DS, Lee, ES, Alam, MM, Jang, JH, Lee, HS, Oh, H. Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate.
					<italic>Metabolism</italic> 2016;65:89–101.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lee</surname>
							<given-names>DS</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>ES</given-names>
						</name>
						<name>
							<surname>Alam</surname>
							<given-names>MM</given-names>
						</name>
						<name>
							<surname>Jang</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>HS</given-names>
						</name>
						<name>
							<surname>Oh</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate</article-title>
					<source>Metabolism</source>
					<year>2016</year>
					<volume>65</volume>
					<fpage>89</fpage>
					<lpage>101</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_210">
				<label>210.</label>
				<mixed-citation>Wronkowitz, N, Görgens, SW, Romacho, T, Villalobos, LA, Sánchez-Ferrer, CF, Peiró, C. Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2.
					<italic>Biochim Biophys Acta</italic> 2014;1842:1613–21.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wronkowitz</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Görgens</surname>
							<given-names>SW</given-names>
						</name>
						<name>
							<surname>Romacho</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Villalobos</surname>
							<given-names>LA</given-names>
						</name>
						<name>
							<surname>Sánchez-Ferrer</surname>
							<given-names>CF</given-names>
						</name>
						<name>
							<surname>Peiró</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2</article-title>
					<source>Biochim Biophys Acta</source>
					<year>2014</year>
					<volume>1842</volume>
					<fpage>1613</fpage>
					<lpage>21</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_211">
				<label>211.</label>
				<mixed-citation>Kawasaki, T, Chen, W, Htwe, YM, Tatsumi, K, Dudek, SM. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice.
					<italic>Am J Physiol Lung Cell Mol Physiol</italic> 2018;315:L834–l845.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kawasaki</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Htwe</surname>
							<given-names>YM</given-names>
						</name>
						<name>
							<surname>Tatsumi</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Dudek</surname>
							<given-names>SM</given-names>
						</name>
					</person-group>
					<article-title>DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice</article-title>
					<source>Am J Physiol Lung Cell Mol Physiol</source>
					<year>2018</year>
					<volume>315</volume>
					<fpage>L834</fpage>
					<lpage>l845</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_212">
				<label>212.</label>
				<mixed-citation>Zhao, X, Zhang, K, Daniel, P, Wisbrun, N, Fuchs, H, Fan, H. Delayed allogeneic skin graft rejection in CD26-deficient mice.
					<italic>Cell Mol Immunol</italic> 2019;16:557–67.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhao</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Daniel</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Wisbrun</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Fuchs</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Fan</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Delayed allogeneic skin graft rejection in CD26-deficient mice</article-title>
					<source>Cell Mol Immunol</source>
					<year>2019</year>
					<volume>16</volume>
					<fpage>557</fpage>
					<lpage>67</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_213">
				<label>213.</label>
				<mixed-citation>Bauvois, B, Dauzonne, D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.
					<italic>Med Res Rev</italic> 2006;26:88–130.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bauvois</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Dauzonne</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects</article-title>
					<source>Med Res Rev</source>
					<year>2006</year>
					<volume>26</volume>
					<fpage>88</fpage>
					<lpage>130</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_214">
				<label>214.</label>
				<mixed-citation>Wang, Q, Wong, G, Lu, G. MERS-CoV spike protein: targets for vaccines and therapeutics.
					<italic>Antiviral Res</italic> 2016;133:165–77.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wang</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Wong</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Lu</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>MERS-CoV spike protein: targets for vaccines and therapeutics</article-title>
					<source>Antiviral Res</source>
					<year>2016</year>
					<volume>133</volume>
					<fpage>165</fpage>
					<lpage>77</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_215">
				<label>215.</label>
				<mixed-citation>Mucha, A, Drag, M, Dalton, JP, Kafarski, P. Metallo-aminopeptidase inhibitors.
					<italic>Biochimie</italic> 2010;92:1509–29.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mucha</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Drag</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Dalton</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>Kafarski</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Metallo-aminopeptidase inhibitors</article-title>
					<source>Biochimie</source>
					<year>2010</year>
					<volume>92</volume>
					<fpage>1509</fpage>
					<lpage>29</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_216">
				<label>216.</label>
				<mixed-citation>Raj, VS, Mou, H, Smits, SL, Dekkers, DH, Müller, MA, Dijkman, R. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
					<italic>Nature</italic> 2013;495:251–4.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Raj</surname>
							<given-names>VS</given-names>
						</name>
						<name>
							<surname>Mou</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Smits</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Dekkers</surname>
							<given-names>DH</given-names>
						</name>
						<name>
							<surname>Müller</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Dijkman</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title>
					<source>Nature</source>
					<year>2013</year>
					<volume>495</volume>
					<fpage>251</fpage>
					<lpage>4</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_217">
				<label>217.</label>
				<mixed-citation>Ohnuma, K, Haagmans, BL, Hatano, R, Raj, VS, Mou, H, Iwata, S. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
					<italic>J Virol</italic> 2013;87:13892–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ohnuma</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Haagmans</surname>
							<given-names>BL</given-names>
						</name>
						<name>
							<surname>Hatano</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Raj</surname>
							<given-names>VS</given-names>
						</name>
						<name>
							<surname>Mou</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Iwata</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody</article-title>
					<source>J Virol</source>
					<year>2013</year>
					<volume>87</volume>
					<fpage>13892</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_218">
				<label>218.</label>
				<mixed-citation>Inn, KS, Kim, Y, Aigerim, A, Park, U, Hwang, ES, Choi, MS. Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus.
					<italic>Virology</italic> 2018;518:324–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Inn</surname>
							<given-names>KS</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Aigerim</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Park</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Hwang</surname>
							<given-names>ES</given-names>
						</name>
						<name>
							<surname>Choi</surname>
							<given-names>MS</given-names>
						</name>
					</person-group>
					<article-title>Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus</article-title>
					<source>Virology</source>
					<year>2018</year>
					<volume>518</volume>
					<fpage>324</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_219">
				<label>219.</label>
				<mixed-citation>Algaissi, A, Agrawal, AS, Han, S, Peng, BH, Luo, C, Li, F. Elevated human dipeptidyl-peptidase 4 expression reduces the susceptibility of hDPP4 transgenic mice to Middle East respiratory syndrome coronavirus infection and disease.
					<italic>J Infect Dis</italic> 2019;219:829–35.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Algaissi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Agrawal</surname>
							<given-names>AS</given-names>
						</name>
						<name>
							<surname>Han</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Peng</surname>
							<given-names>BH</given-names>
						</name>
						<name>
							<surname>Luo</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>Elevated human dipeptidyl-peptidase 4 expression reduces the susceptibility of hDPP4 transgenic mice to Middle East respiratory syndrome coronavirus infection and disease</article-title>
					<source>J Infect Dis</source>
					<year>2019</year>
					<volume>219</volume>
					<fpage>829</fpage>
					<lpage>35</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_220">
				<label>220.</label>
				<mixed-citation>Vankadari, N, Wilce, JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26.
					<italic>Emerg Microbes Infect</italic> 2020;9:601–4.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Vankadari</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Wilce</surname>
							<given-names>JA</given-names>
						</name>
					</person-group>
					<article-title>Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26</article-title>
					<source>Emerg Microbes Infect</source>
					<year>2020</year>
					<volume>9</volume>
					<fpage>601</fpage>
					<lpage>4</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_221">
				<label>221.</label>
				<mixed-citation>Tai, W, He, L, Zhang, X, Pu, J, Voronin, D, Jiang, S. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral Attachment inhibitor and vaccine.
					<italic>Cell Mol Immunol</italic> 2020;17:613–20.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tai</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>He</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Pu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Voronin</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Jiang</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral Attachment inhibitor and vaccine</article-title>
					<source>Cell Mol Immunol</source>
					<year>2020</year>
					<volume>17</volume>
					<fpage>613</fpage>
					<lpage>20</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_222">
				<label>222.</label>
				<mixed-citation>Zhou, F, Yu, T, Du, R, Fan, G, Liu, Y, Liu, Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
					<italic>Lancet</italic> 2020;395:1054–62.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhou</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Du</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Fan</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Z</given-names>
						</name>
					</person-group>
					<article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>
					<source>Lancet</source>
					<year>2020</year>
					<volume>395</volume>
					<fpage>1054</fpage>
					<lpage>62</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_223">
				<label>223.</label>
				<mixed-citation>Solerte, SB, D’addio, F, Trevisan, R, Lovati, E, Rossi, A, Pastore, I. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study.
					<italic>Diabetes Care</italic> 2020;43:2999–3006.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Solerte</surname>
							<given-names>SB</given-names>
						</name>
						<name>
							<surname>D’addio</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Trevisan</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Lovati</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Rossi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Pastore</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<article-title>Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study</article-title>
					<source>Diabetes Care</source>
					<year>2020</year>
					<volume>43</volume>
					<fpage>2999</fpage>
					<lpage>3006</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_224">
				<label>224.</label>
				<mixed-citation>Solerte, SB, Di Sabatino, A, Galli, M, Fiorina, P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
					<italic>Acta Diabeto</italic> 2020;57:779–83.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Solerte</surname>
							<given-names>SB</given-names>
						</name>
						<name>
							<surname>Di Sabatino</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Galli</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Fiorina</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19</article-title>
					<source>Acta Diabeto</source>
					<year>2020</year>
					<volume>57</volume>
					<fpage>779</fpage>
					<lpage>83</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_225">
				<label>225.</label>
				<mixed-citation>Pal, R, Banerjee, M, Mukherjee, S, Bhogal, RS, Kaur, A, Bhadada, SK. Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and MetaAnalysis.
					<italic>Ther Adv Endocrinol Metab</italic> 2021;12:2042018821996482.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pal</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Banerjee</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Mukherjee</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Bhogal</surname>
							<given-names>RS</given-names>
						</name>
						<name>
							<surname>Kaur</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Bhadada</surname>
							<given-names>SK</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and MetaAnalysis</article-title>
					<source>Ther Adv Endocrinol Metab</source>
					<year>2021</year>
					<volume>12</volume>
					<elocation-id>2042018821996482</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_226">
				<label>226.</label>
				<mixed-citation>Rakhmat, II, Kusmala, YY, Handayani, DR, Juliastuti, H, Nawangsih, EN, Wibowo, A. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – a systematic review, meta-analysis, and meta-regression.
					<italic>Diabetes Metab Syndr</italic> 2021;15:777–82.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rakhmat</surname>
							<given-names>II</given-names>
						</name>
						<name>
							<surname>Kusmala</surname>
							<given-names>YY</given-names>
						</name>
						<name>
							<surname>Handayani</surname>
							<given-names>DR</given-names>
						</name>
						<name>
							<surname>Juliastuti</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Nawangsih</surname>
							<given-names>EN</given-names>
						</name>
						<name>
							<surname>Wibowo</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – a systematic review, meta-analysis, and meta-regression</article-title>
					<source>Diabetes Metab Syndr</source>
					<year>2021</year>
					<volume>15</volume>
					<fpage>777</fpage>
					<lpage>82</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_227">
				<label>227.</label>
				<mixed-citation>Zhou, JH, Wu, B, Wang, WX, Lei, F, Cheng, X, Qin, JJ. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.
					<italic>World J Clin Cases</italic> 2020;8:5576–88.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhou</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>WX</given-names>
						</name>
						<name>
							<surname>Lei</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Cheng</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Qin</surname>
							<given-names>JJ</given-names>
						</name>
					</person-group>
					<article-title>No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19</article-title>
					<source>World J Clin Cases</source>
					<year>2020</year>
					<volume>8</volume>
					<fpage>5576</fpage>
					<lpage>88</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_228">
				<label>228.</label>
				<mixed-citation>Roussel, R, Darmon, P, Pichelin, M, Goronflot, T, Abouleka, Y, Ait Bachir, L. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study.
					<italic>Diabetes Obes Metab</italic> 2021;23:1162–72.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Roussel</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Darmon</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Pichelin</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Goronflot</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Abouleka</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Ait Bachir</surname>
							<given-names>L</given-names>
						</name>
					</person-group>
					<article-title>Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2021</year>
					<volume>23</volume>
					<fpage>1162</fpage>
					<lpage>72</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_229">
				<label>229.</label>
				<mixed-citation>Strollo, R, Maddaloni, E, Dauriz, M, Pedone, C, Buzzetti, R, Pozzilli, P. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.
					<italic>Diabetes Res Clin Pract</italic> 2021;171:108444.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Strollo</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Maddaloni</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Dauriz</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Pedone</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Buzzetti</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Pozzilli</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths</article-title>
					<source>Diabetes Res Clin Pract</source>
					<year>2021</year>
					<volume>171</volume>
					<elocation-id>108444</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_230">
				<label>230.</label>
				<mixed-citation>Hariyanto, TI, Kurniawan, A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.
					<italic>J Diabetes Metab Disord</italic> 2021;20:1–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hariyanto</surname>
							<given-names>TI</given-names>
						</name>
						<name>
							<surname>Kurniawan</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression</article-title>
					<source>J Diabetes Metab Disord</source>
					<year>2021</year>
					<volume>20</volume>
					<fpage>1</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_231">
				<label>231.</label>
				<mixed-citation>Shiobara, T, Chibana, K, Watanabe, T, Arai, R, Horigane, Y, Nakamura, Y. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells.
					<italic>Respir Res</italic> 2016;17:28.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Shiobara</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Chibana</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Watanabe</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Arai</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Horigane</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Nakamura</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells</article-title>
					<source>Respir Res</source>
					<year>2016</year>
					<volume>17</volume>
					<fpage>28</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_232">
				<label>232.</label>
				<mixed-citation>Poole, A, Urbanek, C, Eng, C, Schageman, J, Jacobson, S, O’connor, BP. Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease.
					<italic>J Allergy Clin Immunol</italic> 2014;133:670–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Poole</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Urbanek</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Eng</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Schageman</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Jacobson</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>O’connor</surname>
							<given-names>BP</given-names>
						</name>
					</person-group>
					<article-title>Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease</article-title>
					<source>J Allergy Clin Immunol</source>
					<year>2014</year>
					<volume>133</volume>
					<fpage>670</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_233">
				<label>233.</label>
				<mixed-citation>Ranade, K, Pham, TH, Damera, G, Brohawn, PZ, Pilataxi, F, Kuziora, M. Dipeptidyl peptidase-4 (DPP-4) is a novel predictive biomarker for the investigational anti-IL-13 targeted therapy Tralokinumab.
					<italic>Am J Respir Crit Care Med</italic> 2016;193:A4332.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ranade</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Pham</surname>
							<given-names>TH</given-names>
						</name>
						<name>
							<surname>Damera</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Brohawn</surname>
							<given-names>PZ</given-names>
						</name>
						<name>
							<surname>Pilataxi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Kuziora</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 (DPP-4) is a novel predictive biomarker for the investigational anti-IL-13 targeted therapy Tralokinumab</article-title>
					<source>Am J Respir Crit Care Med</source>
					<year>2016</year>
					<volume>193</volume>
					<fpage>A4332</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_234">
				<label>234.</label>
				<mixed-citation>Mitchell, J, Dimov, V, Townley, RG. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease.
					<italic>Curr Opin Investig Drugs</italic> 2010;11:527–34.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mitchell</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Dimov</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Townley</surname>
							<given-names>RG</given-names>
						</name>
					</person-group>
					<article-title>IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease</article-title>
					<source>Curr Opin Investig Drugs</source>
					<year>2010</year>
					<volume>11</volume>
					<fpage>527</fpage>
					<lpage>34</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_235">
				<label>235.</label>
				<mixed-citation>Nader, MA. Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma.
					<italic>Int Immunopharmacol</italic> 2015;29:761–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nader</surname>
							<given-names>MA</given-names>
						</name>
					</person-group>
					<article-title>Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma</article-title>
					<source>Int Immunopharmacol</source>
					<year>2015</year>
					<volume>29</volume>
					<fpage>761</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_236">
				<label>236.</label>
				<mixed-citation>Helal, MG, Megahed, NA, Abd Elhameed, AG. Saxagliptin Mitigates airway inflammation in a mouse model of acute asthma via modulation of NF-kB and TLR4.
					<italic>Life Sci</italic> 2019;239:117017.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Helal</surname>
							<given-names>MG</given-names>
						</name>
						<name>
							<surname>Megahed</surname>
							<given-names>NA</given-names>
						</name>
						<name>
							<surname>Abd Elhameed</surname>
							<given-names>AG</given-names>
						</name>
					</person-group>
					<article-title>Saxagliptin Mitigates airway inflammation in a mouse model of acute asthma via modulation of NF-kB and TLR4</article-title>
					<source>Life Sci</source>
					<year>2019</year>
					<volume>239</volume>
					<elocation-id>117017</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_237">
				<label>237.</label>
				<mixed-citation>Anderluh, M, Kocic, G, Tomovic, K, Kocic, H, Smelcerovic, A. DPP-4 inhibition: a novel therapeutic approach to the treatment of pulmonary hypertension.
					<italic>Pharmacol Ther</italic> 2019;201:1–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Anderluh</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kocic</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Tomovic</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Kocic</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Smelcerovic</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>DPP-4 inhibition: a novel therapeutic approach to the treatment of pulmonary hypertension</article-title>
					<source>Pharmacol Ther</source>
					<year>2019</year>
					<volume>201</volume>
					<fpage>1</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_238">
				<label>238.</label>
				<mixed-citation>Li, Y, Yang, L, Dong, L, Yang, ZW, Zhang, J, Zhang, SL. Crosstalk between the Akt/mTORC1 and NF-Κb signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs.
					<italic>Acta Pharmacol Sin</italic> 2019;40:1322–33.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Li</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Dong</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>ZW</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>SL</given-names>
						</name>
					</person-group>
					<article-title>Crosstalk between the Akt/mTORC1 and NF-Κb signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs</article-title>
					<source>Acta Pharmacol Sin</source>
					<year>2019</year>
					<volume>40</volume>
					<fpage>1322</fpage>
					<lpage>33</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_239">
				<label>239.</label>
				<mixed-citation>Xu, J, Wang, J, He, M, Han, H, Xie, W, Wang, H. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension.
					<italic>Lab Invest</italic> 2018;98:1333–46.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Xu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>He</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Han</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Xie</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension</article-title>
					<source>Lab Invest</source>
					<year>2018</year>
					<volume>98</volume>
					<fpage>1333</fpage>
					<lpage>46</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_240">
				<label>240.</label>
				<mixed-citation>Wang, J, Yu, M, Xu, J, Cheng, Y, Li, X, Wei, G. Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension.
					<italic>J Biomed Sci</italic> 2019;26:6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Xu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Cheng</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Wei</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension</article-title>
					<source>J Biomed Sci</source>
					<year>2019</year>
					<volume>26</volume>
					<fpage>6</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_241">
				<label>241.</label>
				<mixed-citation>Deacon, CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes.
					<italic>Front Endocrinol</italic> 2019;10:80.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Deacon</surname>
							<given-names>CF</given-names>
						</name>
					</person-group>
					<article-title>Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes</article-title>
					<source>Front Endocrinol</source>
					<year>2019</year>
					<volume>10</volume>
					<fpage>80</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_242">
				<label>242.</label>
				<mixed-citation>Gangadharan Komala, M, Gross, S, Zaky, A, Pollock, C, Panchapakesan, U. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
					<italic>Nephrology</italic> 2016;21:423–31.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gangadharan Komala</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Gross</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Zaky</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Pollock</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Panchapakesan</surname>
							<given-names>U</given-names>
						</name>
					</person-group>
					<article-title>Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes</article-title>
					<source>Nephrology</source>
					<year>2016</year>
					<volume>21</volume>
					<fpage>423</fpage>
					<lpage>31</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_243">
				<label>243.</label>
				<mixed-citation>Lay, AJ, Zhang, HE, Mccaughan, GW, Gorrell, MD. Fibroblast activation protein in liver fibrosis.
					<italic>Front Biosci Landmark</italic> 2019;24:1–17.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lay</surname>
							<given-names>AJ</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>HE</given-names>
						</name>
						<name>
							<surname>Mccaughan</surname>
							<given-names>GW</given-names>
						</name>
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
					</person-group>
					<article-title>Fibroblast activation protein in liver fibrosis</article-title>
					<source>Front Biosci Landmark</source>
					<year>2019</year>
					<volume>24</volume>
					<fpage>1</fpage>
					<lpage>17</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_244">
				<label>244.</label>
				<mixed-citation>Soare, A, Györfi, HA, Matei, AE, Dees, C, Rauber, S, Wohlfahrt, T. Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis.
					<italic>Arthritis Rheumatol</italic> 2020;72:137–49.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Soare</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Györfi</surname>
							<given-names>HA</given-names>
						</name>
						<name>
							<surname>Matei</surname>
							<given-names>AE</given-names>
						</name>
						<name>
							<surname>Dees</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Rauber</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Wohlfahrt</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis</article-title>
					<source>Arthritis Rheumatol</source>
					<year>2020</year>
					<volume>72</volume>
					<fpage>137</fpage>
					<lpage>49</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_245">
				<label>245.</label>
				<mixed-citation>Lee, SY, Wu, ST, Liang, YJ, Su, MJ, Huang, CW, Jao, YH. Soluble dipeptidyl peptidase-4 induces fibroblast activation through proteinase-activated receptor-2.
					<italic>Front Pharmacol</italic> 2020;11: 552818.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lee</surname>
							<given-names>SY</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>ST</given-names>
						</name>
						<name>
							<surname>Liang</surname>
							<given-names>YJ</given-names>
						</name>
						<name>
							<surname>Su</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>CW</given-names>
						</name>
						<name>
							<surname>Jao</surname>
							<given-names>YH</given-names>
						</name>
					</person-group>
					<article-title>Soluble dipeptidyl peptidase-4 induces fibroblast activation through proteinase-activated receptor-2</article-title>
					<source>Front Pharmacol</source>
					<year>2020</year>
					<volume>11</volume>
					<elocation-id>552818</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_246">
				<label>246.</label>
				<mixed-citation>Suzuki, T, Tada, Y, Gladson, S, Nishimura, R, Shimomura, I, Karasawa, S. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide induced lung injury by inhibiting endothelial-to-mesenchymal transition.
					<italic>Respir Res</italic> 2017;18:177.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Suzuki</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Tada</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Gladson</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Nishimura</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Shimomura</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Karasawa</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide induced lung injury by inhibiting endothelial-to-mesenchymal transition</article-title>
					<source>Respir Res</source>
					<year>2017</year>
					<volume>18</volume>
					<fpage>177</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_247">
				<label>247.</label>
				<mixed-citation>Liu, Y, Qi, Y. Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.
					<italic>Int Immunopharmacol</italic> 2020;87:106774.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Qi</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix</article-title>
					<source>Int Immunopharmacol</source>
					<year>2020</year>
					<volume>87</volume>
					<elocation-id>106774</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_248">
				<label>248.</label>
				<mixed-citation>Kim, KM, Noh, JH, Bodogai, M, Martindale, JL, Yang, X, Indig, FE. Identification of senescent cell surface targetable protein DPP4.
					<italic>Genes Dev</italic> 2017;31:1529–34.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kim</surname>
							<given-names>KM</given-names>
						</name>
						<name>
							<surname>Noh</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Bodogai</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Martindale</surname>
							<given-names>JL</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Indig</surname>
							<given-names>FE</given-names>
						</name>
					</person-group>
					<article-title>Identification of senescent cell surface targetable protein DPP4</article-title>
					<source>Genes Dev</source>
					<year>2017</year>
					<volume>31</volume>
					<fpage>1529</fpage>
					<lpage>34</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_249">
				<label>249.</label>
				<mixed-citation>Chen, Z, Yu, J, Fu, M, Dong, R, Yang, Y, Luo, J. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway.
					<italic>Biochem Pharmacol</italic> 2020;177:113951.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chen</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Fu</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Dong</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Luo</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway</article-title>
					<source>Biochem Pharmacol</source>
					<year>2020</year>
					<volume>177</volume>
					<elocation-id>113951</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_250">
				<label>250.</label>
				<mixed-citation>Schafer, MJ, White, TA, Iijima, K, Haak, AJ, Ligresti, G, Atkinson, EJ. Cellular senescence mediates fibrotic pulmonary disease.
					<italic>Nat Commun</italic> 2017;8:14532.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Schafer</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>White</surname>
							<given-names>TA</given-names>
						</name>
						<name>
							<surname>Iijima</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Haak</surname>
							<given-names>AJ</given-names>
						</name>
						<name>
							<surname>Ligresti</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Atkinson</surname>
							<given-names>EJ</given-names>
						</name>
					</person-group>
					<article-title>Cellular senescence mediates fibrotic pulmonary disease</article-title>
					<source>Nat Commun</source>
					<year>2017</year>
					<volume>8</volume>
					<elocation-id>14532</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_251">
				<label>251.</label>
				<mixed-citation>Yao, C, Guan, X, Carraro, G, Parimon, T, Liu, X, Huang, G. Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis.
					<italic>Am J Respir Crit Care Med</italic> 2021;203:707–17.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yao</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Guan</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Carraro</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Parimon</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis</article-title>
					<source>Am J Respir Crit Care Med</source>
					<year>2021</year>
					<volume>203</volume>
					<fpage>707</fpage>
					<lpage>17</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_252">
				<label>252.</label>
				<mixed-citation>Zhong, J, Maiseyeu, A, Davis, SN, Rajagopalan, S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
					<italic>Circ Res</italic> 2015;116:1491–504.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhong</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Maiseyeu</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Davis</surname>
							<given-names>SN</given-names>
						</name>
						<name>
							<surname>Rajagopalan</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition</article-title>
					<source>Circ Res</source>
					<year>2015</year>
					<volume>116</volume>
					<fpage>1491</fpage>
					<lpage>504</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_253">
				<label>253.</label>
				<mixed-citation>Kadoglou, N, Korakas, E, Lampropoulos, S, Maratou, E, Kassimis, G, Patsourakos, N, et al.. Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study.
					<italic>Cardiovasc Diabetol</italic> 2021;20:166.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kadoglou</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Korakas</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Lampropoulos</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Maratou</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Kassimis</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Patsourakos</surname>
							<given-names>N</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study</article-title>
					<source>Cardiovasc Diabetol</source>
					<year>2021</year>
					<volume>20</volume>
					<fpage>166</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_254">
				<label>254.</label>
				<mixed-citation>Batchu, SN, Yerra, VG, Liu, Y, Advani, SL, Klein, T, Advani, A. The dipeptidyl peptidase-4 inhibitor linagliptin directly enhances the contractile recovery of mouse hearts at a concentration equivalent to that achieved with standard dosing in humans.
					<italic>Int J Mol Sci</italic> 2020;21:5756.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Batchu</surname>
							<given-names>SN</given-names>
						</name>
						<name>
							<surname>Yerra</surname>
							<given-names>VG</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Advani</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Klein</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Advani</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>The dipeptidyl peptidase-4 inhibitor linagliptin directly enhances the contractile recovery of mouse hearts at a concentration equivalent to that achieved with standard dosing in humans</article-title>
					<source>Int J Mol Sci</source>
					<year>2020</year>
					<volume>21</volume>
					<fpage>5756</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_255">
				<label>255.</label>
				<mixed-citation>Fadini, P, Avogaro, A. Cardiovascular effects of DPP-IV inhibition: beyond GLP-1.
					<italic>Vasc Pharmacol</italic> 2011;55:10–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fadini</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Avogaro</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Cardiovascular effects of DPP-IV inhibition: beyond GLP-1</article-title>
					<source>Vasc Pharmacol</source>
					<year>2011</year>
					<volume>55</volume>
					<fpage>10</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_256">
				<label>256.</label>
				<mixed-citation>Murgai, M, Giles, A, Kaplan, R. Physiological, tumour, and metastatic niches: opportunities and challenges for targeting the tumour microenvironment.
					<italic>Crit Rev Oncog</italic> 2015;20:301–14.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Murgai</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Giles</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kaplan</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Physiological, tumour, and metastatic niches: opportunities and challenges for targeting the tumour microenvironment</article-title>
					<source>Crit Rev Oncog</source>
					<year>2015</year>
					<volume>20</volume>
					<fpage>301</fpage>
					<lpage>14</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_257">
				<label>257.</label>
				<mixed-citation>Busek, P, Duke-Cohan, JS, Sedo, A. Does DPP-IV inhibition offer new avenues for therapeutic intervention in malignant disease.
					<italic>Cancers</italic> 2022;14:2072.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Busek</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Duke-Cohan</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Sedo</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Does DPP-IV inhibition offer new avenues for therapeutic intervention in malignant disease</article-title>
					<source>Cancers</source>
					<year>2022</year>
					<volume>14</volume>
					<fpage>2072</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_258">
				<label>258.</label>
				<mixed-citation>Iwata, S, Morimoto, C. CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation.
					<italic>J Exp Med</italic> 1999, 190, 301-6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Iwata</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation</article-title>
					<source>J Exp Med</source>
					<year>1999</year>
					<volume>190</volume>
					<fpage>301</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_259">
				<label>259.</label>
				<mixed-citation>Wesley, UV, Albino, AP, Tiwari, S, Houghton, AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.
					<italic>J Exp Med</italic> 1999;190:311–22.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wesley</surname>
							<given-names>UV</given-names>
						</name>
						<name>
							<surname>Albino</surname>
							<given-names>AP</given-names>
						</name>
						<name>
							<surname>Tiwari</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Houghton</surname>
							<given-names>AN</given-names>
						</name>
					</person-group>
					<article-title>A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells</article-title>
					<source>J Exp Med</source>
					<year>1999</year>
					<volume>190</volume>
					<fpage>311</fpage>
					<lpage>22</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_260">
				<label>260.</label>
				<mixed-citation>Asada, Y, Aratake, Y, Kotani, T, Marutsuka, K, Araki, Y, Ohtaki, S. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
					<italic>Histopathology</italic> 1993;23:265–70.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Asada</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Aratake</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Kotani</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Marutsuka</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Araki</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Ohtaki</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma</article-title>
					<source>Histopathology</source>
					<year>1993</year>
					<volume>23</volume>
					<fpage>265</fpage>
					<lpage>70</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_261">
				<label>261.</label>
				<mixed-citation>Wesley, UV, Tiwari, S, Houghton, AN. Role for dipeptidyl peptidase IV in tumour suppression of human non small cell lung carcinoma cells.
					<italic>Int J Cancer</italic> 2004;109:855–66.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wesley</surname>
							<given-names>UV</given-names>
						</name>
						<name>
							<surname>Tiwari</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Houghton</surname>
							<given-names>AN</given-names>
						</name>
					</person-group>
					<article-title>Role for dipeptidyl peptidase IV in tumour suppression of human non small cell lung carcinoma cells</article-title>
					<source>Int J Cancer</source>
					<year>2004</year>
					<volume>109</volume>
					<fpage>855</fpage>
					<lpage>66</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_262">
				<label>262.</label>
				<mixed-citation>Dimitrova, M, Ivanov, I, Todorova, R, Stefanova, N, Moskova-Doumanova, V, Topouzova-Hristova, T. Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumour human lung cells.
					<italic>Tissue Cell</italic> 2012;44:74–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dimitrova</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ivanov</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Todorova</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Stefanova</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Moskova-Doumanova</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Topouzova-Hristova</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumour human lung cells</article-title>
					<source>Tissue Cell</source>
					<year>2012</year>
					<volume>44</volume>
					<fpage>74</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_263">
				<label>263.</label>
				<mixed-citation>Khin, EE, Kikkawa, F, Ino, K, Kajiyama, H, Suzuki, T, Shibata, K. Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumour grade.
					<italic>Am J Obstet Gynecol</italic> 2003;188:670–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Khin</surname>
							<given-names>EE</given-names>
						</name>
						<name>
							<surname>Kikkawa</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Ino</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Kajiyama</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Suzuki</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Shibata</surname>
							<given-names>K</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumour grade</article-title>
					<source>Am J Obstet Gynecol</source>
					<year>2003</year>
					<volume>188</volume>
					<fpage>670</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_264">
				<label>264.</label>
				<mixed-citation>Bogenrieder, T, Finstad, CL, Freeman, RH, Papandreou, CN, Scher, HI, Albino, AP. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue.
					<italic>Prostate</italic> 1997;33:225–32.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bogenrieder</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Finstad</surname>
							<given-names>CL</given-names>
						</name>
						<name>
							<surname>Freeman</surname>
							<given-names>RH</given-names>
						</name>
						<name>
							<surname>Papandreou</surname>
							<given-names>CN</given-names>
						</name>
						<name>
							<surname>Scher</surname>
							<given-names>HI</given-names>
						</name>
						<name>
							<surname>Albino</surname>
							<given-names>AP</given-names>
						</name>
					</person-group>
					<article-title>Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue</article-title>
					<source>Prostate</source>
					<year>1997</year>
					<volume>33</volume>
					<fpage>225</fpage>
					<lpage>32</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_265">
				<label>265.</label>
				<mixed-citation>Dinjens, WN, Ten Kate, J, Kirch, JA, Tanke, HJ, Van der Linden, EP, Van den Ingh, HF. Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas.
					<italic>J Pathol</italic> 1990;160:195–20.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dinjens</surname>
							<given-names>WN</given-names>
						</name>
						<name>
							<surname>Ten Kate</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Kirch</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Tanke</surname>
							<given-names>HJ</given-names>
						</name>
						<name>
							<surname>Van der Linden</surname>
							<given-names>EP</given-names>
						</name>
						<name>
							<surname>Van den Ingh</surname>
							<given-names>HF</given-names>
						</name>
					</person-group>
					<article-title>Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas</article-title>
					<source>J Pathol</source>
					<year>1990</year>
					<volume>160</volume>
					<fpage>195</fpage>
					<lpage>20</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_266">
				<label>266.</label>
				<mixed-citation>Wesley, UV, McGroarty, M, Homoyouni, A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway.
					<italic>Cancer Res</italic> 2005;65:1325–34.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wesley</surname>
							<given-names>UV</given-names>
						</name>
						<name>
							<surname>McGroarty</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Homoyouni</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway</article-title>
					<source>Cancer Res</source>
					<year>2005</year>
					<volume>65</volume>
					<fpage>1325</fpage>
					<lpage>34</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_267">
				<label>267.</label>
				<mixed-citation>Urade, M, Komatsu, M, Yamaoka, M, Fukasawa, K, Harada, M, Mima, T. Serum dipeptidyl peptidase activities as a possible marker of oral cancer.
					<italic>Cancer</italic> 1989;64:1274–80.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Urade</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Komatsu</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Yamaoka</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Fukasawa</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Harada</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Mima</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Serum dipeptidyl peptidase activities as a possible marker of oral cancer</article-title>
					<source>Cancer</source>
					<year>1989</year>
					<volume>64</volume>
					<fpage>1274</fpage>
					<lpage>80</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_268">
				<label>268.</label>
				<mixed-citation>de la Haba-Rodriguez, J, Macho, A, Calzado, MA, Blazquez, MV, Gomez, MA, Munoz, EE. Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma.
					<italic>Neoplasma</italic> 2002;49:307–11.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>de la Haba-Rodriguez</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Macho</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Calzado</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Blazquez</surname>
							<given-names>MV</given-names>
						</name>
						<name>
							<surname>Gomez</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Munoz</surname>
							<given-names>EE</given-names>
						</name>
					</person-group>
					<article-title>Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma</article-title>
					<source>Neoplasma</source>
					<year>2002</year>
					<volume>49</volume>
					<fpage>307</fpage>
					<lpage>11</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_269">
				<label>269.</label>
				<mixed-citation>Cordero, OJ, Imbernon, M, Chiara, LD, Martinez-Zorzano, VS, Ayude, D, de la Cadena, MP. Potential of soluble CD26 as a serum marker for colorectal cancer detection.
					<italic>World J Clin Oncol</italic> 2011;2:245–61.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cordero</surname>
							<given-names>OJ</given-names>
						</name>
						<name>
							<surname>Imbernon</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Chiara</surname>
							<given-names>LD</given-names>
						</name>
						<name>
							<surname>Martinez-Zorzano</surname>
							<given-names>VS</given-names>
						</name>
						<name>
							<surname>Ayude</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>de la Cadena</surname>
							<given-names>MP</given-names>
						</name>
					</person-group>
					<article-title>Potential of soluble CD26 as a serum marker for colorectal cancer detection</article-title>
					<source>World J Clin Oncol</source>
					<year>2011</year>
					<volume>2</volume>
					<fpage>245</fpage>
					<lpage>61</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_270">
				<label>270.</label>
				<mixed-citation>Sedo, A, Krepela, E, Kasafirek, E. Dipeptidyl peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumours and lung parenchyma.
					<italic>J Cancer Res Clin Oncol</italic> 1991;117:249–53.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sedo</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Krepela</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Kasafirek</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumours and lung parenchyma</article-title>
					<source>J Cancer Res Clin Oncol</source>
					<year>1991</year>
					<volume>117</volume>
					<fpage>249</fpage>
					<lpage>53</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_271">
				<label>271.</label>
				<mixed-citation>Frohlich, E, Maier, E, Wahl, R. Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies.
					<italic>J Exp Clin Cancer Res</italic> 2012;31:45.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Frohlich</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Maier</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Wahl</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies</article-title>
					<source>J Exp Clin Cancer Res</source>
					<year>2012</year>
					<volume>31</volume>
					<fpage>45</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_272">
				<label>272.</label>
				<mixed-citation>Pro, B, Dang, NH. CD26/dipeptidyl peptidase IV and its role in cancer.
					<italic>Histol Histopathol</italic> 2004, 19, 1345–51.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pro</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
					</person-group>
					<article-title>CD26/dipeptidyl peptidase IV and its role in cancer</article-title>
					<source>Histol Histopathol</source>
					<year>2004</year>
					<volume>19</volume>
					<fpage>1345</fpage>
					<lpage>51</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_273">
				<label>273.</label>
				<mixed-citation>Goscinski, MA, Suo, ZH, Nesland, JM, Florenes, VA, Giercksky, KE. Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines.
					<italic>APMIS</italic> 2008;116:823–31.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Goscinski</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Suo</surname>
							<given-names>ZH</given-names>
						</name>
						<name>
							<surname>Nesland</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Florenes</surname>
							<given-names>VA</given-names>
						</name>
						<name>
							<surname>Giercksky</surname>
							<given-names>KE</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines</article-title>
					<source>APMIS</source>
					<year>2008</year>
					<volume>116</volume>
					<fpage>823</fpage>
					<lpage>31</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_274">
				<label>274.</label>
				<mixed-citation>Kikkawa, F, Kajiyama, H, Ino, K, Shibata, K, Mizutani, S. Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV.
					<italic>Int J Cancer</italic> 2003;105:779–83.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kikkawa</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Kajiyama</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Ino</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Shibata</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Mizutani</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV</article-title>
					<source>Int J Cancer</source>
					<year>2003</year>
					<volume>105</volume>
					<fpage>779</fpage>
					<lpage>83</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_275">
				<label>275.</label>
				<mixed-citation>Jiang, YX, Yang, SW, Li, PA, Luo, X, Li, ZY, Hao, YX, et al.. The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms.
					<italic>Oncogene</italic> 2017;36:1256–64.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jiang</surname>
							<given-names>YX</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>SW</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Luo</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>ZY</given-names>
						</name>
						<name>
							<surname>Hao</surname>
							<given-names>YX</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms</article-title>
					<source>Oncogene</source>
					<year>2017</year>
					<volume>36</volume>
					<fpage>1256</fpage>
					<lpage>64</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_276">
				<label>276.</label>
				<mixed-citation>Bauvois, B, De Meester, I, Dumont, J, Rouillard, D, Zhao, HX, Bosmans, E. Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia.
					<italic>Br J Cancer</italic> 1999;79:1042–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bauvois</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>De Meester</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Dumont</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Rouillard</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>HX</given-names>
						</name>
						<name>
							<surname>Bosmans</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<article-title>Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia</article-title>
					<source>Br J Cancer</source>
					<year>1999</year>
					<volume>79</volume>
					<fpage>1042</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_277">
				<label>277.</label>
				<mixed-citation>Cro, L, Morabito, F, Zucal, N, Fabris, S, Lionetti, M, Cutrona, G. CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.
					<italic>Hematol Oncol</italic> 2009;27:140–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cro</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Morabito</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Zucal</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Fabris</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Lionetti</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Cutrona</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL</article-title>
					<source>Hematol Oncol</source>
					<year>2009</year>
					<volume>27</volume>
					<fpage>140</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_278">
				<label>278.</label>
				<mixed-citation>Havre, PA, Dang, LH, Ohnuma, K, Iwata, S, Morimoto, C, Dang, NH. CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion.
					<italic>BMC Cancer</italic> 2013;13:517.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Havre</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>LH</given-names>
						</name>
						<name>
							<surname>Ohnuma</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Iwata</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
					</person-group>
					<article-title>CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion</article-title>
					<source>BMC Cancer</source>
					<year>2013</year>
					<volume>13</volume>
					<fpage>517</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_279">
				<label>279.</label>
				<mixed-citation>Carbone, A, Cozzi, M, Gloghini, A, Pinto, A. CD26/dipeptidylpeptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of Tcell non-Hodgkin’s lymphomas.
					<italic>Human Pathol</italic> 1994;25:1360–5.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Carbone</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Cozzi</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Gloghini</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Pinto</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>CD26/dipeptidylpeptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of Tcell non-Hodgkin’s lymphomas</article-title>
					<source>Human Pathol</source>
					<year>1994</year>
					<volume>25</volume>
					<fpage>1360</fpage>
					<lpage>5</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_280">
				<label>280.</label>
				<mixed-citation>Carbone, A, Gloghini, A, Zagonel, V, Aldinucci, D, Gattei, V, Degan, M, et al.. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin’s lymphomas/leukemias.
					<italic>Blood</italic> 1995;86:4617–26.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Carbone</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Gloghini</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Zagonel</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Aldinucci</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Gattei</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Degan</surname>
							<given-names>M</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin’s lymphomas/leukemias</article-title>
					<source>Blood</source>
					<year>1995</year>
					<volume>86</volume>
					<fpage>4617</fpage>
					<lpage>26</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_281">
				<label>281.</label>
				<mixed-citation>Dang, NH, Aytac, U, Sato, K, O’Brien, S, Melenhorst, J, Morimoto, C, et al.. T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition.
					<italic>Br J Haematol</italic> 2003;121:857–65.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dang</surname>
							<given-names>NH</given-names>
						</name>
						<name>
							<surname>Aytac</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Sato</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>O’Brien</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Melenhorst</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition</article-title>
					<source>Br J Haematol</source>
					<year>2003</year>
					<volume>121</volume>
					<fpage>857</fpage>
					<lpage>65</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_282">
				<label>282.</label>
				<mixed-citation>Pethiyagoda, CL, Welch, DR, Fleming, TP. Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.
					<italic>Clin Exp Metast</italic> 2001;18:391–400.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pethiyagoda</surname>
							<given-names>CL</given-names>
						</name>
						<name>
							<surname>Welch</surname>
							<given-names>DR</given-names>
						</name>
						<name>
							<surname>Fleming</surname>
							<given-names>TP</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells</article-title>
					<source>Clin Exp Metast</source>
					<year>2001</year>
					<volume>18</volume>
					<fpage>391</fpage>
					<lpage>400</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_283">
				<label>283.</label>
				<mixed-citation>Novelli, M, Savoia, P, Fierro, MT, Verrone, A, Quaglino, P, BernengoMG. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases.
					<italic>Br J Dermatol</italic> 1996;134:1052–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Novelli</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Savoia</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Fierro</surname>
							<given-names>MT</given-names>
						</name>
						<name>
							<surname>Verrone</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Quaglino</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>BernengoMG</surname>
						</name>
					</person-group>
					<article-title>Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases</article-title>
					<source>Br J Dermatol</source>
					<year>1996</year>
					<volume>134</volume>
					<fpage>1052</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_284">
				<label>284.</label>
				<mixed-citation>Ansorge, S, Bank, U, Heimburg, A, Helmuth, M, Koch, G, Tadje, J. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions.
					<italic>Clin Chem Lab Med</italic> 2009;47:253–61.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ansorge</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Bank</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Heimburg</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Helmuth</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Koch</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Tadje</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions</article-title>
					<source>Clin Chem Lab Med</source>
					<year>2009</year>
					<volume>47</volume>
					<fpage>253</fpage>
					<lpage>61</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_285">
				<label>285.</label>
				<mixed-citation>Van Der Velden, VH, Hulsmann, AR. Peptidases: structure, function and modulation of peptide-mediated effects in the human lung.
					<italic>Clin Exp Allergy</italic> 1999;29:445–56.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Van Der Velden</surname>
							<given-names>VH</given-names>
						</name>
						<name>
							<surname>Hulsmann</surname>
							<given-names>AR</given-names>
						</name>
					</person-group>
					<article-title>Peptidases: structure, function and modulation of peptide-mediated effects in the human lung</article-title>
					<source>Clin Exp Allergy</source>
					<year>1999</year>
					<volume>29</volume>
					<fpage>445</fpage>
					<lpage>56</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_286">
				<label>286.</label>
				<mixed-citation>Mentlein, R, Dahms, P, Grandt, D, Kruger, R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV.
					<italic>Regul Pept</italic> 1993;49:133–44.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mentlein</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Dahms</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Grandt</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Kruger</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV</article-title>
					<source>Regul Pept</source>
					<year>1993</year>
					<volume>49</volume>
					<fpage>133</fpage>
					<lpage>44</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_287">
				<label>287.</label>
				<mixed-citation>Ghersi, G, Chen, W, Lee, EW, Zukowska, Z. Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding.
					<italic>Peptides</italic> 2001;22:453–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ghersi</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>EW</given-names>
						</name>
						<name>
							<surname>Zukowska</surname>
							<given-names>Z</given-names>
						</name>
					</person-group>
					<article-title>Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding</article-title>
					<source>Peptides</source>
					<year>2001</year>
					<volume>22</volume>
					<fpage>453</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_288">
				<label>288.</label>
				<mixed-citation>Jang, JH, Janker, F, De Meester, I, Arni, S, Borgeaud, N, Yamada, Y. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
					<italic>Carcinogenesis</italic> 2019;40:324–34.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jang</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Janker</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>De Meester</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Arni</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Borgeaud</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Yamada</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity</article-title>
					<source>Carcinogenesis</source>
					<year>2019</year>
					<volume>40</volume>
					<fpage>324</fpage>
					<lpage>34</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_289">
				<label>289.</label>
				<mixed-citation>Mathew, S, Morrison, ME, Murty, VV, Houghton, AN, Chaganti, RS. Assignment of the DPP4 gene encoding adenosine deaminase binding protein (CD26/dipeptidylpeptidase IV) to 2q23.
					<italic>Genomics</italic> 1994;22:211–2.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mathew</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Morrison</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Murty</surname>
							<given-names>VV</given-names>
						</name>
						<name>
							<surname>Houghton</surname>
							<given-names>AN</given-names>
						</name>
						<name>
							<surname>Chaganti</surname>
							<given-names>RS</given-names>
						</name>
					</person-group>
					<article-title>Assignment of the DPP4 gene encoding adenosine deaminase binding protein (CD26/dipeptidylpeptidase IV) to 2q23</article-title>
					<source>Genomics</source>
					<year>1994</year>
					<volume>22</volume>
					<fpage>211</fpage>
					<lpage>2</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_290">
				<label>290.</label>
				<mixed-citation>Otsuka, T, Kohno, T, Mori, M, Noguchi, M, Hirohashi, S, Yokota, J. Deletion mapping of chromosome 2 in human lung carcinoma.
					<italic>Genes Chromosomes Cancer</italic> 1996;16:113–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Otsuka</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kohno</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Mori</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Noguchi</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Hirohashi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Yokota</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Deletion mapping of chromosome 2 in human lung carcinoma</article-title>
					<source>Genes Chromosomes Cancer</source>
					<year>1996</year>
					<volume>16</volume>
					<fpage>113</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_291">
				<label>291.</label>
				<mixed-citation>Dimitrova, M, Ivanov, I, Todorova, R, Stefanova, N, Moskova-Doumanova, V, Topouzova-Hristova, T. Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumour human lung cells.
					<italic>Tissue Cell</italic> 2012;44:74–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dimitrova</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ivanov</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Todorova</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Stefanova</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Moskova-Doumanova</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Topouzova-Hristova</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumour human lung cells</article-title>
					<source>Tissue Cell</source>
					<year>2012</year>
					<volume>44</volume>
					<fpage>74</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_292">
				<label>292.</label>
				<mixed-citation>Morrison, H, Sherman, LS, Legg, J, Banine, F, Isacke, C, Haipek, CA. The NF2 tumour suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.
					<italic>Genes Dev</italic> 2001;15:968–80.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Morrison</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Sherman</surname>
							<given-names>LS</given-names>
						</name>
						<name>
							<surname>Legg</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Banine</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Isacke</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Haipek</surname>
							<given-names>CA</given-names>
						</name>
					</person-group>
					<article-title>The NF2 tumour suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44</article-title>
					<source>Genes Dev</source>
					<year>2001</year>
					<volume>15</volume>
					<fpage>968</fpage>
					<lpage>80</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_293">
				<label>293.</label>
				<mixed-citation>Yan, P, Muhlethaler, A, Bourloud, KB, Beck, MN, Gross, N. Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma.
					<italic>Genes Chromosomes Cancer</italic> 2003;36:129–38.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yan</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Muhlethaler</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Bourloud</surname>
							<given-names>KB</given-names>
						</name>
						<name>
							<surname>Beck</surname>
							<given-names>MN</given-names>
						</name>
						<name>
							<surname>Gross</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma</article-title>
					<source>Genes Chromosomes Cancer</source>
					<year>2003</year>
					<volume>36</volume>
					<fpage>129</fpage>
					<lpage>38</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_294">
				<label>294.</label>
				<mixed-citation>Yang, X, Zhang, X, Wu, R, Huang, Q, Jiang, Y, Qin, J, et al.. DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumourigenesis.
					<italic>Oncotarget</italic> 2017;8:8679–92.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yang</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Jiang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Qin</surname>
							<given-names>J</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumourigenesis</article-title>
					<source>Oncotarget</source>
					<year>2017</year>
					<volume>8</volume>
					<fpage>8679</fpage>
					<lpage>92</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_295">
				<label>295.</label>
				<mixed-citation>Kajiyama, H, Kikkawa, F, Maeda, O, Suzuki, T, Ino, K, Mizutani, S. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients.
					<italic>Oncology</italic> 2002;63:158–65.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kajiyama</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Kikkawa</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Maeda</surname>
							<given-names>O</given-names>
						</name>
						<name>
							<surname>Suzuki</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Ino</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Mizutani</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients</article-title>
					<source>Oncology</source>
					<year>2002</year>
					<volume>63</volume>
					<fpage>158</fpage>
					<lpage>65</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_296">
				<label>296.</label>
				<mixed-citation>Ware, JL. Growth factor network disruption in prostate cancer progression.
					<italic>Cancer Metastasis Rev</italic> 1998;17:443–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ware</surname>
							<given-names>JL</given-names>
						</name>
					</person-group>
					<article-title>Growth factor network disruption in prostate cancer progression</article-title>
					<source>Cancer Metastasis Rev</source>
					<year>1998</year>
					<volume>17</volume>
					<fpage>443</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_297">
				<label>297.</label>
				<mixed-citation>Giri, D, Ropiquet, F, Ittmann, M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
					<italic>Clin Cancer Res</italic> 1999;5:1063–71.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Giri</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Ropiquet</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Ittmann</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer</article-title>
					<source>Clin Cancer Res</source>
					<year>1999</year>
					<volume>5</volume>
					<fpage>1063</fpage>
					<lpage>71</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_298">
				<label>298.</label>
				<mixed-citation>Dow, JK, deVere White, RW. Fibroblast growth factor 2: its structure and property, paracrine function, tumour angiogenesis, and prostate-related mitogenic and oncogenic functions.
					<italic>Urology</italic> 2000;55:800–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dow</surname>
							<given-names>JK</given-names>
						</name>
						<name>
							<surname>deVere White</surname>
							<given-names>RW</given-names>
						</name>
					</person-group>
					<article-title>Fibroblast growth factor 2: its structure and property, paracrine function, tumour angiogenesis, and prostate-related mitogenic and oncogenic functions</article-title>
					<source>Urology</source>
					<year>2000</year>
					<volume>55</volume>
					<fpage>800</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_299">
				<label>299.</label>
				<mixed-citation>Feldman, BJ, Feldman, D. The development of androgen-independent prostate cancer.
					<italic>Nat Rev Cancer</italic> 2001;1:34–45.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Feldman</surname>
							<given-names>BJ</given-names>
						</name>
						<name>
							<surname>Feldman</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>The development of androgen-independent prostate cancer</article-title>
					<source>Nat Rev Cancer</source>
					<year>2001</year>
					<volume>1</volume>
					<fpage>34</fpage>
					<lpage>45</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_300">
				<label>300.</label>
				<mixed-citation>Isaacs, JT, Isaacs, WB. Androgen receptor outwits prostate cancer drugs.
					<italic>Nat Med</italic> 2004;10:26–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Isaacs</surname>
							<given-names>JT</given-names>
						</name>
						<name>
							<surname>Isaacs</surname>
							<given-names>WB</given-names>
						</name>
					</person-group>
					<article-title>Androgen receptor outwits prostate cancer drugs</article-title>
					<source>Nat Med</source>
					<year>2004</year>
					<volume>10</volume>
					<fpage>26</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_301">
				<label>301.</label>
				<mixed-citation>Nakamoto, T, Chang, CS, Li, AK, Chodak, GW. Basic fibroblast growth factor in human prostate cancer cells.
					<italic>Cancer Res</italic> 1992;52:571–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nakamoto</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Chang</surname>
							<given-names>CS</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>AK</given-names>
						</name>
						<name>
							<surname>Chodak</surname>
							<given-names>GW</given-names>
						</name>
					</person-group>
					<article-title>Basic fibroblast growth factor in human prostate cancer cells</article-title>
					<source>Cancer Res</source>
					<year>1992</year>
					<volume>52</volume>
					<fpage>571</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_302">
				<label>302.</label>
				<mixed-citation>Gioeli, D, Mandell, JW, Petroni, GR, Frierson, HF, Weber, MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression.
					<italic>Cancer Res</italic> 1999;59:279–84.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gioeli</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Mandell</surname>
							<given-names>JW</given-names>
						</name>
						<name>
							<surname>Petroni</surname>
							<given-names>GR</given-names>
						</name>
						<name>
							<surname>Frierson</surname>
							<given-names>HF</given-names>
						</name>
						<name>
							<surname>Weber</surname>
							<given-names>MJ</given-names>
						</name>
					</person-group>
					<article-title>Activation of mitogen-activated protein kinase associated with prostate cancer progression</article-title>
					<source>Cancer Res</source>
					<year>1999</year>
					<volume>59</volume>
					<fpage>279</fpage>
					<lpage>84</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_303">
				<label>303.</label>
				<mixed-citation>Pintucci, G, Moscatelli, D, Saponara, F, Biernacki, PR, Baumann, FG, Bizekis, C. Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells.
					<italic>FASEB J</italic> 2002;16:598–600.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pintucci</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Moscatelli</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Saponara</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Biernacki</surname>
							<given-names>PR</given-names>
						</name>
						<name>
							<surname>Baumann</surname>
							<given-names>FG</given-names>
						</name>
						<name>
							<surname>Bizekis</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells</article-title>
					<source>FASEB J</source>
					<year>2002</year>
					<volume>16</volume>
					<fpage>598</fpage>
					<lpage>600</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_304">
				<label>304.</label>
				<mixed-citation>Giuliani, R, Bastaki, M, Coltrini, D, Presta, M. Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2.
					<italic>J Cell Sci</italic> 1999;112:2597–606.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Giuliani</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Bastaki</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Coltrini</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Presta</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2</article-title>
					<source>J Cell Sci</source>
					<year>1999</year>
					<volume>112</volume>
					<fpage>2597</fpage>
					<lpage>606</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_305">
				<label>305.</label>
				<mixed-citation>Rabbani, SA, Mazar, AP. The role of the plasminogen activation system in angiogenesis and metastasis.
					<italic>Surg Oncol Clin N Am</italic> 2001;10:393–415.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rabbani</surname>
							<given-names>SA</given-names>
						</name>
						<name>
							<surname>Mazar</surname>
							<given-names>AP</given-names>
						</name>
					</person-group>
					<article-title>The role of the plasminogen activation system in angiogenesis and metastasis</article-title>
					<source>Surg Oncol Clin N Am</source>
					<year>2001</year>
					<volume>10</volume>
					<fpage>393</fpage>
					<lpage>415</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_306">
				<label>306.</label>
				<mixed-citation>Bugler, B, Amalric, F, Prats, H. Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor.
					<italic>Mol Cell Biol</italic> 1991;11:573–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bugler</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Amalric</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Prats</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor</article-title>
					<source>Mol Cell Biol</source>
					<year>1991</year>
					<volume>11</volume>
					<fpage>573</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_307">
				<label>307.</label>
				<mixed-citation>Bikfalvi, A, Klein, S, Pintucci, G, Rifkin, DB. Biological roles of fibroblast growth factor-2.
					<italic>Endocr Rev</italic> 1997;18:26–45.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bikfalvi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Klein</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Pintucci</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Rifkin</surname>
							<given-names>DB</given-names>
						</name>
					</person-group>
					<article-title>Biological roles of fibroblast growth factor-2</article-title>
					<source>Endocr Rev</source>
					<year>1997</year>
					<volume>18</volume>
					<fpage>26</fpage>
					<lpage>45</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_308">
				<label>308.</label>
				<mixed-citation>Delrieu, I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism.
					<italic>FEBS Lett</italic> 2000;468:6–10.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Delrieu</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<article-title>The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism</article-title>
					<source>FEBS Lett</source>
					<year>2000</year>
					<volume>468</volume>
					<fpage>6</fpage>
					<lpage>10</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_309">
				<label>309.</label>
				<mixed-citation>Wilson, MJ, Ruhland, AR, Quast, BJ, Reddy, PK, Ewing, SL, Sinha, AA. Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.
					<italic>J Androl</italic> 2000;21:220–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wilson</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Ruhland</surname>
							<given-names>AR</given-names>
						</name>
						<name>
							<surname>Quast</surname>
							<given-names>BJ</given-names>
						</name>
						<name>
							<surname>Reddy</surname>
							<given-names>PK</given-names>
						</name>
						<name>
							<surname>Ewing</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Sinha</surname>
							<given-names>AA</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands</article-title>
					<source>J Androl</source>
					<year>2000</year>
					<volume>21</volume>
					<fpage>220</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_310">
				<label>310.</label>
				<mixed-citation>Lu, Z, Qi, L, Bo, XJ, Liu, GD, Wang, JM, Li, G. Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters.
					<italic>J Res Med Sci</italic> 2013;18:647–52.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lu</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Qi</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Bo</surname>
							<given-names>XJ</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>GD</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters</article-title>
					<source>J Res Med Sci</source>
					<year>2013</year>
					<volume>18</volume>
					<fpage>647</fpage>
					<lpage>52</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_311">
				<label>311.</label>
				<mixed-citation>Boonacker, E, Van Noorden, CJ. The multifunctional or moonlighting protein CD26/DPPIV.
					<italic>Eur J Cell Biol</italic> 2003;82:53–73.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Boonacker</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Van Noorden</surname>
							<given-names>CJ</given-names>
						</name>
					</person-group>
					<article-title>The multifunctional or moonlighting protein CD26/DPPIV</article-title>
					<source>Eur J Cell Biol</source>
					<year>2003</year>
					<volume>82</volume>
					<fpage>53</fpage>
					<lpage>73</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_312">
				<label>312.</label>
				<mixed-citation>Proost, P, Struyf, S, Schols, D, Opdenakker, G, Sozzani, S, Allavena, P. Truncation of macrophage-derived chemokine by CD26/ipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction.
					<italic>J Biol Chem</italic> 1999;274:3988–93.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Proost</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Struyf</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Schols</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Opdenakker</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Sozzani</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Allavena</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Truncation of macrophage-derived chemokine by CD26/ipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction</article-title>
					<source>J Biol Chem</source>
					<year>1999</year>
					<volume>274</volume>
					<fpage>3988</fpage>
					<lpage>93</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_313">
				<label>313.</label>
				<mixed-citation>Tang, AC, Raphael, SJ, Lampe, HB, Matthews, TW, Becks, GP. Expression of dipeptidyl aminopeptidase IV activity in thyroid tumours: a possible marker of thyroid malignancy.
					<italic>J Otolaryngol</italic> 1996;25:14–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tang</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Raphael</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Lampe</surname>
							<given-names>HB</given-names>
						</name>
						<name>
							<surname>Matthews</surname>
							<given-names>TW</given-names>
						</name>
						<name>
							<surname>Becks</surname>
							<given-names>GP</given-names>
						</name>
					</person-group>
					<article-title>Expression of dipeptidyl aminopeptidase IV activity in thyroid tumours: a possible marker of thyroid malignancy</article-title>
					<source>J Otolaryngol</source>
					<year>1996</year>
					<volume>25</volume>
					<fpage>14</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_314">
				<label>314.</label>
				<mixed-citation>Lee, JJ, Wang, TY, Liu, CL, Chien, MN, Chen, MJ, Hsu, YC, et al.. Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma.
					<italic>J Clin Endocrinol Metab</italic> 2017;102:2930–40.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lee</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>TY</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>CL</given-names>
						</name>
						<name>
							<surname>Chien</surname>
							<given-names>MN</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Hsu</surname>
							<given-names>YC</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma</article-title>
					<source>J Clin Endocrinol Metab</source>
					<year>2017</year>
					<volume>102</volume>
					<fpage>2930</fpage>
					<lpage>40</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_315">
				<label>315.</label>
				<mixed-citation>Kotani, T, Asada, Y, Aratake, Y, Umeki, K, Yamamoto, I, Tokudome, R. Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours.
					<italic>J Pathol</italic> 1992;168:41–5.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kotani</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Asada</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Aratake</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Umeki</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yamamoto</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Tokudome</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours</article-title>
					<source>J Pathol</source>
					<year>1992</year>
					<volume>168</volume>
					<fpage>41</fpage>
					<lpage>5</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_316">
				<label>316.</label>
				<mixed-citation>Maruta, J, Hashimoto, H, Yamashita, H, Yamashita, H, Noguchi, S. Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma.
					<italic>Arch Surg</italic> 2004;139:83–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Maruta</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Hashimoto</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Yamashita</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Yamashita</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Noguchi</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma</article-title>
					<source>Arch Surg</source>
					<year>2004</year>
					<volume>139</volume>
					<fpage>83</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_317">
				<label>317.</label>
				<mixed-citation>Stremenova, J, Krepela, E, Mares, V, Trim, J, Dbaly, V, Marek, J. Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade.
					<italic>Int J Oncol</italic> 2007;31:785–92.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Stremenova</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Krepela</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Mares</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Trim</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Dbaly</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Marek</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade</article-title>
					<source>Int J Oncol</source>
					<year>2007</year>
					<volume>31</volume>
					<fpage>785</fpage>
					<lpage>92</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_318">
				<label>318.</label>
				<mixed-citation>Ehtesham, M, Winston, JA, Kabos, P, Thompson, RC. CXCR4 expression mediates glioma cell invasiveness.
					<italic>Oncogene</italic> 2006;25:2801–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ehtesham</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Winston</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Kabos</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Thompson</surname>
							<given-names>RC</given-names>
						</name>
					</person-group>
					<article-title>CXCR4 expression mediates glioma cell invasiveness</article-title>
					<source>Oncogene</source>
					<year>2006</year>
					<volume>25</volume>
					<fpage>2801</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_319">
				<label>319.</label>
				<mixed-citation>Christopherson, KW, Hangoc, G, Broxmeyer, HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells.
					<italic>J Immunol</italic> 2002;169:7000–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Christopherson</surname>
							<given-names>KW</given-names>
						</name>
						<name>
							<surname>Hangoc</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Broxmeyer</surname>
							<given-names>HE</given-names>
						</name>
					</person-group>
					<article-title>Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells</article-title>
					<source>J Immunol</source>
					<year>2002</year>
					<volume>169</volume>
					<fpage>7000</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_320">
				<label>320.</label>
				<mixed-citation>Stremenova, J, Mares, V, Lisa, V, Hilser, M, Krepela, E, Vanickova, Z. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
					<italic>Int J Oncol</italic> 2010;36:351–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Stremenova</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Mares</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Lisa</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Hilser</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Krepela</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Vanickova</surname>
							<given-names>Z</given-names>
						</name>
					</person-group>
					<article-title>Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas</article-title>
					<source>Int J Oncol</source>
					<year>2010</year>
					<volume>36</volume>
					<fpage>351</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_321">
				<label>321.</label>
				<mixed-citation>Arscott, WT, LaBauve, AE, May, V, Wesley, UV. Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation.
					<italic>Oncogene</italic> 2009;28:479–91.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Arscott</surname>
							<given-names>WT</given-names>
						</name>
						<name>
							<surname>LaBauve</surname>
							<given-names>AE</given-names>
						</name>
						<name>
							<surname>May</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Wesley</surname>
							<given-names>UV</given-names>
						</name>
					</person-group>
					<article-title>Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation</article-title>
					<source>Oncogene</source>
					<year>2009</year>
					<volume>28</volume>
					<fpage>479</fpage>
					<lpage>91</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_322">
				<label>322.</label>
				<mixed-citation>Pass, H, Vogelzang, N, Hahn, S, Carbone, M. Malignant pleural mesothelioma.
					<italic>Curr Proble Cancer</italic> 2004;28:93–104.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pass</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Vogelzang</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Hahn</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Carbone</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Malignant pleural mesothelioma</article-title>
					<source>Curr Proble Cancer</source>
					<year>2004</year>
					<volume>28</volume>
					<fpage>93</fpage>
					<lpage>104</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_323">
				<label>323.</label>
				<mixed-citation>Amatya, V, Takeshima, Y, Kushitani, K, Yamada, T, Morimoto, C. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.
					<italic>Oncol Rep</italic> 2011;26:1369–75.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Amatya</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Takeshima</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Kushitani</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yamada</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Morimoto</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines</article-title>
					<source>Oncol Rep</source>
					<year>2011</year>
					<volume>26</volume>
					<fpage>1369</fpage>
					<lpage>75</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_324">
				<label>324.</label>
				<mixed-citation>Angevin, E, Isambert, N, Trillet-Lenoir, V, You, B, Alexandre, J, Zalcman, G, et al.. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
					<italic>Br J Cancer</italic> 2017;116:1126–34.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Angevin</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Isambert</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Trillet-Lenoir</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>You</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Alexandre</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Zalcman</surname>
							<given-names>G</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers</article-title>
					<source>Br J Cancer</source>
					<year>2017</year>
					<volume>116</volume>
					<fpage>1126</fpage>
					<lpage>34</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_325">
				<label>325.</label>
				<mixed-citation>Ghani, FI, Yamazaki, H, Iwata, S, Okamoto, K, Okabe, K, Mimura, Y, et al.. Identification of cancer stem cell markers in human malignant mesothelioma cells.
					<italic>Biochem Biophys Res Commun</italic> 2011;404:735–42.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ghani</surname>
							<given-names>FI</given-names>
						</name>
						<name>
							<surname>Yamazaki</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Iwata</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Okamoto</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Okabe</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Mimura</surname>
							<given-names>Y</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Identification of cancer stem cell markers in human malignant mesothelioma cells</article-title>
					<source>Biochem Biophys Res Commun</source>
					<year>2011</year>
					<volume>404</volume>
					<fpage>735</fpage>
					<lpage>42</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_326">
				<label>326.</label>
				<mixed-citation>Dietrich, P, Wormser, L, Fritz, V, Seitz, T, De Maria, M, Schambony, A, et al.. Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer.
					<italic>J Clin Investig</italic> 2020;130:2509–26.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dietrich</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Wormser</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Fritz</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Seitz</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>De Maria</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Schambony</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer</article-title>
					<source>J Clin Investig</source>
					<year>2020</year>
					<volume>130</volume>
					<fpage>2509</fpage>
					<lpage>26</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_327">
				<label>327.</label>
				<mixed-citation>Stecca, BA, Nardo, B, Chieco, P, Mazziotti, A, Bolondi, L, Cavallari, A. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma.
					<italic>J Hepatol</italic> 1997;27:337–45.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Stecca</surname>
							<given-names>BA</given-names>
						</name>
						<name>
							<surname>Nardo</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Chieco</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Mazziotti</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Bolondi</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Cavallari</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma</article-title>
					<source>J Hepatol</source>
					<year>1997</year>
					<volume>27</volume>
					<fpage>337</fpage>
					<lpage>45</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_328">
				<label>328.</label>
				<mixed-citation>Hollande, C, Boussier, J, Ziai, J, Nozawa, T, Bondet, V, Phung, W, et al.. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumour growth.
					<italic>Nat Immunol</italic> 2019;20:257–64.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hollande</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Boussier</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ziai</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Nozawa</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Bondet</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Phung</surname>
							<given-names>W</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumour growth</article-title>
					<source>Nat Immunol</source>
					<year>2019</year>
					<volume>20</volume>
					<fpage>257</fpage>
					<lpage>64</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_329">
				<label>329.</label>
				<mixed-citation>Nishina, S, Yamauchi, A, Kawaguchi, T, Kaku, K, Goto, M, Sasaki, K, et al.. Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice.
					<italic>Cell Mol Gastroenterol Hepatol</italic> 2019;7:115–34.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nishina</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Yamauchi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kawaguchi</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kaku</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Goto</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Sasaki</surname>
							<given-names>K</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice</article-title>
					<source>Cell Mol Gastroenterol Hepatol</source>
					<year>2019</year>
					<volume>7</volume>
					<fpage>115</fpage>
					<lpage>34</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_330">
				<label>330.</label>
				<mixed-citation>Henderson, JM, Xiang, MS, Huang, JC, Wetzel, S, Jiang, L, Lai, JH, et al.. Dipeptidyl peptidase inhibition enhances CD8 T cell recruitment and activates Intrahepatic inflammasome in a murine model of hepatocellular carcinoma.
					<italic>Cancers</italic> 2021;13:5495.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Henderson</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Xiang</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>JC</given-names>
						</name>
						<name>
							<surname>Wetzel</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Jiang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Lai</surname>
							<given-names>JH</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidyl peptidase inhibition enhances CD8 T cell recruitment and activates Intrahepatic inflammasome in a murine model of hepatocellular carcinoma</article-title>
					<source>Cancers</source>
					<year>2021</year>
					<volume>13</volume>
					<fpage>5495</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_331">
				<label>331.</label>
				<mixed-citation>Gaetaniello, L, Fiore, M, de Filippo, S, Pozzi, N, Tamasi, S, Pignata, C. Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells.
					<italic>Hepatology</italic> 1998;27:934–42.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gaetaniello</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Fiore</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>de Filippo</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Pozzi</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Tamasi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Pignata</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells</article-title>
					<source>Hepatology</source>
					<year>1998</year>
					<volume>27</volume>
					<fpage>934</fpage>
					<lpage>42</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_332">
				<label>332.</label>
				<mixed-citation>Itou, M, Kawaguchi, T, Taniguchi, E, Sumie, S, Oriishi, T, Mitsuyama, K, et al.. Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance.
					<italic>J Gastroenterol Hepatol</italic> 2008;23:244–51.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Itou</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kawaguchi</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Taniguchi</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Sumie</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Oriishi</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Mitsuyama</surname>
							<given-names>K</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance</article-title>
					<source>J Gastroenterol Hepatol</source>
					<year>2008</year>
					<volume>23</volume>
					<fpage>244</fpage>
					<lpage>51</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_333">
				<label>333.</label>
				<mixed-citation>Kaji, K, Yoshiji, H, Ikenaka, Y, Noguchi, R, Aihara, Y, Douhara, A, et al.. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.
					<italic>J Gastroenterol</italic> 2014;49:481–91.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kaji</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yoshiji</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Ikenaka</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Noguchi</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Aihara</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Douhara</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats</article-title>
					<source>J Gastroenterol</source>
					<year>2014</year>
					<volume>49</volume>
					<fpage>481</fpage>
					<lpage>91</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_334">
				<label>334.</label>
				<mixed-citation>Abd Elmaaboud, M, Khattab, H, Shalaby, S. Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice.
					<italic>Can J Physiol Pharmacol</italic> 2021;99:294–302.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Abd Elmaaboud</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Khattab</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Shalaby</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice</article-title>
					<source>Can J Physiol Pharmacol</source>
					<year>2021</year>
					<volume>99</volume>
					<fpage>294</fpage>
					<lpage>302</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_335">
				<label>335.</label>
				<mixed-citation>Sokar, SS, El-Sayad, ME, Ghoneim, ME, Shebl, AM. Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats.
					<italic>Biomed Pharmacother</italic> 2017;89:98–107.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sokar</surname>
							<given-names>SS</given-names>
						</name>
						<name>
							<surname>El-Sayad</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Ghoneim</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Shebl</surname>
							<given-names>AM</given-names>
						</name>
					</person-group>
					<article-title>Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats</article-title>
					<source>Biomed Pharmacother</source>
					<year>2017</year>
					<volume>89</volume>
					<fpage>98</fpage>
					<lpage>107</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_336">
				<label>336.</label>
				<mixed-citation>Wang, XM, Holz, LE, Chowdhury, S, Cordoba, SP, Evans, KA, Gall, MG, et al.. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury.
					<italic>Immunol Cell Biol</italic> 2017;95:443–53.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wang</surname>
							<given-names>XM</given-names>
						</name>
						<name>
							<surname>Holz</surname>
							<given-names>LE</given-names>
						</name>
						<name>
							<surname>Chowdhury</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Cordoba</surname>
							<given-names>SP</given-names>
						</name>
						<name>
							<surname>Evans</surname>
							<given-names>KA</given-names>
						</name>
						<name>
							<surname>Gall</surname>
							<given-names>MG</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury</article-title>
					<source>Immunol Cell Biol</source>
					<year>2017</year>
					<volume>95</volume>
					<fpage>443</fpage>
					<lpage>53</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_337">
				<label>337.</label>
				<mixed-citation>Nagami, Y, Ominami, M, Otani, K, Tanaka, F, Taira, K, Yamagami, H. Endoscopic submucosal dissection for adenocarcinomas of the esophagogastric junction.
					<italic>Digestion</italic> 2018;97:38–44.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nagami</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Ominami</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Otani</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Tanaka</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Taira</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yamagami</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Endoscopic submucosal dissection for adenocarcinomas of the esophagogastric junction</article-title>
					<source>Digestion</source>
					<year>2018</year>
					<volume>97</volume>
					<fpage>38</fpage>
					<lpage>44</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_338">
				<label>338.</label>
				<mixed-citation>Sharman, P, Sidorenko, EI. Are screening and surveillance for Barrett’s oesophagus really worthwhile.
					<italic>Gut</italic> 2005;54:27–31.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sharman</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Sidorenko</surname>
							<given-names>EI</given-names>
						</name>
					</person-group>
					<article-title>Are screening and surveillance for Barrett’s oesophagus really worthwhile</article-title>
					<source>Gut</source>
					<year>2005</year>
					<volume>54</volume>
					<fpage>27</fpage>
					<lpage>31</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_339">
				<label>339.</label>
				<mixed-citation>Omae, M, Fujisaki, J, Shimizu, T, Igarashi, M, Yamamoto, N. Magnifying endoscopy with narrow-band imaging finding in the diagnosis of Barrett’s esophageal adenocarcinoma spreading below squamous epithelium.
					<italic>Dig Endosc</italic> 2013;225:162–7.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Omae</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Fujisaki</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Shimizu</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Igarashi</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Yamamoto</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Magnifying endoscopy with narrow-band imaging finding in the diagnosis of Barrett’s esophageal adenocarcinoma spreading below squamous epithelium</article-title>
					<source>Dig Endosc</source>
					<year>2013</year>
					<volume>225</volume>
					<fpage>162</fpage>
					<lpage>7</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_340">
				<label>340.</label>
				<mixed-citation>Yamamoto, K, Ohnishi, S, Mizushima, T, Kodaira, J, Ono, M, Hatanaka, Y, et al.. Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV.
					<italic>BMC Cancer</italic> 2020;20:64.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yamamoto</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Ohnishi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Mizushima</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kodaira</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ono</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Hatanaka</surname>
							<given-names>Y</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV</article-title>
					<source>BMC Cancer</source>
					<year>2020</year>
					<volume>20</volume>
					<fpage>64</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_341">
				<label>341.</label>
				<mixed-citation>Onoyama, H, Kamiya, M, Kuriki, Y, Komatsu, T, Abe, H, Tsuji, Y. Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV.
					<italic>Sci Rep</italic> 2016;6:26399.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Onoyama</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Kamiya</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kuriki</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Komatsu</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Abe</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Tsuji</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV</article-title>
					<source>Sci Rep</source>
					<year>2016</year>
					<volume>6</volume>
					<elocation-id>26399</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_342">
				<label>342.</label>
				<mixed-citation>Larrinaga, G, Perez, I, Sanz, B, Beitia, M, Errarte, P, Fernandez, A, et al.. Dipeptidylpeptidase IV activity is correlated with colorectal cancer prognosis.
					<italic>PLoS One</italic> 2015;10:e0119436.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Larrinaga</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Perez</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Sanz</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Beitia</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Errarte</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Fernandez</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidylpeptidase IV activity is correlated with colorectal cancer prognosis</article-title>
					<source>PLoS One</source>
					<year>2015</year>
					<volume>10</volume>
					<elocation-id>e0119436</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_343">
				<label>343.</label>
				<mixed-citation>Pang, R, Law, WL, Chu, AC, Poon, JT, Lam, CS, Chow, AK, et al.. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
					<italic>Cell Stem Cell</italic> 2010;6:603–15.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pang</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Law</surname>
							<given-names>WL</given-names>
						</name>
						<name>
							<surname>Chu</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Poon</surname>
							<given-names>JT</given-names>
						</name>
						<name>
							<surname>Lam</surname>
							<given-names>CS</given-names>
						</name>
						<name>
							<surname>Chow</surname>
							<given-names>AK</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer</article-title>
					<source>Cell Stem Cell</source>
					<year>2010</year>
					<volume>6</volume>
					<fpage>603</fpage>
					<lpage>15</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_344">
				<label>344.</label>
				<mixed-citation>Kumaravelu, P, Chellathai, D. Evaluation of anti cancer effects of DPP-4Inhibitors in colon cancer- an Invitro study.
					<italic>J Clin Diagn Res</italic> 2015;9:14–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kumaravelu</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Chellathai</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Evaluation of anti cancer effects of DPP-4Inhibitors in colon cancer- an Invitro study</article-title>
					<source>J Clin Diagn Res</source>
					<year>2015</year>
					<volume>9</volume>
					<fpage>14</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_345">
				<label>345.</label>
				<mixed-citation>Gorrell, MD, Gysbers, V, McCaughan, GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.
					<italic>Scand J Immunol</italic> 2001;54:249–64.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gorrell</surname>
							<given-names>MD</given-names>
						</name>
						<name>
							<surname>Gysbers</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>McCaughan</surname>
							<given-names>GW</given-names>
						</name>
					</person-group>
					<article-title>CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes</article-title>
					<source>Scand J Immunol</source>
					<year>2001</year>
					<volume>54</volume>
					<fpage>249</fpage>
					<lpage>64</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_346">
				<label>346.</label>
				<mixed-citation>Gonzalez-Gronow, M, Misra, UK, Gawdi, G, Pizzo, SV. Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumour cells.
					<italic>J Biol Chem</italic> 2005;280:27173–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gonzalez-Gronow</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Misra</surname>
							<given-names>UK</given-names>
						</name>
						<name>
							<surname>Gawdi</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Pizzo</surname>
							<given-names>SV</given-names>
						</name>
					</person-group>
					<article-title>Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumour cells</article-title>
					<source>J Biol Chem</source>
					<year>2005</year>
					<volume>280</volume>
					<fpage>27173</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_347">
				<label>347.</label>
				<mixed-citation>Cheng, HC, Abdel-Ghany, M, Elble, RC, Pauli, BU. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumour cell surface-associated fibronectin.
					<italic>J Biol Chem</italic> 1998;273:24207–15.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cheng</surname>
							<given-names>HC</given-names>
						</name>
						<name>
							<surname>Abdel-Ghany</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Elble</surname>
							<given-names>RC</given-names>
						</name>
						<name>
							<surname>Pauli</surname>
							<given-names>BU</given-names>
						</name>
					</person-group>
					<article-title>Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumour cell surface-associated fibronectin</article-title>
					<source>J Biol Chem</source>
					<year>1998</year>
					<volume>273</volume>
					<fpage>24207</fpage>
					<lpage>15</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_348">
				<label>348.</label>
				<mixed-citation>Korach, S, Poupon, MF, Du Villard, JA, Becker, M. Differential adhesiveness of rhabdomyosarcoma-derived cloned metastatic cell lines to vascular endothelial monolayers.
					<italic>Cancer Res</italic> 1986;46:3624–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Korach</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Poupon</surname>
							<given-names>MF</given-names>
						</name>
						<name>
							<surname>Du Villard</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Becker</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Differential adhesiveness of rhabdomyosarcoma-derived cloned metastatic cell lines to vascular endothelial monolayers</article-title>
					<source>Cancer Res</source>
					<year>1986</year>
					<volume>46</volume>
					<fpage>3624</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_349">
				<label>349.</label>
				<mixed-citation>Kato, Y, Saijo, N. Developed new agents for lung cancer.
					<italic>Nihon Geka Gakkai Zasshi</italic> 2002;103:218–23.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kato</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Saijo</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Developed new agents for lung cancer</article-title>
					<source>Nihon Geka Gakkai Zasshi</source>
					<year>2002</year>
					<volume>103</volume>
					<fpage>218</fpage>
					<lpage>23</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_350">
				<label>350.</label>
				<mixed-citation>Beckenkamp, A, Davies, S, Willig, JB, Buffon, A. DPPIV/CD26: a tumour suppressor or a marker of malignancy.
					<italic>Tumour Biol</italic> 2016;37:7059–73.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Beckenkamp</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Davies</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Willig</surname>
							<given-names>JB</given-names>
						</name>
						<name>
							<surname>Buffon</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>DPPIV/CD26: a tumour suppressor or a marker of malignancy</article-title>
					<source>Tumour Biol</source>
					<year>2016</year>
					<volume>37</volume>
					<fpage>7059</fpage>
					<lpage>73</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_351">
				<label>351.</label>
				<mixed-citation>Ehtesham, M, Winston, JA, Kabos, P, Thompson, RC. CXCR4 expression mediates glioma cell invasiveness.
					<italic>Oncogene</italic> 2006;25:2801–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ehtesham</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Winston</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Kabos</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Thompson</surname>
							<given-names>RC</given-names>
						</name>
					</person-group>
					<article-title>CXCR4 expression mediates glioma cell invasiveness</article-title>
					<source>Oncogene</source>
					<year>2006</year>
					<volume>25</volume>
					<fpage>2801</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_352">
				<label>352.</label>
				<mixed-citation>Vangoitsenhoven, R, Mathieu, C, Van der Schueren, B. GLP1 and cancer: friend or foe?
					<italic>Endocr Relat Cancer</italic> 2012;19:F77–88.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Vangoitsenhoven</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Mathieu</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Van der Schueren</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>GLP1 and cancer: friend or foe?</article-title>
					<source>Endocr Relat Cancer</source>
					<year>2012</year>
					<volume>19</volume>
					<fpage>F77</fpage>
					<lpage>88</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_353">
				<label>353.</label>
				<mixed-citation>Korner, M, Stockli, M, Waser, B, Reubi, JC. GLP-1 receptor expression in human tumours and human normal tissues: potential for in vivo targeting.
					<italic>J Nucl Med</italic> 2007;48:736–43.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Korner</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Stockli</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Waser</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Reubi</surname>
							<given-names>JC</given-names>
						</name>
					</person-group>
					<article-title>GLP-1 receptor expression in human tumours and human normal tissues: potential for in vivo targeting</article-title>
					<source>J Nucl Med</source>
					<year>2007</year>
					<volume>48</volume>
					<fpage>736</fpage>
					<lpage>43</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_354">
				<label>354.</label>
				<mixed-citation>Koehler, JA, Drucker, DJ. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells.
					<italic>Diabetes</italic> 2006;55:1369–79.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Koehler</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Drucker</surname>
							<given-names>DJ</given-names>
						</name>
					</person-group>
					<article-title>Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells</article-title>
					<source>Diabetes</source>
					<year>2006</year>
					<volume>55</volume>
					<fpage>1369</fpage>
					<lpage>79</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_355">
				<label>355.</label>
				<mixed-citation>Girman, CJ, Kou, TD, Cai, B, Alexander, CM, O’Neill, EA, Williams-Herman, DE. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes.
					<italic>Diabetes Obes Metab</italic> 2010;2:766–71.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Girman</surname>
							<given-names>CJ</given-names>
						</name>
						<name>
							<surname>Kou</surname>
							<given-names>TD</given-names>
						</name>
						<name>
							<surname>Cai</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Alexander</surname>
							<given-names>CM</given-names>
						</name>
						<name>
							<surname>O’Neill</surname>
							<given-names>EA</given-names>
						</name>
						<name>
							<surname>Williams-Herman</surname>
							<given-names>DE</given-names>
						</name>
					</person-group>
					<article-title>Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2010</year>
					<volume>2</volume>
					<fpage>766</fpage>
					<lpage>71</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_356">
				<label>356.</label>
				<mixed-citation>Garg, R, Chen, W, Pendergrass, M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
					<italic>Diabetes Care</italic> 2010;33:2349–54.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Garg</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Pendergrass</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis</article-title>
					<source>Diabetes Care</source>
					<year>2010</year>
					<volume>33</volume>
					<fpage>2349</fpage>
					<lpage>54</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_357">
				<label>357.</label>
				<mixed-citation>Dore, DD, Bloomgren, GL, Wenten, M, Hoffman, C, Clifford, CR, Quinn, SG, et al.. A cohort study of acute pancreatitis in relation to exenatide use.
					<italic>Diabetes Obes Metab</italic> 2011;13:559–66.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dore</surname>
							<given-names>DD</given-names>
						</name>
						<name>
							<surname>Bloomgren</surname>
							<given-names>GL</given-names>
						</name>
						<name>
							<surname>Wenten</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Hoffman</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Clifford</surname>
							<given-names>CR</given-names>
						</name>
						<name>
							<surname>Quinn</surname>
							<given-names>SG</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>A cohort study of acute pancreatitis in relation to exenatide use</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2011</year>
					<volume>13</volume>
					<fpage>559</fpage>
					<lpage>66</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_358">
				<label>358.</label>
				<mixed-citation>Ueberberg, S, Jutte, H, Uhl, W, Schmidt, W, Nauck, M, Montanya, E, et al.. Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
					<italic>Diabetes Obes Metab</italic> 2016;18:1253–62.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ueberberg</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Jutte</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Uhl</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Schmidt</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Nauck</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Montanya</surname>
							<given-names>E</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2016</year>
					<volume>18</volume>
					<fpage>1253</fpage>
					<lpage>62</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_359">
				<label>359.</label>
				<mixed-citation>Aston-Mourney, K, Subramanian, SL, Zraika, S, Samarasekera, T, Meier, DT, Goldstein, LC, et al.. One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
					<italic>Am J Physiol Endocrinol Metab</italic> 2013;305:E475–E484.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Aston-Mourney</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Subramanian</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Zraika</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Samarasekera</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Meier</surname>
							<given-names>DT</given-names>
						</name>
						<name>
							<surname>Goldstein</surname>
							<given-names>LC</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice</article-title>
					<source>Am J Physiol Endocrinol Metab</source>
					<year>2013</year>
					<volume>305</volume>
					<fpage>E475</fpage>
					<lpage>E484</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_360">
				<label>360.</label>
				<mixed-citation>Cox, AR, Lam, CJ, Rankin, MM, Rios, JS, Chavez, J, Bonnyman, CW, et al.. Incretin therapies do not expand beta-cell mass or alter pancreatic histology in young male mice.
					<italic>Endocrinology</italic> 2017;158:1701–14.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cox</surname>
							<given-names>AR</given-names>
						</name>
						<name>
							<surname>Lam</surname>
							<given-names>CJ</given-names>
						</name>
						<name>
							<surname>Rankin</surname>
							<given-names>MM</given-names>
						</name>
						<name>
							<surname>Rios</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Chavez</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Bonnyman</surname>
							<given-names>CW</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Incretin therapies do not expand beta-cell mass or alter pancreatic histology in young male mice</article-title>
					<source>Endocrinology</source>
					<year>2017</year>
					<volume>158</volume>
					<fpage>1701</fpage>
					<lpage>14</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_361">
				<label>361.</label>
				<mixed-citation>Busch, SJ, Hoffmann, P, Sahota, P, Johnson, R, Kothny, W, Meyer, F, et al.. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.
					<italic>Diabetes Obes Metab</italic> 2013;15:72–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Busch</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Hoffmann</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Sahota</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Johnson</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Kothny</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Meyer</surname>
							<given-names>F</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man</article-title>
					<source>Diabetes Obes Metab</source>
					<year>2013</year>
					<volume>15</volume>
					<fpage>72</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_362">
				<label>362.</label>
				<mixed-citation>Bjerre Knudsen, L, Madsen, LW, Andersen, S, Almholt, K, de Boer, AS, Drucker, DJ. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
					<italic>Endocrinology</italic> 2010;151:1473–86.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bjerre Knudsen</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Madsen</surname>
							<given-names>LW</given-names>
						</name>
						<name>
							<surname>Andersen</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Almholt</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>de Boer</surname>
							<given-names>AS</given-names>
						</name>
						<name>
							<surname>Drucker</surname>
							<given-names>DJ</given-names>
						</name>
					</person-group>
					<article-title>Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation</article-title>
					<source>Endocrinology</source>
					<year>2010</year>
					<volume>151</volume>
					<fpage>1473</fpage>
					<lpage>86</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_363">
				<label>363.</label>
				<mixed-citation>Waser, B, Beetschen, K, Pellegata, NS, Reubi, JC. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.
					<italic>Neuroendocrinology</italic> 2011;94:291–301.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Waser</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Beetschen</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Pellegata</surname>
							<given-names>NS</given-names>
						</name>
						<name>
							<surname>Reubi</surname>
							<given-names>JC</given-names>
						</name>
					</person-group>
					<article-title>Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy</article-title>
					<source>Neuroendocrinology</source>
					<year>2011</year>
					<volume>94</volume>
					<fpage>291</fpage>
					<lpage>301</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_364">
				<label>364.</label>
				<mixed-citation>Roman, S, Lin, R, Sosa, JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.
					<italic>Cancer</italic> 2006;107:2134–42.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Roman</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Lin</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Sosa</surname>
							<given-names>JA</given-names>
						</name>
					</person-group>
					<article-title>Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases</article-title>
					<source>Cancer</source>
					<year>2006</year>
					<volume>107</volume>
					<fpage>2134</fpage>
					<lpage>42</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_365">
				<label>365.</label>
				<mixed-citation>Koehler, JA, Kain, T, Drucker, DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
					<italic>Endocrinology</italic> 2011;152:3362–72.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Koehler</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Kain</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Drucker</surname>
							<given-names>DJ</given-names>
						</name>
					</person-group>
					<article-title>Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells</article-title>
					<source>Endocrinology</source>
					<year>2011</year>
					<volume>152</volume>
					<fpage>3362</fpage>
					<lpage>72</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_366">
				<label>366.</label>
				<mixed-citation>Greenberg, ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
					<italic>Science</italic> 1995;270:1326–31.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Greenberg</surname>
							<given-names>ME</given-names>
						</name>
					</person-group>
					<article-title>Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis</article-title>
					<source>Science</source>
					<year>1995</year>
					<volume>270</volume>
					<fpage>1326</fpage>
					<lpage>31</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_367">
				<label>367.</label>
				<mixed-citation>Arrebola, Y, Díaz, L, García, G, Pascual, I. Dipeptidil peptidasa IV: inhibidores y sus potenciales aplicaciones biomédicas.
					<italic>Rev Cuba Cien Biol</italic> 2014;3:14–26.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Arrebola</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Díaz</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>García</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidil peptidasa IV: inhibidores y sus potenciales aplicaciones biomédicas</article-title>
					<source>Rev Cuba Cien Biol</source>
					<year>2014</year>
					<volume>3</volume>
					<fpage>14</fpage>
					<lpage>26</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_368">
				<label>368.</label>
				<mixed-citation>Pascual, I, Arrebola, Y, Almeida, F, Valdés, ME, Rivera, L, Hernández-Zanuy, A, et al.. Marine and coastal organisms: a source of biomedically relevant dipeptidyl peptidase IV inhibitors.
					<italic>Rev Cuba Cien Biol</italic> 2020;8:1–16.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Arrebola</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Almeida</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Valdés</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Rivera</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Hernández-Zanuy</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Marine and coastal organisms: a source of biomedically relevant dipeptidyl peptidase IV inhibitors</article-title>
					<source>Rev Cuba Cien Biol</source>
					<year>2020</year>
					<volume>8</volume>
					<fpage>1</fpage>
					<lpage>16</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_369">
				<label>369.</label>
				<mixed-citation>Lu, Y, Lu, P, Wang, Y, Fang, X. A novel dipeptidyl peptidase IV inhibitory tea peptide improves pancreatic β-cell function and reduces α-cell proliferation in StreptozotocinInduced diabetic mice.
					<italic>Int J Mol Sci</italic> 2019;20:322.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Lu</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Fang</surname>
							<given-names>X</given-names>
						</name>
					</person-group>
					<article-title>A novel dipeptidyl peptidase IV inhibitory tea peptide improves pancreatic β-cell function and reduces α-cell proliferation in StreptozotocinInduced diabetic mice</article-title>
					<source>Int J Mol Sci</source>
					<year>2019</year>
					<volume>20</volume>
					<fpage>322</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_370">
				<label>370.</label>
				<mixed-citation>Lin, SR, Chang, CH, Tsai, MJ, Cheng, H. The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo.
					<italic>Thera Adv Chron Dis</italic> 2019;10:2040622319875305.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lin</surname>
							<given-names>SR</given-names>
						</name>
						<name>
							<surname>Chang</surname>
							<given-names>CH</given-names>
						</name>
						<name>
							<surname>Tsai</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Cheng</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo</article-title>
					<source>Thera Adv Chron Dis</source>
					<year>2019</year>
					<volume>10</volume>
					<elocation-id>2040622319875305</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_371">
				<label>371.</label>
				<mixed-citation>Pascual, I, Lopéz, A, Gómez, H, Chappé, M. Screening of inhibitors of porcine dipeptidyl peptidase IV activity in aqueous extracts from marine organisms.
					<italic>Enz Microb Tech</italic> 2007;40:414–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Lopéz</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Gómez</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Chappé</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Screening of inhibitors of porcine dipeptidyl peptidase IV activity in aqueous extracts from marine organisms</article-title>
					<source>Enz Microb Tech</source>
					<year>2007</year>
					<volume>40</volume>
					<fpage>414</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_372">
				<label>372.</label>
				<mixed-citation>Turdu, G, Gao, H, Jiang, Y, Kabas, M. Plant dipeptidyl peptidase-iv inhibitors as antidiabetic agents: a brief review.
					<italic>Future Med Chem</italic> 2018;10:1229–39.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Turdu</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Gao</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Jiang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Kabas</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Plant dipeptidyl peptidase-iv inhibitors as antidiabetic agents: a brief review</article-title>
					<source>Future Med Chem</source>
					<year>2018</year>
					<volume>10</volume>
					<fpage>1229</fpage>
					<lpage>39</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_373">
				<label>373.</label>
				<mixed-citation>Singh, AK, Patel, PK, Choudhary, K, Joshi, J. Quercetin and coumarin inhibit dipeptidyl peptidase-IV and exhibits antioxidant properties: in silico, in vitro, ex vivo.
					<italic>Biomolecules</italic> 2020;10:207.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Singh</surname>
							<given-names>AK</given-names>
						</name>
						<name>
							<surname>Patel</surname>
							<given-names>PK</given-names>
						</name>
						<name>
							<surname>Choudhary</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Joshi</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Quercetin and coumarin inhibit dipeptidyl peptidase-IV and exhibits antioxidant properties: in silico, in vitro, ex vivo</article-title>
					<source>Biomolecules</source>
					<year>2020</year>
					<volume>10</volume>
					<fpage>207</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_374">
				<label>374.</label>
				<mixed-citation>Liu, R, Cheng, J, Wu, H. Discovery of food-derived dipeptidyl peptidase IV inhibitory peptides: a review.
					<italic>Int J Mol Sci</italic> 2019;20:3463.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liu</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Cheng</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<article-title>Discovery of food-derived dipeptidyl peptidase IV inhibitory peptides: a review</article-title>
					<source>Int J Mol Sci</source>
					<year>2019</year>
					<volume>20</volume>
					<fpage>3463</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_375">
				<label>375.</label>
				<mixed-citation>Gomez, HL, Peralta, JP, Tejano, LA, Chang, YW. In silico and in vitro assessment of Portuguese oyster (Crassostrea angulata) proteins as precursor of bioactive peptides.
					<italic>Int J Mol Sci</italic> 2019, 20, 5191.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gomez</surname>
							<given-names>HL</given-names>
						</name>
						<name>
							<surname>Peralta</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>Tejano</surname>
							<given-names>LA</given-names>
						</name>
						<name>
							<surname>Chang</surname>
							<given-names>YW</given-names>
						</name>
					</person-group>
					<article-title>In silico and in vitro assessment of Portuguese oyster (Crassostrea angulata) proteins as precursor of bioactive peptides</article-title>
					<source>Int J Mol Sci</source>
					<year>2019</year>
					<volume>20</volume>
					<fpage>5191</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_376">
				<label>376.</label>
				<mixed-citation>Chakraborty, K, Joy, M. Anti-diabetic and anti-inflammatory activities of commonly available cephalopods.
					<italic>Int J Food Prop</italic> 2017;20:1655–65.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chakraborty</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Joy</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Anti-diabetic and anti-inflammatory activities of commonly available cephalopods</article-title>
					<source>Int J Food Prop</source>
					<year>2017</year>
					<volume>20</volume>
					<fpage>1655</fpage>
					<lpage>65</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_377">
				<label>377.</label>
				<mixed-citation>Lauritano, C, Ianora, A. Marine organisms with anti-diabetes properties.
					<italic>Mar Drugs</italic> 2016;14:220.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lauritano</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Ianora</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Marine organisms with anti-diabetes properties</article-title>
					<source>Mar Drugs</source>
					<year>2016</year>
					<volume>14</volume>
					<fpage>220</fpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_378">
				<label>378.</label>
				<mixed-citation>Nongonierma, A, Mooney, C, Shields, D, FitzGerald, R. Inhibition of dipeptidyl peptidase IV and xanthine oxidase by amino acids and dipeptides.
					<italic>Food Chem</italic> 2013;141:644–53.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nongonierma</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Mooney</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Shields</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>FitzGerald</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Inhibition of dipeptidyl peptidase IV and xanthine oxidase by amino acids and dipeptides</article-title>
					<source>Food Chem</source>
					<year>2013</year>
					<volume>141</volume>
					<fpage>644</fpage>
					<lpage>53</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_379">
				<label>379.</label>
				<mixed-citation>Kelly, TA, Adams, J, Bachovchin, WW, Barton, RW, Campbell, SJ, Coutts, SJ, et al.. Immunosuppressive boronic acid dipeptides: correlation between conformation and activity.
					<italic>J Am Chem Soc</italic> 1993;115:12637–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kelly</surname>
							<given-names>TA</given-names>
						</name>
						<name>
							<surname>Adams</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Bachovchin</surname>
							<given-names>WW</given-names>
						</name>
						<name>
							<surname>Barton</surname>
							<given-names>RW</given-names>
						</name>
						<name>
							<surname>Campbell</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Coutts</surname>
							<given-names>SJ</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Immunosuppressive boronic acid dipeptides: correlation between conformation and activity</article-title>
					<source>J Am Chem Soc</source>
					<year>1993</year>
					<volume>115</volume>
					<fpage>12637</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_380">
				<label>380.</label>
				<mixed-citation>Lam, B, Zhang, Z, Stafford, J, Skene, R, Shi, L, Gwaltney, S. Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.
					<italic>Bioorg Med Chem Lett</italic> 2012;22:6628–31.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lam</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Stafford</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Skene</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Shi</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Gwaltney</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors</article-title>
					<source>Bioorg Med Chem Lett</source>
					<year>2012</year>
					<volume>22</volume>
					<fpage>6628</fpage>
					<lpage>31</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_381">
				<label>381.</label>
				<mixed-citation>Motoshima, K, Sugita, K, Hashimoto, Y, Ishikawa, M. Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related a-glucosidase inhibitors and liver X receptor antagonists.
					<italic>Bioorg Med Chem Lett</italic> 2011;21:3041–5.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Motoshima</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Sugita</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Hashimoto</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Ishikawa</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related a-glucosidase inhibitors and liver X receptor antagonists</article-title>
					<source>Bioorg Med Chem Lett</source>
					<year>2011</year>
					<volume>21</volume>
					<fpage>3041</fpage>
					<lpage>5</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_382">
				<label>382.</label>
				<mixed-citation>Gómez, H, Chappé, M, Valiente, P, Pons, T. Effect of zinc and calcium ions on the rat kidney membrane-bound form of dipeptidyl peptidase IV.
					<italic>J Biosci</italic> 2013;38:1–9.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gómez</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Chappé</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Valiente</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Pons</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Effect of zinc and calcium ions on the rat kidney membrane-bound form of dipeptidyl peptidase IV</article-title>
					<source>J Biosci</source>
					<year>2013</year>
					<volume>38</volume>
					<fpage>1</fpage>
					<lpage>9</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_383">
				<label>383.</label>
				<mixed-citation>Pascual, I, Gómez, H, Pons, T, Chappé, M. Effect of divalent cations on the porcine kidney cortex membrane-bound form of dipeptidyl peptidase IV.
					<italic>Int J Biochem Cell Biol</italic> 2011;4:2–16.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Gómez</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Pons</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Chappé</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Effect of divalent cations on the porcine kidney cortex membrane-bound form of dipeptidyl peptidase IV</article-title>
					<source>Int J Biochem Cell Biol</source>
					<year>2011</year>
					<volume>4</volume>
					<fpage>2</fpage>
					<lpage>16</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_384">
				<label>384.</label>
				<mixed-citation>Pascual, I, Valiente, P, Valdés-Tresanco, ME, Arrebola, Y, Almeida, F, Díaz, L, et al..
					<italic>Int J Biol Macromol</italic> 2022;196:120–30.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pascual</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Valiente</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Valdés-Tresanco</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Arrebola</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Almeida</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Díaz</surname>
							<given-names>L</given-names>
						</name>
						<etal/>
					</person-group>
					<source>Int J Biol Macromol</source>
					<year>2022</year>
					<volume>196</volume>
					<fpage>120</fpage>
					<lpage>30</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_385">
				<label>385.</label>
				<mixed-citation>Wang, H, Liu, X, Long, M, Huang, Y, Zhang, L, Zhang, R, et al.. NRF2 activation by antioxidant antidiabetic agents accelerates tumour metastasis.
					<italic>Sci Transl Med</italic> 2016;8:334–51.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wang</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Long</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>R</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>NRF2 activation by antioxidant antidiabetic agents accelerates tumour metastasis</article-title>
					<source>Sci Transl Med</source>
					<year>2016</year>
					<volume>8</volume>
					<fpage>334</fpage>
					<lpage>51</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_386">
				<label>386.</label>
				<mixed-citation>Russo, JW, Gao, C, Bhasin, SS, Voznesensky, OS, Calagua, C, Arai, S, et al.. Downregulation of dipeptidyl peptidase 4 accelerates progression to castration-resistant prostate cancer.
					<italic>Cancer Res</italic> 2018;78:6354–62.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Russo</surname>
							<given-names>JW</given-names>
						</name>
						<name>
							<surname>Gao</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Bhasin</surname>
							<given-names>SS</given-names>
						</name>
						<name>
							<surname>Voznesensky</surname>
							<given-names>OS</given-names>
						</name>
						<name>
							<surname>Calagua</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Arai</surname>
							<given-names>S</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Downregulation of dipeptidyl peptidase 4 accelerates progression to castration-resistant prostate cancer</article-title>
					<source>Cancer Res</source>
					<year>2018</year>
					<volume>78</volume>
					<fpage>6354</fpage>
					<lpage>62</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_387">
				<label>387.</label>
				<mixed-citation>Yang, F, Takagaki, Y, Yoshitomi, Y, Ikeda, T, Li, J, Kitada, M, et al.. Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR Axis.
					<italic>Cancer Res</italic> 2019;79:735–46.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yang</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Takagaki</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Yoshitomi</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Ikeda</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Kitada</surname>
							<given-names>M</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR Axis</article-title>
					<source>Cancer Res</source>
					<year>2019</year>
					<volume>79</volume>
					<fpage>735</fpage>
					<lpage>46</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_388">
				<label>388.</label>
				<mixed-citation>Pech, V, Abusaada, K, Alemany, C. Dipeptidyl peptidase-4 inhibition may stimulate progression of carcinoid tumour.
					<italic>Case Rep Endocrinol</italic> 2015;2015:952019.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pech</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Abusaada</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Alemany</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase-4 inhibition may stimulate progression of carcinoid tumour</article-title>
					<source>Case Rep Endocrinol</source>
					<year>2015</year>
					<volume>2015</volume>
					<elocation-id>952019</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_389">
				<label>389.</label>
				<mixed-citation>Ali, A, Fuentes, A, Skelton, WP, Wang, Y, Mcgorray, S, Shah, C. A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.
					<italic>Mol Clin Oncol</italic> 2019;10:118–24.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ali</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Fuentes</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Skelton</surname>
							<given-names>WP</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Mcgorray</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Shah</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers</article-title>
					<source>Mol Clin Oncol</source>
					<year>2019</year>
					<volume>10</volume>
					<fpage>118</fpage>
					<lpage>24</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_390">
				<label>390.</label>
				<mixed-citation>Bishnoi, R, Hong, YR, Shah, C, Ali, A, Skelton, WP, Huo, J. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: a surveillance epidemiology and endpoint research medicare study.
					<italic>Cancer Med</italic> 2019;8:3918–27.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bishnoi</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Hong</surname>
							<given-names>YR</given-names>
						</name>
						<name>
							<surname>Shah</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Ali</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Skelton</surname>
							<given-names>WP</given-names>
						</name>
						<name>
							<surname>Huo</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: a surveillance epidemiology and endpoint research medicare study</article-title>
					<source>Cancer Med</source>
					<year>2019</year>
					<volume>8</volume>
					<fpage>3918</fpage>
					<lpage>27</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_391">
				<label>391.</label>
				<mixed-citation>Tseng, CH. Sitagliptin may reduce breast cancer risk in women with type 2 diabetes.
					<italic>Clin Breast Cancer</italic> 2017;17:211–8.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tseng</surname>
							<given-names>CH</given-names>
						</name>
					</person-group>
					<article-title>Sitagliptin may reduce breast cancer risk in women with type 2 diabetes</article-title>
					<source>Clin Breast Cancer</source>
					<year>2017</year>
					<volume>17</volume>
					<fpage>211</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_392">
				<label>392.</label>
				<mixed-citation>Tseng, CH. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.
					<italic>Oncotarget</italic> 2017;8:19057–64.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tseng</surname>
							<given-names>CH</given-names>
						</name>
					</person-group>
					<article-title>Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes</article-title>
					<source>Oncotarget</source>
					<year>2017</year>
					<volume>8</volume>
					<fpage>19057</fpage>
					<lpage>64</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_393">
				<label>393.</label>
				<mixed-citation>Hsu, WH, Sue, SP, Liang, HL, Tseng, CW, Lin, HC, Wen, WL, et al.. Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: a Nationwide study in Taiwan.
					<italic>Front Public Health</italic> 2021;9:711723.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hsu</surname>
							<given-names>WH</given-names>
						</name>
						<name>
							<surname>Sue</surname>
							<given-names>SP</given-names>
						</name>
						<name>
							<surname>Liang</surname>
							<given-names>HL</given-names>
						</name>
						<name>
							<surname>Tseng</surname>
							<given-names>CW</given-names>
						</name>
						<name>
							<surname>Lin</surname>
							<given-names>HC</given-names>
						</name>
						<name>
							<surname>Wen</surname>
							<given-names>WL</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: a Nationwide study in Taiwan</article-title>
					<source>Front Public Health</source>
					<year>2021</year>
					<volume>9</volume>
					<elocation-id>711723</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_394">
				<label>394.</label>
				<mixed-citation>Kamada, S, Namekawa, T, Ikeda, K, Suzuki, T, Kagawa, M, Takeshita, H, et al.. Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma.
					<italic>Oncogene</italic> 2021;40:3899–913.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kamada</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Namekawa</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Ikeda</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Suzuki</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kagawa</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Takeshita</surname>
							<given-names>H</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma</article-title>
					<source>Oncogene</source>
					<year>2021</year>
					<volume>40</volume>
					<fpage>3899</fpage>
					<lpage>913</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_395">
				<label>395.</label>
				<mixed-citation>Kabel, AM, Atef, A, Estfanous, RS. Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma.
					<italic>Biomed Pharmacother</italic> 2018;97:667–74.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kabel</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Atef</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Estfanous</surname>
							<given-names>RS</given-names>
						</name>
					</person-group>
					<article-title>Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma</article-title>
					<source>Biomed Pharmacother</source>
					<year>2018</year>
					<volume>97</volume>
					<fpage>667</fpage>
					<lpage>74</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_396">
				<label>396.</label>
				<mixed-citation>Arwert, EN, Mentink, RA, Driskell, RR, Hoste, E, Goldie, SJ, Quist, WFM. Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.
					<italic>Oncogene</italic> 2012;31:992–1000.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Arwert</surname>
							<given-names>EN</given-names>
						</name>
						<name>
							<surname>Mentink</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Driskell</surname>
							<given-names>RR</given-names>
						</name>
						<name>
							<surname>Hoste</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Goldie</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Quist</surname>
							<given-names>WFM</given-names>
						</name>
					</person-group>
					<article-title>Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation</article-title>
					<source>Oncogene</source>
					<year>2012</year>
					<volume>31</volume>
					<fpage>992</fpage>
					<lpage>1000</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_397">
				<label>397.</label>
				<mixed-citation>Choi, HJ, Kim, JY, Lim, SC, Kim, G, Yun, HJ, Choi, HS. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.
					<italic>Br J Pharmacol</italic> 2015;172:5096–109.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Choi</surname>
							<given-names>HJ</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>JY</given-names>
						</name>
						<name>
							<surname>Lim</surname>
							<given-names>SC</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Yun</surname>
							<given-names>HJ</given-names>
						</name>
						<name>
							<surname>Choi</surname>
							<given-names>HS</given-names>
						</name>
					</person-group>
					<article-title>Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression</article-title>
					<source>Br J Pharmacol</source>
					<year>2015</year>
					<volume>172</volume>
					<fpage>5096</fpage>
					<lpage>109</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_398">
				<label>398.</label>
				<mixed-citation>Wang, Q, Lu, P, Wang, T, Zheng, Q, Li, Y, Leng, SX, et al.. Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation.
					<italic>Cancer Med</italic> 2020;9:3816–28.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wang</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Lu</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Zheng</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Leng</surname>
							<given-names>SX</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation</article-title>
					<source>Cancer Med</source>
					<year>2020</year>
					<volume>9</volume>
					<fpage>3816</fpage>
					<lpage>28</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_399">
				<label>399.</label>
				<mixed-citation>Sliwinska, A, Rogalska, A, Marczak, A, Kasznicki, J, Drzewoski, J. Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death.
					<italic>Toxicol Vitr</italic> 2015;29:1116–23.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sliwinska</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Rogalska</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Marczak</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kasznicki</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Drzewoski</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death</article-title>
					<source>Toxicol Vitr</source>
					<year>2015</year>
					<volume>29</volume>
					<fpage>1116</fpage>
					<lpage>23</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_400">
				<label>400.</label>
				<mixed-citation>Beckenkamp, A, Willig, JB, Santana, DB, Nascimento, J, Paccez, JD, Zerbini, LF, et al.. Differential expression and enzymatic activity of DPPIV/CD26 affects migration ability of cervical carcinoma cells.
					<italic>PLoS One</italic> 2015;10:e0134305.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Beckenkamp</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Willig</surname>
							<given-names>JB</given-names>
						</name>
						<name>
							<surname>Santana</surname>
							<given-names>DB</given-names>
						</name>
						<name>
							<surname>Nascimento</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Paccez</surname>
							<given-names>JD</given-names>
						</name>
						<name>
							<surname>Zerbini</surname>
							<given-names>LF</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Differential expression and enzymatic activity of DPPIV/CD26 affects migration ability of cervical carcinoma cells</article-title>
					<source>PLoS One</source>
					<year>2015</year>
					<volume>10</volume>
					<elocation-id>e0134305</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_401">
				<label>401.</label>
				<mixed-citation>Herrmann, H, Sadovnik, I, Cerny-Reiterer, S, Rulicke, T, Stefanzl, G, Willmann, M, et al.. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
					<italic>Blood</italic> 2014;123:3951–62.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Herrmann</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Sadovnik</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Cerny-Reiterer</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Rulicke</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Stefanzl</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Willmann</surname>
							<given-names>M</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia</article-title>
					<source>Blood</source>
					<year>2014</year>
					<volume>123</volume>
					<fpage>3951</fpage>
					<lpage>62</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_402">
				<label>402.</label>
				<mixed-citation>Spagnuolo, PA, Hurren, R, Gronda, M, MacLean, N, Datti, A, Basheer, A, et al.. Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity.
					<italic>Leukemia</italic> 2013;27:1236–44.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Spagnuolo</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Hurren</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Gronda</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>MacLean</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Datti</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Basheer</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity</article-title>
					<source>Leukemia</source>
					<year>2013</year>
					<volume>27</volume>
					<fpage>1236</fpage>
					<lpage>44</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_403">
				<label>403.</label>
				<mixed-citation>Sato, T, Tatekoshi, A, Takada, K, Iyama, S, Kamihara, Y, Jawaid, P, et al.. DPP8 is a novel therapeutic target for multiple myeloma.
					<italic>Sci Rep</italic> 2019;9:18094.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sato</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Tatekoshi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Takada</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Iyama</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Kamihara</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Jawaid</surname>
							<given-names>P</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>DPP8 is a novel therapeutic target for multiple myeloma</article-title>
					<source>Sci Rep</source>
					<year>2019</year>
					<volume>9</volume>
					<elocation-id>18094</elocation-id>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_404">
				<label>404.</label>
				<mixed-citation>Nabeno, M, Akahoshi, F, Kishida, H, Miyaguchi, I, Tanaka, Y, Ishii, S, et al.. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
					<italic>Biochem Biophys Res Commun</italic> 2013;434:191–6.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nabeno</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Akahoshi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Kishida</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Miyaguchi</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Tanaka</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Ishii</surname>
							<given-names>S</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site</article-title>
					<source>Biochem Biophys Res Commun</source>
					<year>2013</year>
					<volume>434</volume>
					<fpage>191</fpage>
					<lpage>6</lpage>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_405">
				<label>405.</label>
				<mixed-citation>Roppongi, S, Suzuki, Y, Tateoka, C, Fujimoto, M, Morisawa, S, Iizuka, I, et al.. Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues.
					<italic>Sci Rep</italic>, 2018, 8:2714, 1–18.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Roppongi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Suzuki</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Tateoka</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Fujimoto</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Morisawa</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Iizuka</surname>
							<given-names>I</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues</article-title>
					<source>Sci Rep</source>
					<year>2018</year>
					<volume>8</volume>
					<fpage>2714</fpage>
					<comment>, 1–18</comment>
				</element-citation>
			</ref>
			<ref id="j_psr-2022-0288_ref_406">
				<label>406.</label>
				<mixed-citation>Yoshida, T, Akahoshi, F, Sakashita, H, Kitajima, H, Nakamura, M, Sonda, S, et al.. Discovery and preclinical profile of teneleglptin (3-[(2S,4S)-4[4-(3-methyl-1-phenyl-1H-pyrazol-5yl)piperazin-1yl]pyrrolidin-2-ylcarbonyl]thiazolidyne): a highly potent, selective, longlasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
					<italic>Bioorg Med Chem</italic> 2012;20:5705–19.
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yoshida</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Akahoshi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Sakashita</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Kitajima</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Nakamura</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Sonda</surname>
							<given-names>S</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Discovery and preclinical profile of teneleglptin (3-[(2S,4S)-4[4-(3-methyl-1-phenyl-1H-pyrazol-5yl)piperazin-1yl]pyrrolidin-2-ylcarbonyl]thiazolidyne): a highly potent, selective, longlasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes</article-title>
					<source>Bioorg Med Chem</source>
					<year>2012</year>
					<volume>20</volume>
					<fpage>5705</fpage>
					<lpage>19</lpage>
				</element-citation>
			</ref>
		</ref-list>
	</back>
</article>
